Document:

EX-4.1

 Exhibit 4.1 

ATEA PHARMACEUTICALS, INC. 

FOURTH AMENDED AND RESTATED 

STOCKHOLDERS AGREEMENT 

THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of May 19, 2020, by and
among Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Founder (as defined below), each of the investors listed on Schedule A hereto (together with any subsequent investors or transferees, who become
parties hereto as “Investors” pursuant to Subsections 11.9(a) or 11.12 below, the “Investors”), and those certain stockholders of the Company listed on Schedule B (together with any subsequent
stockholders or transferees, who become parties hereto as “Key Holders” pursuant to Subsection 11.9(b) or 11.12 below, the “Key Holders,” and together collectively with the Investors, the
“Stockholders”). 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to the Third Amended and
Restated Stockholders Agreement dated as of June 29, 2018, by and among the Company and such Investors (the “Prior Agreement”); and 

WHEREAS, the Existing Investors constitute the Requisite Preferred Holders (as defined in the Prior Agreement) and the holders of a
majority of the outstanding shares of Series C Preferred Stock, and the Company and the Existing Investors desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the
rights granted to them under the Prior Agreement in order to induce certain of the Investors to invest funds in the Company pursuant to that certain Preferred Stock Purchase Agreement, of even date herewith, by and among the Company and certain of
the Investors (the “Purchase Agreement”). 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital, registered investment company or other investment fund now or
hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. 

1.2 “Board” means the Board of Directors of the Company. 

 

 1.3 “Capital Stock” means (a) shares of Common Stock and Preferred
Stock (whether now outstanding or hereafter issued in any context), (b) shares of Common Stock issued or issuable upon conversion of Preferred Stock, and (c) shares of Common Stock issued or issuable upon exercise or conversion, as applicable,
of stock options, warrants or other convertible securities of the Company, in each case now owned or subsequently acquired by any Key Holder, any Investor, or their respective successors or permitted transferees or assigns. For purposes of the
number of shares of Capital Stock held by an Investor or Key Holder (or any other calculation based thereon), all shares of Preferred Stock shall be deemed to have been converted into Common Stock at the
then-applicable conversion ratio. 
 1.4 “Certificate of Incorporation” means the
Company’s certificate of incorporation, as it may be amended and/or restated from time to time. 
 1.5 “Common Stock”
means shares of the Company’s common stock, par value $0.001 per share. 
 1.6 “Company Notice” means written notice
from the Company notifying the selling Rights Holder that the Company intends to exercise its Right of First Refusal as to some or all of the Transfer Stock with respect to any Proposed Restricted Holder Transfer. 

1.7 “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability
company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in discovering, developing or commercializing antivirals for the treatment or prophylaxis of human diseases or conditions resulting from
infection by or exposure to RNA or DNA viruses, but shall not include any financial investment firm, venture capital firm or collective investment vehicle that, together with its Affiliates, holds less than ten percent (10%) of the outstanding
equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor. Notwithstanding anything to the contrary in no event shall Ally Bridge Medalpha Master Fund L.P.
or any Affiliate thereof, Bain Capital Life Sciences, LP or any Affiliate thereof, RA Capital Healthcare Fund, L.P. or any Affiliate thereof, Redmile Biopharma Investments II, L.P. (“Redmile”) or any Affiliate thereof or Rock
Springs Capital Master Fund LP or any Affiliate thereof constitute a Competitor. 
 1.8 “Damages” means any loss, damage,
claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation
by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. 

  
 2 

 1.9 “Deemed Liquidation Event” shall have the meaning ascribed to it in the
Certificate of Incorporation. 
 1.10 “Defaulting Investor” shall have the meaning ascribed to it in the Purchase Agreement.

 1.11 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.12 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.13 “Excluded
Registration” means: (i) a registration relating to the sale of securities to employees, consultants and/or members of the Board of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a
registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.14 “Form S-1” means such form under the Securities Act as in effect on the
date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.15 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.16 “Founder” means Jean-Pierre
Sommadossi, Ph.D.; provided, however, upon the death or total and permanent disability of Jean-Pierre Sommadossi, Ph.D., “Founder” shall mean the Key Holders holding a majority of the outstanding shares of Common Stock held by Key Holders.

 1.17 “Founder Holders” means (a) Jean-Pierre Sommadossi, Ph.D., (b) any Affiliate of Dr. Sommadossi,
(c) the Jean-Pierre Sommadossi Trust 12/10/98 and (d) JPM Partners LLC. 
 1.18 “GAAP” means generally accepted
accounting principles in the United States. 
 1.19 “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 
 1.20 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

  
 3 

 1.21 “Initiating Holders” means, collectively, Holders who properly
initiate a registration request under this Agreement. 
 1.22 “IPO” means the Company’s first underwritten public
offering of its Common Stock under the Securities Act. 
 1.23 “Major Investor” means any Investor that, individually or
together with such Investor’s Affiliates, holds at least 400,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), and
is not a Defaulting Investor. 
 1.24 “New Securities” means, collectively, equity securities of the Company, whether or not
currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.25 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.26 “Preferred Stock” means, collectively, the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred
Stock, Series D Preferred Stock and Series D-1 Preferred Stock. 
 1.27 “Proposed Restricted
Holder Transfer” means any assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance, disposition of or any other like transfer or encumbering of any Transfer Stock (or any interest therein) proposed by any of the
Restricted Holders. 
 1.28 “Proposed Transfer Notice” means written notice from a Restricted Holder setting forth the terms
and conditions of a Proposed Restricted Holder Transfer. 
 1.29 “Prospective Transferee” means any person to whom a
Restricted Holder proposes to make a Proposed Restricted Holder Transfer. 
 1.30 “Registrable Securities” means
(i) the Common Stock issuable or issued upon conversion of the Preferred Stock; and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, (A) any Registrable Securities sold by a Person in a transaction in which the
applicable rights under this Agreement are not assigned pursuant to Subsection 11.1 and (B) any Common Stock issued upon conversion of Preferred Stock and Common Stock pursuant to the “Special Mandatory Conversion”
provisions of the Certificate of Incorporation, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.12 of this Agreement. 

1.31 “Registrable Securities then Outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

  
 4 

 1.32 “Requisite Preferred Holders” means the holders of a majority in
voting power of the outstanding shares of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series D-1 Preferred Stock, voting together as a single class. 

1.33 “Restricted Holders” means the Founder Holders and the Investors; provided, however, upon the death or total and
permanent disability of Jean-Pierre Sommadossi, Ph.D., “Restricted Holders” shall not include the Founder Holders. 
 1.34
“Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.11(b) hereof. 

1.35 “Right of Co-Sale” means the right, but not an obligation, of a Rights Holder to
participate in a Proposed Restricted Holder Transfer on the terms and conditions specified in the Proposed Transfer Notice. 
 1.36
“Right of First Refusal” means the right, but not an obligation, of the Company, or its permitted transferees or assigns, to purchase some or all of the Transfer Stock with respect to a Proposed Restricted Holder Transfer, on the
terms and conditions specified in the Proposed Transfer Notice. 
 1.37 “Rights Holder” means (i) with respect to a
Proposed Restricted Holder Transfer by any Founder Holder, the Investors (who are not Defaulting Investors) and (ii) with respect to a Proposed Restricted Holder Transfer by any Investor, the Founder Holders and each Investor (who is not
Defaulting Investor) other than the Investor effecting such Proposed Restricted Holder Transfer. 
 1.38 “Rights Holder
Notice” means written notice from a Rights Holder notifying the Company and the selling Restricted Holder that such Rights Holder intends to exercise its Secondary Refusal Right as to a portion of the Transfer Stock with respect to any
Proposed Restricted Holder Transfer. 
 1.39 “Sale of the Company” either: (a) a transaction or series of related
transactions in which a Person, or a group of related Persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a “Stock Sale”); or
(b) a transaction that qualifies as a Deemed Liquidation Event. 
 1.40 “SEC” means the Securities and Exchange
Commission. 
 1.41 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.42 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

  
 5 

 1.43 “Secondary Notice” means written notice from the Company notifying the
Rights Holders and the selling Restricted Holder that the Company does not intend to exercise its Right of First Refusal as to all shares of Transfer Stock with respect to any Proposed Restricted Holder Transfer. 

1.44 “Secondary Refusal Right” means the right, but not an obligation, of each Rights Holder to purchase up to its pro rata
portion (based upon the total number of shares of Capital Stock then held by all Rights Holders other than the Rights Holder effecting such Proposed Restricted Holder Transfer) of any Transfer Stock not purchased pursuant to the Right of First
Refusal, on the terms and conditions specified in the Proposed Transfer Notice. 
 1.45 “Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 
 1.46 “Selling Expenses” means
all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in Subsection 2.6. 
 1.47 “Series A Preferred Stock” means shares of the
Company’s Series A Preferred Stock, par value $0.001 per share. 
 1.48 “Series B Preferred Stock” means shares of the
Company’s Series B Preferred Stock, par value $0.001 per share. 
 1.49 “Series C Preferred Stock” means shares of the
Company’s Series C Preferred Stock, par value $0.001 per share. 
 1.50 “Series D Preferred Stock” means shares of the
Company’s Series D Preferred Stock, par value $0.001 per share. 
 1.51 “Series D-1
Preferred Stock” means shares of the Company’s Series D-1 Preferred Stock, par value $0.001 per share. 

1.52 “Shares” means any securities of the Company the holders of which are entitled to vote for members of the Board,
including without limitation, all shares of Common Stock and Preferred Stock, by whatever name called, now owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits, stock dividends, reclassifications,
recapitalizations, similar events or otherwise. 
 1.53 “Transfer Stock” means shares of Capital Stock owned by a Restricted
Holder, or issued to a Restricted Holder after the date hereof (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like). 

1.54 “Undersubscription Notice” means written notice from a Rights Holder notifying the Company and the selling Restricted
Holder that such Rights Holder intends to exercise its option to purchase all or any portion of the Transfer Stock not purchased pursuant to the Right of First Refusal or the Secondary Refusal Right. 

  
 6 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date
of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then Outstanding that the
Company file a Form S-1 registration statement with respect to the Registrable Securities then Outstanding having an anticipated gross aggregate offering price of at least $15 million, then the
Company shall (x) within twenty (20) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections
2.1(c) and 2.3. 
 (b) Form S-3 Demand. If at any time when it is eligible
to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then Outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated gross aggregate offering price of at least $5 million, then the Company shall (i) within
ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is
given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as
specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its stockholders for such registration statement to either become
effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other
similar transaction involving the Company, (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential, or (iii) render the Company unable to comply with
requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than twice in any twelve (12) month period.

  
 7 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected two (2) registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (x)
during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided
that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (y) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the
twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement
has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to
Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in the IPO or an Excluded Registration), the Company shall, at such time,
promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be
registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before
the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in
accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary 

  
 8 

 
form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing
that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of
Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned
by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be
reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any
Holder to the nearest one hundred (100) shares. 
 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the
number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities
included in the offering be reduced below twenty percent (20%) of the total number of securities included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a
partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners,
members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon
the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the
underwriter’s cutback provisions in Subsection 2.3(a), fewer than one hundred percent (100%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.

  
 9 

 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 

  
 10 

 (h) promptly make available for inspection by the selling Holders, any managing
underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent
corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or
agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $20,000, of one (1) counsel for the selling Holders (“Selling Holder
Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration
request is subsequently withdrawn at the request of the Initiating Holders (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration),
unless the Initiating Holders agree to forfeit their right to one (1) registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the
Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of
such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one (1) registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable
Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

  
 11 

 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder,
and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls
such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company
be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling
Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of
any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by
way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by
such Holder. 

  
 12 

 (c) Promptly after receipt by an indemnified party under this Subsection 2.8
of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection
2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Unless otherwise
superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable
Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement. 

  
 13 

 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c) furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after
ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it
qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 
 2.10 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or
contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable (directly or indirectly) for Common Stock (in each case, solely with respect to shares or any such securities held as of immediately prior to the IPO) or (ii) enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise.
The foregoing provisions of this Subsection 2.10 shall apply only to the IPO and shall apply to each Investor only if each officer, director and each stockholder of the Company (together with their Affiliates or related investment funds) owning 1%
or more of the Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock are subject to the same restrictions and are bound by similar agreements, shall not apply to: (A) the sale
of any shares to an underwriter pursuant to an underwriting agreement, (B) any shares 

  
 14 

 
purchased in the IPO or in open market transactions from and after the IPO, (C) the transfer of any shares owned by a Holder to its affiliates or any of the Holder’s stockholders,
members, partners or other equity holders; provided that the affiliate, stockholder, member, partner or other equity holder of the Holder agrees to be bound in writing by the restrictions set forth herein, or (D) the transfer of any shares to
any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein. The underwriters in connection with such
registration are intended third-party beneficiaries of this Subsection 2.10 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder
further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.10 or that are necessary to give further effect thereto. Any discretionary
waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata only to all Holders that, together with such Holder’s Affiliates, own at least 550,000 shares of Series D
Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series D Preferred Stock), based on the number of shares subject to such
agreements. 
 2.11 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement. A transferring Holder will cause any proposed purchaser, pledgee,
or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the
Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case, to be bound by the terms of this Agreement. 

(b) Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and
(iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the
provisions of Subsection 2.11(c)) be notated with a legend substantially in the following form: 
 THE SECURITIES REPRESENTED HEREBY
HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND
PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.11. 

  
 15 

 (c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to
comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering
the proposed transaction or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall
describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal
counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no
action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or
(iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the
Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or
“no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided
that, with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Subsection 2.11. Each certificate, instrument, or book entry representing the Restricted Securities
transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in Subsection 2.11(b), except that
such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. 
 2.12 Termination of Registration Rights. The right of any Holder to request registration or inclusion of
Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event; 

(b) such time after consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is available for the sale of
all of such Holder’s shares without limitation during a three-month period without registration; and 
 (c) the third anniversary of
the IPO. 

  
 16 

 3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board has not
reasonably determined that such Major Investor is a Competitor: 
 (a) as soon as practicable, but in any event within one hundred eighty
days (180) after the end of the fiscal year of the Company ended December 31, 2019 and within one hundred twenty (120) days after the end of each fiscal year of the Company thereafter (or such later date as may be approved by the
Board) (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all prepared in accordance with GAAP;

 (b) as soon as practicable, but in any event within sixty (60) days after the end of each of the first three (3) quarters of
each fiscal year of the Company (or such later date as may be approved by the Board), unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in
accordance with GAAP (except that such financial statements may (i) be subject to normal year-end adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);
and 
 (c) If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of
such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules
applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Major
Investor (provided that the Board has not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, upon not less than 7 days prior notice, to visit and inspect the Company’s properties;
examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided,
however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that (i) it reasonably and in good faith considers to be a trade secret or confidential information (unless
covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) upon the advice of counsel, it determines that the disclosure of which would adversely affect the attorney-client privilege between the Company and
its counsel. 
 3.3 Termination of Information Rights. The covenants set forth in Subsection 3.1 and Subsection 3.2
shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act,
or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 

  
 17 

 3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s
intention to file a registration statement or any information provided in connection with a request for a waiver under or an amendment of any term of this Agreement), unless such confidential information (a) is known or becomes known to the
public in general (other than as a result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is
or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential
information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any
Registrable Securities from such Investor, provided that prior to such disclosure such prospective purchaser has agreed to be bound to provisions which are the same or substantially similar to the provisions of this Subsection 3.4 (and
further provided such purchaser is not a Competitor); (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person
that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure
and takes reasonable steps to minimize the extent of any such required disclosure. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor who is not a Defaulting Investor. Each such Investor shall be entitled to apportion the right of first offer hereby granted to
it in such proportions as it deems appropriate, among itself and its Affiliates (provided such Affiliates are not a Competitor). Defaulting Investors shall not be entitled to any of the rights set forth in this Section 4.1. 

(a) The Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within ten (10) days after the Offer Notice is given, each Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor (including all shares of Common Stock then issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion
and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such ten (10) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available
to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the five (5) day period commencing after the Company has given such notice,

  
 18 

 
each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities
for which Investors were entitled to subscribe but that were not subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as
applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the
Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of
one hundred and twenty (120) days of the date that the Offer Notice is given and the date of the initial sale of New Securities pursuant to Subsection 4.1(c). 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not
less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated
within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Subsection 4.1.

 (d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the
Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Preferred Stock pursuant to the Purchase Agreement. 

(e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Subsection 4.1, the Company
may elect to give notice to the Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Investor shall have twenty (20) days from the date
notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Investor, maintain such Investor’s percentage-ownership position, calculated as set forth in Subsection 4.1(b) before giving effect
to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Investors. 

4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event,
whichever event occurs first. 
 5. Voting Provisions Regarding Board of Directors. 

5.1 Size of the Board. Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such
Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and remain at nine (9) directors and may be increased only with the written consent
of the Founder Holders and the Requisite Preferred Holders. 

  
 19 

 5.2 Board Composition. Each Stockholder agrees to vote, or cause to be voted, all
Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election
of directors is held or pursuant to any written consent of the stockholders, the following persons shall be elected to the Board: 
 (a) one
person designated by the Investor holding the greatest number of shares of Series A Preferred Stock held by any of the Investors, other than RMI Investments S.A.R.L. or any of its Affiliates (the “Series A Designee”), who shall be
the Series A Director (as defined in the Certificate of Incorporation), which individual shall initially be Isaac Cheng, for so long as at least 5,000,000 shares of Series A Preferred Stock are issued and outstanding (which number is subject to
appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like); 
 (b) one person designated by RMI
Investments S.A.R.L. (the “RMI Designee”), which individual shall initially be Grigory Borisenko, for so long as such Stockholder and its Affiliates collectively continue to beneficially own at least 1,500,000 shares of Series A
Preferred Stock (which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like); 

(c) one person designated by AJU Growth & Healthcare Fund (the “Series B Designee”), who shall be the Series B
Director (as defined in the Certificate of Incorporation), which seat shall initially be vacant, for so long as (i) such Stockholder and its Affiliates collectively continue to beneficially own at least 300,000 shares of Series B Preferred
Stock (which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like) and (ii) at least 5,000,000 shares of Series B Preferred Stock are issued and outstanding (which number is
subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like); 
 (d) one person
designated by Cormorant Private Healthcare Fund I, LP (the “Cormorant Designee”), who shall be the Series C Director (as defined in the Certificate of Incorporation), which individual shall initially be Bihua Chen, for so long as
(i) such Stockholder and its Affiliates collectively continue to beneficially own at least 1,100,000 shares of Series C Preferred Stock (which number is subject to appropriate adjustment for all stock splits, dividends, combinations,
recapitalizations and the like) and (ii) at least 2,741,228 shares of Series C Preferred Stock are issued and outstanding (which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and
the like); 
 (e) one person designated by Bain Capital Life Sciences, LP (the “Bain Designee”), who shall be the Series D
Director (as defined in the Certificate of Incorporation), which individual shall initially be Andrew Hack, for so long as such Stockholder and its Affiliates collectively continue to beneficially own at least 1,500,000 shares of Series D Preferred
Stock (which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like); 

  
 20 

 (f) One person designated by the holders of a majority of the outstanding shares of Common
Stock held by the Key Holders (the “Key Holder Designee”), who shall be the director elected by the holders of record of the shares of Common Stock, exclusively and as a separate class, under the Certificate of Incorporation, which
individual shall initially be Jean-Pierre Sommadossi, Ph.D.; and 
 (g) Three (3) persons who are each not otherwise an Affiliate of the
Company or of any Stockholder and who are mutually acceptable to (i) the Founder and (ii) the holders of a majority in voting power of the outstanding shares of Preferred Stock (the “Independent Designees”), who shall
initially be Franklin Berger, Bruce Polsky and Bruno Lucidi. 
 To the extent that any of clauses (a) through (f) above shall not be
applicable, any member of the Board who would otherwise have been designated in accordance with the terms thereof shall instead be voted upon by all the stockholders of the Company entitled to vote thereon in accordance with, and pursuant to, the
Certificate of Incorporation. 
 5.3 Failure to Designate a Board Member. In the absence of any designation from the Persons or groups
with the right to designate a director as specified above, the director previously designated by them and then serving shall be reelected if still eligible to serve as provided herein. 

5.4 Removal of Board Members. Each Stockholder also agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over
which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: 

(a) no director elected pursuant to Subsections 5.2 or 5.3 of this Agreement may be removed from office unless
(i) such removal is directed or approved by the affirmative vote of the Person, or of the holders of a majority of the shares of stock, entitled under Subsection 5.2 to designate that director; or (ii) the
Person(s) originally entitled to designate or approve such director pursuant to Subsection 5.2 is no longer so entitled to designate or approve such director; 

(b) any vacancies created by the resignation, removal or death of a director elected pursuant to Subsections 5.2 or
5.3 shall be filled pursuant to the provisions of this Section 5; and 
 (c) upon the request of any party
entitled to designate a director as provided in Subsection 5.2(a), Subsection 5.2(b), Subsection 5.2(c), Subsection 5.2(d), Subsection 5.2(e) or Subsection 5.2(f) to remove such director,
such director shall be removed. 
 All Stockholders agree to execute any written consents required to perform the obligations of this Agreement, and the
Company agrees at the request of any party entitled to designate directors to call a special meeting of stockholders for the purpose of electing directors. 

5.5 No Liability for Election of Recommended Directors. No Stockholder, nor any Affiliate of any Stockholder, shall have any liability
as a result of designating a person for election as a director for any act or omission by such designated person in his or her capacity as a director of the Company, nor shall any Stockholder have any liability as a result of voting for any such
designee in accordance with the provisions of this Agreement 

  
 21 

 5.6 No “Bad Actor” Designees. Each Person with the right to designate or
participate in the designation of a director as specified above hereby represents and warrants to the Company that, to such Person’s knowledge, none of the “bad actor” disqualifying events described in Rule 506(d)(1)(i)-(viii)
promulgated under the Securities Act (each, a “Disqualification Event”), is applicable to such Person’s initial designee named above except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or
(iii) or (d)(3) is applicable. Any director designee to whom any Disqualification Event is applicable, except for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable, is hereinafter referred to as a
“Disqualified Designee”. Each Person with the right to designate or participate in the designation of a director as specified above hereby covenants and agrees (A) not to designate or participate in the designation of any
director designee who, to such Person’s knowledge, is a Disqualified Designee and (B) that in the event such Person becomes aware that any individual previously designated by any such Person is or has become a Disqualified Designee, such
Person shall as promptly as practicable take such actions as are necessary to remove such Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified Designee. 

6. Vote to Increase Authorized Common Stock. Each Stockholder agrees to vote or cause to be voted all Shares owned by such Stockholder, or over which
such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common
Stock available for conversion of all of the shares of Preferred Stock outstanding at any given time. 
 7. Drag-Along Right. 

7.1 Actions to be Taken. In the event that (i) the Requisite Preferred Holders (the “Selling Investors”); (ii) the
Board; (iii) the Founder Holders; (iv) if the amount per share payable in respect of outstanding shares of Series D Preferred Stock in connection with such Sale of the Company is less than twice the Series D Original Issue Price (as
defined in the Certificate of Incorporation), the holders of a majority of the outstanding Series D Preferred Stock; and (v) if the amount per share payable in respect of outstanding shares of Series D-1
Preferred Stock in connection with such Sale of the Company is less than twice the Series D-1 Original Issue Price (as defined in the Certificate of Incorporation), the holders of a majority of the outstanding
Series D-1 Preferred Stock approve a Sale of the Company in writing, specifying that this Section 7 shall apply to such transaction, then each Stockholder and the Company hereby
agree: 
 (a) if such transaction requires stockholder approval, with respect to all Shares that such Stockholder owns or over which such
Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of, and adopt, such Sale of the Company (together with any related amendment to the Restated Certificate
required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to consummate such Sale of the Company; 

(b) if such transaction is a Stock Sale, to sell the same proportion of shares of capital stock of the Company beneficially held by such
Stockholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their Shares, and, except as permitted in Subsection 7.2 below, on the same terms and conditions as the Selling Investors; 

  
 22 

 (c) to execute and deliver all related documentation and take such other action in support
of the Sale of the Company as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 7, including, without limitation, executing and delivering
instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens,
claims and encumbrances), and any similar or related documents; 
 (d) not to deposit, and to cause their Affiliates not to deposit, except
as provided in this Agreement, any Shares of the Company owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by
the acquiror in connection with the Sale of the Company; 
 (e) to refrain from exercising any dissenters’ rights or rights of appraisal
under applicable law at any time with respect to such Sale of the Company; 
 (f) if the consideration to be paid in exchange for the Shares
pursuant to this Section 7 includes any securities and due receipt thereof by any Stockholder would require under applicable law: (x) the registration or qualification of such securities or of any person as a broker or
dealer or agent with respect to such securities; or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors”
as defined in Regulation D promulgated under the Securities Act the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Stockholder, an amount in cash
equal to the fair value (as determined in good faith by the Company) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such securities in exchange for the Shares; and 

(g) in the event that the Selling Investors, in connection with such Sale of the Company, appoint a stockholder representative (the
“Stockholder Representative”) with respect to matters affecting the Stockholders under the applicable definitive transaction agreements following consummation of such Sale of the Company, (x) to consent to (i) the
appointment of such Stockholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of such Stockholder’s pro
rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative’s services and duties in connection with
such Sale of the Company and its related service as the representative of the Stockholders, and (y) not to assert any claim or commence any suit against the Stockholder Representative or any other Stockholder with respect to any action or
inaction taken or failed to be taken by the Stockholder Representative in connection with its service as the Stockholder Representative, absent fraud or willful misconduct. 

  
 23 

 7.2 Exceptions. Notwithstanding the foregoing, a Stockholder will not be required to
comply with Subsection 7.1 above in connection with any proposed Sale of the Company (the “Proposed Sale”), unless: 

(a) any representations and warranties to be made by such Stockholder in connection with the Proposed Sale are limited to representations and
warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and warranties that (i) the Stockholder holds all right, title and interest in and to the Shares such
Stockholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Stockholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be entered into by the
Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder in accordance with their respective terms; and (iv) neither the execution and delivery of documents to be entered
into in connection with the transaction, nor the performance of the Stockholder’s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or governmental agency; 

(b) the Stockholder shall not be liable for the inaccuracy of any representation or warranty made by any other Person in connection with the
Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any of identical
representations, warranties and covenants provided by all stockholders); 
 (c) the liability for indemnification, if any, of such
Stockholder in the Proposed Sale and for the inaccuracy of any representations and warranties made by the Company or its Stockholders in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent that
funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all
stockholders), and subject to the provisions of the Certificate of Incorporation related to the allocation of the escrow, is pro rata in proportion to, and does not exceed, the amount of consideration paid to such Stockholder in connection with such
Proposed Sale; 
 (d) upon the consummation of the Proposed Sale (i) each holder of each class or series of the Company’s stock
will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock, (ii) each holder of Common Stock will receive the same amount
of consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (iii) unless (A) the Requisite Preferred Holders and (B) the holders of a majority in voting power of the then
outstanding shares of Series D Preferred Stock and Series D-1 Preferred Stock, voting separately as a class, elect to receive a lesser amount by written notice given to the Company at least three (3) days
prior to the effective date of any such Proposed Sale, the aggregate consideration receivable by all holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the
relative liquidation preferences to which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation
Event) in accordance with the Company’s 

  
 24 

 
Certificate of Incorporation in effect immediately prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing, if the consideration to be paid
in exchange for the Key Holder Shares or Investor Shares, as applicable, pursuant to this Subsection 7.2(d) includes any securities and due receipt thereof by any Key Holder or Investor would require under applicable law (x) the
registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the provision to any Key Holder or Investor of any information other than such information as a prudent
issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Key Holder or Investor in lieu thereof,
against surrender of the Key Holder Shares or Investor Shares, as applicable, which would have otherwise been sold by such Key Holder or Investor, an amount in cash equal to the fair value (as determined in good faith by the Company) of the
securities which such Key Holder or Investor would otherwise receive as of the date of the issuance of such securities in exchange for the Key Holder Shares or Investor Shares, as applicable; and 

(e) no Stockholder that is a venture capital fund, investment fund or similar investment vehicle shall be required, in connection with such
Proposed Sale, to enter into any agreements with non-competition, non-solicitation, non-hire provisions or similar restrictive
covenants (other than customary covenants regarding confidentiality). 
 8. Additional Covenants. 

8.1 Insurance. The Company shall use its commercially reasonable efforts to maintain, from financially sound and reputable insurers
Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board determines that
such insurance should be discontinued. 
 8.2 Board Matters. The Company shall reimburse the Key Holder Designee and Independent
Designees for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the
Board. The Company may reimburse any other director for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in
connection with attending meetings of the Board; provided, however, if the Company decides to reimburse such expenses incurred by any of the Series B Designee, Series A Designee, RMI Designee, Cormorant Designee or Bain Designee, then
the Company shall reimburse such expenses of each of the Series B Designee, Series A Designee, RMI Designee, Cormorant Designee and Bain Designee. 

8.3 Equity Incentive Plan. So long as holders of Series A Preferred Stock are entitled to elect the Series A Director (as defined in the
Certificate of Incorporation), holders of Series B Preferred Stock are entitled to elect the Series B Director (as defined in the Certificate of Incorporation), holders of Series C Preferred Stock are entitled to elect the Series C Director (as
defined in the Certificate of Incorporation) and holders of Series D Preferred Stock are entitled to elect the Series D Director (as defined in the Certificate of Incorporation), the Company hereby covenants and agrees with each of the Investors
that it shall not, without approval of the Board, which approval must include the affirmative vote of at least two out of the four of (i) the Series A Director, (ii) the Series B Director, (iii) the Series C Director and (iv) the
Series D Director (the 

  
 25 

 
“Special Board Approval”), amend the Company’s 2013 Equity Incentive Plan (the “Plan”) to increase the aggregate number of shares of Common Stock issuable
pursuant to the Plan to in excess of 10,979,971 shares of Common Stock, or approve or adopt any other stock option or equity compensation plan. 

8.4 Proprietary Information and Inventions Agreements. Unless otherwise approved by the Board, including the Special Board Approval, the
Company shall require all employees and consultants to enter into the Company’s standard form of proprietary information and inventions agreement or a different agreement containing substantially similar terms with respect to proprietary
information and the assignment of inventions. 
 8.5 Successor Indemnification. If the Company or any of its successors or assignees
consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the
Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate
of Incorporation, or elsewhere, as the case may be. 
 8.6 Indemnification Matters. The Company hereby acknowledges that one
(1) or more of the directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or
more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are
primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount
of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as
required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors,
and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company
further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and
the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor
Indemnitors are intended third party beneficiaries of this Subsection 8.6 and shall have the right, power and authority to enforce the provisions of this Subsection 8.6 as though they were a party to this Agreement. 

  
 26 

 8.7 Right to Conduct Activities. The Company hereby agrees and acknowledges that each
of Ally Bridge MedAlpha Master Fund L.P. (together with its Affiliates), Bain Capital Life Sciences, LP (together with its Affiliates), Omega Fund VI, L.P. (together with its Affiliates), RA Capital Healthcare Fund, L.P. (together with its
Affiliates), Redmile (together with its Affiliates) and Rock Springs Capital Master Fund LP (together with its Affiliates) is a professional investment organization, and as such reviews the business plans and related proprietary information of many
enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, each of
Ally Bridge MedAlpha Master Fund L.P. (and its Affiliates), Bain Capital Life Sciences, LP (and its Affiliates), Omega Fund VI, L.P. (and its Affiliates), RA Capital Healthcare Fund, L.P. (and its Affiliates), Redmile (and its Affiliates) and Rock
Springs Capital Master Fund LP (and its Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by Ally Bridge MedAlpha Master Fund L.P. (or its Affiliates), Bain Capital Life Sciences, LP
(or its Affiliates), Omega Fund VI, L.P. (or its Affiliates), RA Capital Healthcare Fund, L.P. (or its Affiliates), Redmile (or its Affiliates) or Rock Springs Capital Master Fund LP (or its Affiliates), respectively, in any entity competitive with
the Company, or (ii) actions taken by any partner, officer, employee or other representative of Ally Bridge MedAlpha Master Fund L.P. (or its Affiliates), Bain Capital Life Sciences, LP (or its Affiliates), Omega Fund VI, L.P. (or its
Affiliates), RA Capital Healthcare Fund, L.P. (or its Affiliates), Redmile (or its Affiliates) or Rock Springs Capital Master Fund LP (or its Affiliates), respectively, to assist any such competitive company, whether or not such action was taken as
a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability
associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the
Company. 
 9. Agreement Among the Company, the Investors and the Founder. 

9.1 Right of First Refusal. 

(a) Grant. Subject to the terms of Section 10 below, each Restricted Holder hereby unconditionally and
irrevocably grants to the Company, a Right of First Refusal to purchase all or any portion of Transfer Stock that such Restricted Holder may propose to transfer in a Proposed Restricted Holder Transfer, at the same price and on the same terms and
conditions as those offered to the Prospective Transferee. 
 (b) Notice. Each Restricted Holder proposing to make a Proposed
Restricted Holder Transfer must deliver a Proposed Transfer Notice to the Company and each Rights Holder not later than forty-five (45) days prior to the consummation of such Proposed Restricted Holder Transfer. Such Proposed Transfer Notice
shall contain the material terms and conditions (including price and form of consideration) of the Proposed Restricted Holder Transfer, the identity of the Prospective Transferee and the intended date of the Proposed Restricted Holder Transfer. To
exercise its Right of First Refusal under this Section 9, the Company must deliver a Company Notice to the selling Restricted Holder within fifteen (15) days after receipt of the Proposed Transfer Notice. In the event
of a conflict between this Agreement and any other agreement that may have been entered into by a Restricted Holder with the Company that contains a preexisting right of first refusal, the Company and the Restricted Holder acknowledge and agree that
the terms of this Agreement shall control and the preexisting right of first refusal shall be deemed satisfied by compliance with Subsection 9.1(a) and this Subsection 9.1(b). 

  
 27 

 (c) Grant of Secondary Refusal Right. Subject to the terms of
Section 10 below, each Restricted Holder hereby unconditionally and irrevocably grants to the Rights Holders a Secondary Refusal Right to purchase all or any portion of the Transfer Stock not purchased by the Company
pursuant to the Right of First Refusal, as provided in this Subsection 9.1(c). If the Company does not intend to exercise its Right of First Refusal with respect to all Transfer Stock subject to a Proposed Restricted Holder Transfer, the
Company must deliver a Secondary Notice to the selling Restricted Holder and to each Rights Holder to that effect no later than fifteen (15) days after the selling Restricted Holder delivers the Proposed Transfer Notice to the Company. To
exercise its Secondary Refusal Right, a Rights Holder must deliver a Rights Holder Notice to the selling Restricted Holder and the Company within ten (10) days after the Company’s deadline for its delivery of the Secondary Notice as
provided in the preceding sentence. 
 (d) Undersubscription of Transfer Stock. If options to purchase have been exercised by the
Company and the Rights Holders with respect to some but not all of the Transfer Stock by the end of the ten (10) day period specified in the last sentence of Subsection 9.1(c) (the “Rights Holder Notice Period”), then
the Company shall, immediately after the expiration of the Rights Holder Notice Period, send written notice (the “Company Undersubscription Notice”) to those Rights Holders who fully exercised their Secondary Refusal Right within
the Rights Holder Notice Period (the “Exercising Rights Holders”). Each Exercising Rights Holder shall, subject to the provisions of this Subsection 9.1(d), have an additional option to purchase all or any part of the balance
of any such remaining unsubscribed shares of Transfer Stock on the terms and conditions set forth in the Proposed Transfer Notice. To exercise such option, an Exercising Rights Holder must deliver an Undersubscription Notice to the selling
Restricted Holder and the Company within ten (10) days after the expiration of the Rights Holder Notice Period. In the event there are two (2) or more such Exercising Rights Holders that choose to exercise the last-mentioned option for a
total number of remaining shares in excess of the number available, the remaining shares available for purchase under this Subsection 9.1(d) shall be allocated to such Exercising Rights Holders pro rata based on the number of shares of
Transfer Stock such Exercising Rights Holders have elected to purchase pursuant to the Secondary Refusal Right (without giving effect to any shares of Transfer Stock that any such Exercising Rights Holder has elected to purchase pursuant to the
Company Undersubscription Notice). If the options to purchase the remaining shares are exercised in full by the Exercising Rights Holders, the Company shall immediately notify all of the Exercising Rights Holders and the selling Restricted Holder of
that fact. 
 (e) Forfeiture of Rights. Notwithstanding the foregoing, if the total number of shares of Transfer Stock that the
Company and the Rights Holders have agreed to purchase in the Company Notice, Rights Holder Notices and Undersubscription Notices is less than the total number of shares of Transfer Stock, then the Company and the Rights Holders shall be deemed to
have forfeited any right to purchase such Transfer Stock, and the selling Restricted Holder shall be free to sell all, but not less than all, of the Transfer Stock to the Prospective Transferee on terms and conditions substantially similar to (and
in no event more favorable than) the terms and conditions set forth in the Proposed Transfer Notice, it being understood and agreed that (i) any such sale or transfer shall be subject to the other terms and restrictions of this Agreement,
including, without limitation, the terms and restrictions set forth in Subsections 9.2 and 11.1; (ii) 

  
 28 

 
any future Proposed Restricted Holder Transfer shall remain subject to the terms and conditions of this Agreement, including this Section 9; and (iii) such sale
shall be consummated within sixty (60) days after receipt of the Proposed Transfer Notice by the Company and, if such sale is not consummated within such sixty (60) day period, such sale shall again become subject to the Right of First
Refusal and Secondary Refusal Right on the terms set forth herein. 
 (f) Consideration; Closing. If the consideration proposed to be
paid for the Transfer Stock is in property, services or other non-cash consideration, the fair market value of the consideration shall be as determined in good faith by the Board and as set forth in the
Company Notice. If the Company or any Rights Holder cannot for any reason pay for the Transfer Stock in the same form of non-cash consideration, the Company or such Rights Holder may pay the cash value
equivalent thereof, as determined in good faith by the Board and as set forth in the Company Notice. The closing of the purchase of Transfer Stock by the Company and the Rights Holders shall take place, and all payments from the Company and the
Rights Holders shall have been delivered to the selling Restricted Holder, by the later of (i) the date specified in the Proposed Transfer Notice as the intended date of the Proposed Restricted Holder Transfer; and (ii) sixty (60) days
after delivery of the Proposed Transfer Notice. 
 9.2 Right of Co-Sale. 

(a) Exercise of Right. If the Transfer Stock subject to a Proposed Restricted Holder Transfer is not purchased pursuant to Subsection
9.1 above and thereafter is to be sold to a Prospective Transferee, each respective Rights Holder may elect to exercise its Right of Co-Sale and participate on a pro rata basis in the Proposed Restricted
Holder Transfer as set forth in Subsection 9.2(b) below and, subject to Subsection 9.2(d), otherwise on the same terms and conditions specified in the Proposed Transfer Notice. Each Rights Holder who desires to exercise its Right of Co-Sale (each, a “Participating Rights Holder”) must give the selling Restricted Holder written notice to that effect within fifteen (15) days after the deadline for delivery of the Secondary
Notice described above, and upon giving such notice such Participating Rights Holder shall be deemed to have effectively exercised the Right of Co-Sale. 

(b) Shares Includable. Each Participating Rights Holder may include in the Proposed Restricted Holder Transfer all or any part of such
Participating Rights Holder’s Capital Stock equal to the product obtained by multiplying (i) the aggregate number of shares of Transfer Stock subject to the Proposed Restricted Holder Transfer by (ii) a fraction, the numerator of
which is the number of shares of Capital Stock owned by such Participating Rights Holder immediately before consummation of the Proposed Restricted Holder Transfer and the denominator of which is the total number of shares of Capital Stock owned, in
the aggregate, by all Participating Rights Holders immediately prior to the consummation of the Proposed Restricted Holder Transfer, plus the number of shares of Transfer Stock held by the selling Restricted Holder. To the extent one (1) or
more of the Participating Rights Holders exercise such right of participation in accordance with the terms and conditions set forth herein, the number of shares of Transfer Stock that the selling Restricted Holder may sell in the Proposed Restricted
Holder Transfer shall be correspondingly reduced. 

  
 29 

 (c) Purchase and Sale Agreement. The Participating Rights Holders and the selling
Restricted Holder agree that the terms and conditions of any Proposed Restricted Holder Transfer in accordance with Subsection 9.2 will be memorialized in, and governed by, a written purchase and sale agreement with the Prospective Transferee
(the “Purchase and Sale Agreement”) with customary terms and provisions for such a transaction, and the Participating Rights Holders and the selling Restricted Holder further covenant and agree to enter into such Purchase and Sale
Agreement as a condition precedent to any sale or other transfer in accordance with this Subsection 9.2. 
 (d) Allocation of
Consideration. 
 (i) Subject to Subsection 9.2(d)(ii), the aggregate consideration payable to the Participating Rights Holders
and the selling Restricted Holder shall be allocated based on the number of shares of Capital Stock sold to the Prospective Transferee by each Participating Rights Holder and the selling Restricted Holder as provided in Subsection 9.2(b),
provided that if a Participating Rights Holder wishes to sell Preferred Stock, the price set forth in the Proposed Transfer Notice shall be appropriately adjusted based on the conversion ratio of the Preferred Stock into Common Stock. 

(ii) In the event that the Proposed Restricted Holder Transfer constitutes a Stock Sale of the Company, the terms of the Purchase and Sale
Agreement shall provide that the aggregate consideration from such transfer shall be allocated to the Participating Rights Holders and the selling Restricted Holder in accordance with Sections 2.1, 2.2, 2.3 and 2.4 of Article FOURTH, Part
(B) of the Certificate of Incorporation as if (A) such transfer were a Deemed Liquidation Event (as defined in the Certificate of Incorporation), and (B) the Capital Stock sold in accordance with the Purchase and Sale Agreement were
the only Capital Stock outstanding. In the event that a portion of the aggregate consideration payable to the Participating Rights Holder(s) and selling Restricted Holder is placed into escrow, the Purchase and Sale Agreement shall provide that
(x) the portion of such consideration that is not placed in escrow (the “Initial Consideration”) shall be allocated in accordance with Sections 2.1, 2.2, 2.3 and 2.4 of Article FOURTH, Part (B) of the Certificate of
Incorporation as if the Initial Consideration were the only consideration payable in connection with such transfer, and (y) any additional consideration which becomes payable to the Participating Rights Holder(s) and selling Restricted Holder
upon release from escrow shall be allocated in accordance with Sections 2.1, 2.2, 2.3 and 2.4 of Article FOURTH, Part (B) of the Certificate of Incorporation after taking into account the previous payment of the Initial Consideration as part of
the same transfer. 
 (e) Purchase by Selling Restricted Holder; Deliveries. Notwithstanding Subsection 9.2(c) above, if any
Prospective Transferee or Transferees refuse(s) to purchase securities subject to the Right of Co-Sale from any Participating Rights Holder or upon the failure to negotiate in good faith a Purchase and Sale
Agreement reasonably satisfactory to the Participating Rights Holders, no Restricted Holder may sell any Transfer Stock to such Prospective Transferee or Transferees unless and until, simultaneously with such sale, such Restricted Holder purchases
all securities subject to the Right of Co-Sale from such Participating Rights Holder on the same terms and conditions (including the proposed purchase price) as set forth in the Proposed Transfer Notice and as
provided in Subsection 9.2(d)(i); provided, however, if such sale constitutes a Stock Sale of the Company, the aggregate consideration paid by the Selling Restricted Holder to such Participating Rights Holders, shall be
allocated in accordance with Subsection 9.2(d)(ii) and further, the portion of the aggregate consideration received by the selling Restricted Holder from 

  
 30 

 
the Transferees that exceeds the aggregate consideration payable by the selling Restricted Holder to such Participating Rights Holders (pursuant to this sentence) shall also be allocated in
accordance with Subsection 9.2(d)(ii). In connection with such purchase by the selling Restricted Holder, such Participating Rights Holder shall deliver to the selling Restricted Holder any stock certificate or certificates, properly endorsed
for transfer, representing the Capital Stock being purchased by the selling Restricted Holder (or request that the Company effect such transfer in the name of the selling Restricted Holder). Any such shares transferred to the selling Restricted
Holder will be transferred to the Prospective Transferee against payment therefor in consummation of the sale of the Transfer Stock pursuant to the terms and conditions specified in the Proposed Transfer Notice, and the selling Restricted Holder
shall concurrently therewith remit or direct payment to each such Participating Rights Holder the portion of the aggregate consideration to which each such Participating Rights Holder is entitled by reason of its participation in such sale as
provided in this Subsection 9.2(e). 
 (f) Additional Compliance. If any Proposed Restricted Holder Transfer is not consummated
within sixty (60) days after receipt of the Proposed Transfer Notice by the Company, the Restricted Holders proposing the Proposed Restricted Holder Transfer may not sell any Transfer Stock unless they first comply in full with each provision
of this Section 9. The exercise or election not to exercise any right by any Rights Holder hereunder shall not adversely affect its right to participate in any other sales of Transfer Stock subject to this
Subsection 9.2. 
 9.3 Effect of Failure to Comply. 

(a) Transfer Void; Equitable Relief. Any Proposed Restricted Holder Transfer not made in compliance with the requirements of this
Agreement shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. Each party hereto acknowledges and agrees that any breach of this Agreement would result
in substantial harm to the other parties hereto for which monetary damages alone could not adequately compensate. Therefore, the parties hereto unconditionally and irrevocably agree that any non-breaching
party hereto shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific performance or the rescission of purchases, sales and other transfers of
Transfer Stock not made in strict compliance with this Agreement). 
 (b) Violation of First Refusal Right. If any Restricted Holder
becomes obligated to sell any Transfer Stock to the Company or any Rights Holder under this Agreement and fails to deliver such Transfer Stock in accordance with the terms of this Agreement, the Company and/or such Rights Holder may, at its option,
in addition to all other remedies it may have, send to such Restricted Holder the purchase price for such Transfer Stock as is herein specified and transfer to the name of the Company or such Rights Holder (or request that the Company effect such
transfer in the name of an Rights Holder) on the Company’s books any certificates, instruments, or book entry representing the Transfer Stock to be sold. 

(c) Violation of Co-Sale Right. If any Restricted Holder purports to sell any Transfer Stock in
contravention of the Right of Co-Sale (a “Prohibited Transfer”), each Rights Holder who desires to exercise its Right of Co-Sale under Subsection
9.2 may, in addition to such remedies as may be available by law, in equity or hereunder, require such Restricted Holder to 

  
 31 

 
purchase from such Rights Holder the type and number of shares of Capital Stock that such Rights Holder would have been entitled to sell to the Prospective Transferee had the Prohibited Transfer
been effected in compliance with the terms of Subsection 9.2. The sale will be made on the same terms, including, without limitation, as provided in Subsection 9.2(d)(i) and the first sentence of Subsection 9.2(d)(ii), as
applicable, and subject to the same conditions as would have applied had the Restricted Holder not made the Prohibited Transfer, except that the sale (including, without limitation, the delivery of the purchase price) must be made within ninety
(90) days after the Rights Holder learns of the Prohibited Transfer, as opposed to the timeframe proscribed in Subsection 9.2. Such Restricted Holder shall also reimburse each Rights Holder for any and all reasonable
and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Rights
Holder’s rights under Subsection 9.2. 
 10. Exempt Transfers. 

10.1 Notwithstanding the foregoing or anything to the contrary herein, the provisions of Subsections 9.1 and 9.2 shall not apply
(a) in the case of a Restricted Holder that is an entity, upon a transfer by such Restricted Holder to its stockholders, members, partners, other equity holders or Affiliates, (b) to a repurchase of Transfer Stock from a Key Holder by the
Company at a price no greater than that originally paid by such Key Holder for such Transfer Stock and pursuant to an agreement containing vesting and/or repurchase provisions approved by a majority of the Board, or (c) in the case of a
Restricted Holder that is a natural person or a trust, upon a transfer of Transfer Stock by such Restricted Holder made for bona fide estate planning purposes, either to one or more Immediate Family Members, or any other relative approved by the
Board, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by such Restricted Holder or any such Immediate Family Members; provided that in the
case of clause(s) (a) and (c), the Restricted Holder shall deliver prior written notice to the Rights Holders of such pledge, gift or transfer and such shares of Transfer Stock shall at all times remain subject to the terms and restrictions set
forth in this Agreement and such transferee shall, as a condition to such issuance, deliver a counterpart signature page to this Agreement as confirmation that such transferee shall be bound by all the terms and conditions of this Agreement as a
Restricted Holder (but only with respect to the securities so transferred to the transferee), including the obligations of a Restricted Holder with respect to Proposed Restricted Holder Transfers of such Transfer Stock pursuant to
Section 9; and provided further in the case of any transfer pursuant to clause (a) or (c) above, that such transfer is made pursuant to a transaction in which there is no consideration actually paid for such transfer.

 10.2 Exempted Offerings. Notwithstanding the foregoing or anything to the contrary herein, the provisions of
Section 9 shall not apply to the sale of any Transfer Stock (a) to the public in an offering pursuant to an effective registration statement under the Securities Act; or (b) pursuant to a Sale of the Company. 

10.3 Prohibited Transferees. Notwithstanding the foregoing, no Restricted Holder shall transfer any Transfer Stock to (a) any
Competitor; or (b) any customer, distributor or supplier of the Company, if the Board should determine that such transfer would result in such customer, distributor or supplier receiving information that would place the Company at a competitive
disadvantage with respect to such customer, distributor or supplier. 

  
 32 

 11. Miscellaneous. 

11.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that: (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company
is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in
a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11, in substantially the form attached hereto as Exhibit A. For the
purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or
(3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this
Agreement. Any successor or permitted assignee of any Restricted Holder, including any Prospective Transferee who purchases shares of Transfer Stock in accordance with the terms hereof, shall deliver to the Company and the Rights Holders, as a
condition to any transfer or assignment, a counterpart signature page hereto pursuant to which such successor or permitted assignee shall confirm their agreement to be subject to and bound by all of the provisions set forth in this Agreement that
were applicable to the predecessor or assignor of such successor or permitted assignee. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing
in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided herein. 
 11.2 Governing Law. This Agreement shall be governed by the internal law of the Commonwealth
of Massachusetts, with the exception of Sections 5, 6 and 7, which shall be governed by the internal law of the State of Delaware, without regard to its conflict of laws principles that would cause the application of laws of any
other jurisdiction. 
 11.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

11.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 

  
 33 

 11.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B hereto (as applicable), or to the principal office of the Company and to the attention of the Chief Executive
Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 11.5. If notice is given to the Company, a copy shall also be sent
to Latham & Watkins LLP, 27th Floor, 200 Clarendon Street, Boston, MA 02116, Attention: Peter N. Handrinos, facsimile: (617) 948-6001, email: peter.handrinos@lw.com. 

11.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company, the Founder and the Requisite Preferred Holders; provided that the Company may in its sole discretion
waive compliance with Subsection 2.11(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.11(c) shall be deemed to be a waiver); and
provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) Section 5.2(e), the last sentence of Section 1.7
(with regard to itself only), and this clause (a) may not be amended or waived without the written consent of Bain Capital Life Sciences, LP, (b) Section 7.2(d)(iii)(B) and this clause (b) may not be amended or waived without the
written consent of the holders of a majority in voting power of the outstanding shares of Series D Preferred Stock and Series D-1 Preferred Stock, voting together as a single class, (c) clause (iv) in the
first paragraph of Section 7.1 and this clause (c) may not be amended or waived without the written consent of the holders of a majority of the outstanding shares of Series D Preferred Stock, (d) clause (v) in the first paragraph of
Section 7.1 and this clause (d) may not be amended or waived without the written consent of the holders of a majority of the outstanding shares of Series D-1 Preferred Stock, (e) the last
sentence of Section 1.7 and Section 8.7 may not be amended or waived with regard to any of the Investors specifically named therein without the written consent of the applicable Investor, and this clause (e) may not be amended or
waived without the written consent of each Investor specifically named in Section 8.7, and (f) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the
written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular
transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction).
Further, this Agreement may not be amended, and no provision hereof may be waived, in each case, in any way which would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment or
waiver would have on the rights of the Investors hereunder, without also the written consent of the holders 

  
 34 

 
of at least a majority of the Shares held by the Key Holders. Any amendment, termination, or waiver effected in accordance with this Subsection 11.6 shall be binding on all parties hereto,
regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any
such term, condition, or provision. 
 11.7 Severability. In case any one or more of the provisions contained in this Agreement is for
any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed
and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 11.8 Aggregation of Stock.
All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among
themselves in any manner they deem appropriate. 
 11.9 Additional Parties. 

(a) Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Preferred Stock after the date
hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and
thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in
writing to be bound by all of the obligations as an “Investor” hereunder. 
 (b) In the event that after the date of this
Agreement, the Company enters into an agreement with any Person to issue shares of capital stock to such Person (other than to a purchaser of Preferred Stock described in Subsection 11.9(a) above), following which such Person shall hold
Shares constituting one percent (1%) or more of the Company’s then outstanding capital stock (treating for this purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or convertible
securities, as if exercised and/or converted or exchanged), then, the Company shall cause such Person, as a condition precedent to entering into such agreement, to become a party to this Agreement by executing an Adoption Agreement in the form
attached hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement as a Stockholder and thereafter such person shall be deemed a Stockholder for all purposes under this Agreement. 

11.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

  
 35 

 11.11 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

11.12 Transfers. Each transferee or assignee of any Shares subject to this Agreement shall continue to be subject to the terms hereof,
and, as a condition precedent to the Company’s recognizing such transfer, each transferee or assignee shall agree in writing to be subject to each of the terms of this Agreement by executing and delivering an Adoption Agreement substantially in
the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any transferee, such transferee shall be deemed to be a party hereto as if such transferee were the transferor and such transferee’s
signature appeared on the signature pages of this Agreement and shall be deemed to be an Investor and Stockholder, or a Key Holder and Stockholder, as applicable. The Company shall not permit the transfer of the Shares subject to this Agreement on
its books or issue a new certificate representing any such shares unless and until such transferee shall have complied with the terms of this Subsection 11.12. Each certificate instrument, or book entry representing the Shares subject to this
Agreement if issued on or after the date of this Agreement shall be notated by the Company with the legend set forth in Subsection 11.13. 

11.13 Share Certificate Legend. Each certificate, instrument, or book entry representing any Shares issued after the date hereof shall
be notated by the Company with a legend reading substantially as follows: 
 “THE SHARES REPRESENTED HEREBY ARE SUBJECT TO A FOURTH
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME (A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED
TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, INCLUDING CERTAIN RESTRICTIONS ON TRANSFER AND OWNERSHIP SET FORTH THEREIN.” 

The Company, by its execution of this Agreement, agrees that it will cause the certificates instruments, or book entry evidencing the Shares issued after the
date hereof to be notated with the legend required by this Subsection 11.13 of this Agreement, and it shall supply, free of charge, a copy of this Agreement to any holder of such Shares upon written request from such holder to the Company at
its principal office. The parties to this Agreement do hereby agree that the failure to cause the certificates, instruments, or book entry evidencing the Shares to be notated with the legend required by this Subsection 11.13 herein and/or the
failure of the Company to supply, free of charge, a copy of this Agreement as provided hereunder shall not affect the validity or enforcement of this Agreement. 

  
 36 

 11.14 Stock Splits, Stock Dividends, etc. In the event of any issuance of Shares of
the Company’s voting securities hereafter to any of the Stockholders (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such Shares shall become subject to this
Agreement and shall be endorsed with the legend set forth in Subsection 11.13. 
 11.15 Term. The terms and conditions of
Sections 5, 6, 7, 8, 9 and 10 of this Agreement shall terminate upon the earliest to occur of (a) the consummation of the IPO (other than a registration statement relating either to the sale of
securities to employees of the Company pursuant to its stock option, stock purchase or similar plan or an SEC Rule 145 transaction); or (b) the consummation of a Sale of the Company and distribution of proceeds to or escrow for the benefit of
the Stockholders in accordance with the Certificate of Incorporation, provided that the provisions of Section 7 hereof will continue after the closing of any Sale of the Company to the extent necessary to enforce the
provisions of Section 7 with respect to such Sale of the Company. 
 11.16 Specific Performance. In addition
to any and all other remedies that may be available at law in the event of any breach of this Agreement, each party to this Agreement shall be entitled to seek specific performance of the agreements and obligations of the other parties hereto under
this Agreement and to seek such other injunction or other equitable relief as may be granted by a court of competent jurisdiction. 
 11.17
Ownership. EACH RESTRICTED HOLDER REPRESENTS AND WARRANTS THAT SUCH RESTRICTED HOLDER IS THE SOLE LEGAL AND BENEFICIAL OWNER OF THE SHARES OF TRANSFER STOCK SUBJECT TO THIS AGREEMENT AND THAT NO OTHER PERSON OR ENTITY HAS ANY INTEREST IN SUCH
SHARES (OTHER THAN A COMMUNITY PROPERTY INTEREST AS TO WHICH THE HOLDER THEREOF HAS ACKNOWLEDGED AND AGREED IN WRITING TO THE RESTRICTIONS AND OBLIGATIONS HEREUNDER). 

[Remainder of Page Intentionally Left Blank] 
  

  
 37 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMPANY:
	
	ATEA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jean Pierre Sommadossi

	Name:Jean Pierre Sommadossi
	Title: Chief Executive Officer and President
	
	FOUNDER:
	
	 /s/ Jean Pierre Sommadossi

	Jean-Pierre Sommadossi, Ph.D.

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	9W INVESTMENT FUND I LP
		
	By:	 	 /s/ Brandon L. Jones

	Name:	 	Brandon L. Jones
	Title:	 	General Partner

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

					
	INVESTORS:
		
		 	ABG-ATEAB LIMITED
			
	    	 	By:	 	 /s/ Shan-Ju Yeh

		 	Name: Shan-Ju Yeh
		 	Title: Director
		
		 	ABG-ATEA LIMITED
			
		 	By:	 	 /s/ Shan-Ju Yeh

		 	Name: Shan-Ju Yeh
		 	Title: Director
		
		 	ALLY BRIDGE MEDALPHA MASTER FUND L.P.
		
		 	By: Ally Bridge MedAlpha General Partner L.P., its General Partner
		
		 	By: Ally Bridge MedAlpha GP LLC, its General Partner
			
		 	By:	 	 /s/ Fan Yu

		 	Name: Fan Yu
		 	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ADAGE CAPITAL PARTNERS, L.P.
		
	By:	 	 /s/ Dan Lehan

	Name: Dan Lehan
	Title: COO

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	AJU GROWTH & HEALTHCARE FUND
		
	By:	 	 /s/ Derek Yoon

	Name: Derek Yoon
	Title: Managing Partner
	
	AJU LIFE SCIENCE OVERSEAS EXPANSION PLATFORM FUND, LP
		
	By:	 	 /s/ Derek Yoon

	Name: Derek Yoon
	Title: Managing Partner

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ARCTIC FUNDS PLC
	
	By: Arctic Fund Management AS, the Investment Manager for Arctic Funds plc
		
	By:	 	 /s/ Torbjorn Bjerke

	Name: Torbjorn Bjerke
	Title: Portfolio Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ATEA BROOKLINE LLC
		
	By:	 	 /s/ William B. Buchanan, Jr.

	Name: William B. Buchanan, Jr.
	Title: Managing Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	BAIN CAPITAL LIFE SCIENCES FUND II, L.P.
	
	By: Bain Capital Life Sciences Investors II, LLC, its General Partner
	
	By: Bain Capital Life Sciences Investors, LLC, its Manager
		
	By:	 	 /s/ Andrew Hack

	Name: Andrew Hack
	Title: Managing Director
	
	BCIP LIFE SCIENCES ASSOCIATES, LP
	
	By: Boylston Coinvestors, LLC, its General Partner
		
	By:	 	 /s/ Andrew Hack

	Name: Andrew Hack
	Title: Authorized Signatory
	
	BAIN CAPITAL PUBLIC EQUITY GLOBAL PARTNERS FUND, L.P.
	
	By: Bain Capital Public Equity Global Investors, LLC, its General Partner
	
	By: Bain Capital Public Equity Management II, LLC, its Manager
		
	By:	 	 /s/ Joshua Ross

	Name: Joshua Ross
	Title: Managing Director
	
	BAIN CAPITAL PUBLIC EQUITY COINVEST (III), L.P.
	
	By: Bain Capital Public Equity Global Investors, LLC, its General Partner
	
	By: Bain Capital Public Equity Management II, LLC, its Manager
		
	By:	 	 /s/ Andrew S. Viens

	Name: Andrew S. Viens
	Title: Managing Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTORS:
	
	 /s/ Richard Beleson

	Richard Beleson

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	BLACKWELL PARTNERS LLC – SERIES a
		
	By:	 	 /s/ Abayomi A. Adigun

	Name: Abayomi A. Adigun
	Title: Investment Manager
		 	  DUMAC, Inc. Authorized Signatory
		
	By:	 	 /s/ Jannine M. Lall

	Name: Jannine M. Lall
	Title: Head of Finance & Controller
		 	  DUMAC, Inc. Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTORS:
	
	 /s/ David C L Chiu

	David C L Chiu

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTORS:
	
	 /s/ Chung K. Chu

	Chung K. Chu
	
	 /s/ Chung K. Chu and Jee H. Chu

	Chung K. Chu and Jee H. Chu

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	FRED E. COHEN AND CAROLYN B. KLEBANOFF TRUST
		
	By:	 	 /s/ Fred Cohen

	Name: Fred Cohen
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTORS:
	
	 /s/ Andrea Corcoran

	Andrea Corcoran

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

					
	INVESTORS:
		
	    	 	CORMORANT GLOBAL HEALTHCARE MASTER
		 	FUND, LP
		 	By: Cormorant Global Healthcare GP, LLC
		 	By: Bihua Chen, Managing Member of the GP
			
		 	By:	 	 /s/ Bihua Chen

		 	Name: Bihua Chen
		 	Title: Managing Member
		
		 	CORMORANT PRIVATE HEALTHCARE FUND I, LP
		 	By: Cormorant Private Healthcare GP, LLC
		 	By: Bihua Chen, Managing Member of the GP
			
		 	By:	 	 /s/ Bihua Chen

		 	Name: Bihua Chen
		 	Title: Managing Member
		
		 	CRMA SPV, L.P.
		 	By: Cormorant Asset Management, LP
		 	By: Bihua Chen, Managing Member of the Special Limited Partner
			
		 	By:	 	 /s/ Bihua Chen

		 	Name: Bihua Chen
		 	Title: Managing Member

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	CY CAPITAL LIMITED
		
	By:	 	 /s/ David C L CHIU

	Name: David CL CHIU
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Finance 1805 SA acting as nominee on behalf of undisclosed clients
		
	By:	 	 /s/ Gérald Formaz

	Name: Gérald Formaz
	Title: Attorney
		
	By:	 	 /s/ Frédéric Bertrand-Verdier

	Name: Frédéric Bertrand-Verdier
	Title: Attorney

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	HARNAT CAPITAL HOLDINGS LIMITED
		
	By:	 	 /s/ David C L CHIU

	Name: David CL CHIU
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	JAMBOREE INVESTMENTS LIMITED
		
	By:	 	 /s/ David C L CHIU

	Name: David CL CHIU
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	JEM FAMILY PARTNERSHIP, LLC
		
	By:	 	 /s/ Laurence Blumberg, M.D.

	Name: Laurence Blumberg, M.D.
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	JPM PARTNERS LLC
		
	By:	 	 /s/ Jean-Pierre Sommadossi

	Name: Jean-Pierre Sommadossi
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTORS:
	
	 /s/ Mark McDade

	Mark McDade

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	For and on behalf of
	MORNINGSIDE VENTURE INVESTMENTS LIMITED
		
	By:	 	 /s/ Jill Marie Franklin/Frances Anne Elizabeth Richard

	Name: Jill Marie Franklin/Frances Anne Elizabeth Richard
	Title: Authorized Signatures

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	MARC & POLLY MURPHY REVOCABLE FAMILY TRUST DATED MARCH 13, 2002
		
	By:	 	 /s/ Polly A. Murphy

	Name: Polly A. Murphy
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	 /s/ Robert L. Murphy

	Robert L. Murphy
	JEAN-PIERRE SOMMADOSSI TRUST 12/10/98
		
	By:	 	 /s/ Robert L. Murphy

	Name: Robert L. Murphy
	Title: Trustee
	
	ROBERT L. MURPHY, TRUSTEE OF THE ROBERT LEO MURPHY GRANTOR TRUST
		
	By:	 	 /s/ Robert L. Murphy

	Name: Robert L. Murphy
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	NEW EMERGING MEDICAL OPPORTUNITIES FUND II by its investment manager
		
	By:	 	 /s/ Michael Sjöström

	Name: Michael Sjöström
	Title: Senior Partner
	
	 Sectoral Asset Management
 1010
Sherbrooke Str. W.

	Suite 1810
	Montreal, QC, H3A 2R7
	Canada

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	NEW EMERGING MEDICAL OPPORTUNITIES FUND IV
	
	By: Sectoral Asset Management Inc., its Manager
		
	By:	 	 /s/ Michael Sjöström

	Name: Michael Sjöström
	Title: Senior Partner

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	OMEGA FUND VI, L.P.
	
	By: Omega Fund VI GP, L.P., its General Partner
	
	By: Omega Fund VI GP Manager, Ltd., its General Partner
		
	By:	 	 /s/ Anne Mari-Paster

	Name:	 	Anne Mari-Paster
	Title:	 	Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
		
	By:	 	 /s/ James H. Mannix

	Name:	 	James H. Mannix
	Title:	 	C.O.O.

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Healthcare Fund GP, LLC, its General Partner
		
	By:	 	 /s/ Peter Kolchinsky

	Name:	 	Peter Kolchinsky
	Title:	 	Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	RA CAPITAL NEXUS FUND, L.P.
	
	By: RA Capital Nexus Fund GP, LLC, its General Partner
		
	By:	 	 /s/ Peter Kolchinsky

	Name:	 	Peter Kolchinsky
	Title:	 	Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	REDMILE BIOPHARMA INVESTMENTS II, L.P.
	
	By: Redmile Biopharma Investments II (GP), LLC its General Partner
		
	By:	 	 /s/ Joshua Garcia

	Name:	 	Joshua Garcia
	Title:	 	CFO and Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ROCK SPRINGS CAPITAL MASTER FUND LP
	
	By: Rock Springs General Partner LLC, its General Partner
		
	By:	 	 /s/ Kris Jenner

	Name:	 	Kris Jenner
	Title:	 	Manager

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	T. ROWE PRICE HEALTH SCIENCES FUND, INC.
	
	TD MUTUAL FUNDS – TD HEALTH SCIENCES FUND
	
	VALIC COMPANY I – HEALTH SCIENCES FUND
	
	T. ROWE PRICE HEALTH SCIENCES PORTFOLIO
	
	Each account, severally and not jointly
	
	By: T. Rowe Price Associates, Inc.,
	Investment Adviser or Subadvisor, as applicable
		
	By:	 	 /s/ Andrew Baek

 
			
	Name:	 	Andrew Baek
	Title:	 	Vice President

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTORS:
	
	 /s/ Marie M. Warburg

	Marie Warburg

 
	
	INVESTORS:
	
	  

	Jean-Marc Allaire
	
	  

	Jean Luc Allavena
	
	  

	Khalil Michel Amiouni
	
	AMP FAMILY PARTNERSHIP III, LP
	
	By: _____________________________________________
	Name:
	Title:
	
	____________________________________________
	Josiah T. Austin
	
	BERDON VENTURE ASSOCIATES LLC
	
	By: _____________________________________________
	Name:
	Title:
	
	 /s/ Franklin M. Berger

	Franklin M. Berger
	
	  

	John G. Bradley

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	WESTLAND PROMENADE INVESTMENT INC.
		
	By:	 	 /s/ David C L CHIU

			
	Name:	 	David CL CHIU
	Title:	 	Director

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	WINDSOR SQUARE INVESTMENT HOLDING INC.
		
	By:	 	 /s/ David C L CHIU

			
	Name:	 	David CL CHIU
	Title:	 	Director

 
			
	INVESTORS:
	
	KATO INVESTMENTS, LLC
		
	By:	 	
                 

	Name:
	Title:
	
	  

	John Kellenyi
	
	 /s/ Joong Kil Kim

	Joong Kil Kim
	
	 /s/ Sung Koo Kim

	Sung Koo Kim
	
	  

	Mario Kozma
	
	  

	Klaus Kretschmer
	
	  

	Robert Masters
	
	  

	Blandine Medecin

 
	
	INVESTORS:
	
	9W INVESTMENT FUND I LP
	
	By: ______________________________________________
	Name:
	Title:
	
	BROOKLINE SPECIAL SITUATIONS FUND, LLC
	
	By: ______________________________________________
	Name:
	Title:
	
	CARINA LEVINTOFF,
	TRUSTEE OF THE CARINA LEVINTOFF TRUST
	
	By: ______________________________________________
	Name:
	Title:
	
	 /s/ Susan Chu Walley

	Susan Chu Walley
	
	 /s/ Chung K. Chu

	Chung K. Chu
	
	 /s/ Jaclyn Chu

	Jaclyn Chu
	
	  

	Andrea J. Corcoran

 SCHEDULE A 

Investors 
 9W Investment Fund I LP 

Attn: Erik M.W. Caspersen or Brandon L. Jones 
 46 White Street #1

 New York, NY 10012 

ABG-AteaB Limited 
 Unit
3002-3004 30/F Gloucester Tower 
 The Landmark 
 15
Queen’s Road 
 Central Hong Kong 
 ABG-ATEA Limited 
 PO Box 173 

Kingston Chambers, British Virgin Islands MC275203 
 Ally Bridge
MedAlpha Master Fund 
 Room 3002-3004, 30th Floor, Gloucester Tower, The Landmark, 15 Queens Road Central, 

Hong Kong 
 Attn: Frank Yu 

Tel: +852 3121 9688 
 Email: frank.yu@ally-bridge.com 

Pauline Abou Gergi 
 [XXX] 

[XXX] 
 [XXX] 

Mark Afrasiabi 
 [XXX] 

[XXX] 
 AJU Growth and Healthcare Fund 

c/o AJU IB Investment Co., Ltd. 
 Attn: JT Won Kim, CEO 

201 Teheran-ro 
 5th Floor

 Gangnum-gu, Seoul, Korean 06141 

AJU Life Science Overseas Expansion Platform Fund, LP 
 Attn:
Jung Kyoo Yang 
 4F AJU Bldg 
 Yeoksam-dong 

Gangnam-gu, Seoul, South Korea 

 Aju Pharm Co., Ltd. 

662 Garden Circle 
 Statham, GA 30666 

Jean-Marc Allaire 
 [XXX] 

[XXX] 
 Jean Luc Allavena 

[XXX] 
 [XXX] 

Khalil Michel Amiouni 
 [XXX] 

[XXX] 
 [XXX] 

[XXX] 
 AMP Family Partnership III, LP 

Attn: Art Pappas 
 [XXX] 

[XXX] 
 ATEA-Brookline LLC 

509 Madison Avenue – Suite 1006 
 New York NY 10022 

Josiah T. Austin 
 [XXX] 

[XXX] 
 Berdon Venture Associates LLC 

37 Westerleigh Road 
 Purchase, NY 10577 

Franklin M. Berger 
 [XXX] 

[XXX] 
 [XXX] 

Catherine Bettis 
 [XXX] 

[XXX] 

 John G. Bradley 

[XXX] 
 [XXX] 

Brookline Special Situations Fund, LLC 
 2501 20th Place, South

 Suite 275 
 Attn: Madding King, III 

Birmingham, AL 35223 
 Carina Levintoff, Trustee of The Carina
Levintoff Trust 
 [XXX] 
 [XXX] 

David CL Chiu 
 [XXX] 

[XXX] 
 [XXX] 

Susan Chu Walley 
 [XXX] 

[XXX] 
 Chung K. Chu 

[XXX] 
 [XXX] 

Chung K. Chu and Jee H. Chu 
 [XXX] 

[XXX] 
 Jaclyn Chu 

[XXX] 
 [XXX] 

John A. Coleman 
 [XXX] 

[XXX] 
 [XXX] 

Andrea J. Corcoran 
 [XXX] 

[XXX] 

 Cormorant Global Healthcare Master Fund, LP 

Attn: Bihua Chen 
 200 Clarendon Street, 52nd Floor 
 Boston, MA 02116 

Cormorant Private Healthcare Fund I, LP 
 Attn: Bihua Chen 

200 Clarendon Street, 52nd Floor 

Boston, MA 02116 
 CRMA SPV, L.P. 

PO Box 309 
 Ugland House 

Grand Cayman, Cayman Islands KY1-1104 

CY Capital Limited 
 4/F, Acme Building 

22 Nanking Street 
 Yaumatei, Kowloon, Hong Kong 

Thomas M. Fitzgerald, III 
 [XXX] 

[XXX] 
 Robert Flammang 

[XXX] 
 [XXX] 

Ellen Friedler 
 [XXX] 

[XXX] 
 Steven J. Gilson 

[XXX] 
 [XXX] 

The James S. Ginsburg Dynasty Trust 
 [XXX] 

Glencoe IL 60022 
 Harnat Capital Holdings Limited 

4/F, Acme Building 
 22 Nanking Street 

Yaumatei, Kowloon, Hong Kong 

 Jimmie Harvey 

[XXX] 
 [XXX] 

Helms Family Trust 
 [XXX] 

[XXX] 
 Hessler Finance Limited 

Marcy Bldg 2nd Fl, Purcell Estate 
 PO Box 2416, Road Town,
Tortola BVI 
 c/o Nextgen Financial Advisors 
 Via Guisan 6, PO
Box 20 
 6902 Lugano Switzerland 
 Roman Ivanov 

[XXX] 
 [XXX] 

Jamboree Investments Limited 
 4/F, Acme Building 

22 Nanking Street 
 Yaumatei, Kowloon, Hong Kong 

Jean-Pierre Sommadossi Irrevocable Trust 12/10/98 
 [XXX] 

[XXX] 
 JPM Partners LLC 

[XXX] 
 [XXX] 

Kato Investments, LLC 
 1494 Treeline Drive 

Malvern, PA 19355 
 John Kellenyi 

[XXX] 
 [XXX] 

Joong Kil Kim 
 [XXX] 

[XXX] 

 Sung Koo Kim 

[XXX] 
 [XXX] 

Mario Kozma 
 [XXX] 

[XXX] 
 Klaus Kretschmer 

[XXX] 
 [XXX] 

Laurence Lytton 
 [XXX] 

[XXX] 
 Robert Masters 

[XXX] 
 [XXX] 

Charles S. Magolske 
 [XXX] 

[XXX] 
 Peter A. Magolske 

[XXX] 
 [XXX] 

Blandine Medecin 
 [XXX] 

[XXX] 
 Morningside Venture Investments Limited 

Attn: Louise Mary Garbarino 
 2nd Floor, Le Prince de Galles, 3-5 
 Avenue des Citronniers 

Monaco MC 98000 
 Robert L. Murphy 

[XXX] 
 [XXX] 

Campbell Murray 
 [XXX] 

[XXX] 

 New Emerging Medical Opportunities Fund II 

c/o Codan Trust Company (Cayman) Limited 
 PO Bx 2681 Cricket Sq,
Hutchkins Dr. 
 Attn: Michael Sjostrom 
 Grand Cayman, Cayman
Islands KY1-1111 
 New Emerging Medical Opportunities Fund IV SCSp 

Sectoral Asset Management 
 1010 Sherbrooke St West, suite 1610

 Montreal, QC CANADA H3A 2R7 
 Tel: +1 514 940 8083

Email: francois@sectoral.com 
 Robert Niecestro 

[XXX] 
 [XXX] 

[XXX] 
 Orderspeak Holding Limited Karava 2 

Attn: Patricia Haddad Abouhalka 
 Ergates , Nicosia, Cyprus 2643

 Ryan Pearson 
 [XXX] 

[XXX] 
 The Ryan Pearson & Brittany McQuarry Pearson as co-trustees of the 
 Ryan & Brittany Pearson Living Trust 

[XXX] 
 [XXX] 

PharmaPros LLC 
 Kenneth D. Pearsen 

6467 Main Street 
 Williamsville, NY 14221 

RAQ, LLC 
 3 Columbus Circle, 15th Floor 

Attn: Lindsay A. Rosenwald, MD 
 New York, NY 10019 

Reinfrank Living Trust dtd 6/13/95 
 [XXX] 

[XXX] 

 Jay Prystawosky, Trustee of the Rey Family Trust 

[XXX] 
 [XXX] 

RMI Investments S.A.R.L. 
 7, rue Robert Stimper 

Luxembourg, L-2557 

Lindsay A. Rosenwald 
 [XXX] 

[XXX] 
 Samambia Investments Ltd 

The Lake Building, Suite 120, 
 Wickhams Cays, Road Town, Torts,
BVI 
 Satterfield Vintage Investments, L.P. 
 571 McDonald
Road, Rockwall, Texas 75032 
 Mail correspondence: 2609 Caldwell Mill Lane, Mountain Brook, AL 35243 

Carl and Toni Sadowsky, Tenants by Entirety 
 [XXX] 

[XXX] 
 [XXX] 

Nicholas S. Sadowsky 
 [XXX] 

[XXX] 
 Richard A. Smith 

[XXX] 
 [XXX] 

Starlight Investment Holdings Limited (Anguilla) 
 9 Burrard
Street Heritage Suite 
 The Valley, Anguilla 
 Stefan P. and
Jane R. Shoup as Trustees of the Shoup Revocable Trust U/A/D 4/29/03 
 [XXX] 

[XXX] 
 John Sonnier 

[XXX] 
 [XXX] 

 Striker Asia Opportunities Fund Corporation 

Attn: Huen Chung or Yuen Ian c/o Campbell Corporate Services Limited 

Willow House Cricket Square, 4th Floor 
 PO Box 268 

Grand Cayman, Cayman Islands KY1-1104 

Goran Strokirk Living Trust (08/27/2002) 
 [XXX] 

[XXX] 
 Sally H. Sullivan 

[XXX] 
 [XXX] 

Tisu Investments Limited 
 Bert K. Waits 

306 Wild Olive Lane 
 Longwood, FL 32799 

John F. Vavricka Deed of Trust 
 [XXX] 

[XXX] 
 Bert K. Waits 

[XXX] 
 [XXX] 

Marie M. Warburg 
 [XXX] 

[XXX] 
 Westland Promenade Investment Inc. 

4/F, Acme Building 
 22 Nanking Street 

Yaumatei, Kowloon, Hong Kong 
 Steven J. Wice 

[XXX] 
 [XXX] 

Widder Family Limited Partnership 
 PO Box 676250 

Attn: M. Jacqueline Johnson 
 Santa Fe, CA 92067 

 Patrick S. Wilmerding 

[XXX] 
 [XXX] 

Windsor Square Investment Holding Inc. 
 4/F, Acme Building 

22 Nanking Street 
 Yaumatei, Kowloon, Hong Kong 

The Diana Wu Family Trust 
 [XXX] 

[XXX] 
 Finance 1805 S.A., acting as nominee 

60, Route des Acacias 
 1227 Carouge, Geneva 

Switzerland 
 Valence Helix Investments II LLC 

Attn: Eric W. Roberts Manager 
 590 Madison Avenue, 21st Floor 
 New York, NY 10022 

Ernest W. Moody Revocable Trust 
 [XXX] 

[XXX] 
 [XXX] 

Bain Capital Life Sciences Fund II, L.P. 
 c/o Bain Capital Life
Sciences, LP 
 200 Clarendon Street 
 Boston, MA 02116 

Attn: Andrew Hack 
 Electronic Mail: AHack@BainCapital.com 

BCIP Life Sciences Associates, LP 
 c/o Bain Capital Life
Sciences, LP 
 200 Clarendon Street 
 Boston, MA 02116 

Attn: Andrew Hack 
 Electronic Mail: AHack@BainCapital.com 

Bain Capital Public Equity Coinvest (III), L.P. 
 c/o Bain
Capital Life Sciences, LP 
 200 Clarendon Street 
 Boston, MA
02116 
 Attn: Andrew Viens 
 Electronic Mail:
AViens@BainCapital.com 

 Bain Capital Public Equity Global Partners Fund, L.P. 

200 Clarendon Street 
 Boston, MA 02116 

Attn: Josh Ross 
 Email: JRoss@BainCapital.com 

Adage Capital Partners, L.P. 
 Adage Capital Management, L.P.

 200 Clarendon Street, 52nd FL 
 Boston, MA 02116 

Attn: Dan Lehan COO 
 Tel: (617)
867-2543 
 Email: djl@adagecapital.com 

Arctic Funds plc 
 Regeringsgatan 38, SE-11156 
 Stockholm, Sweden 

Attn: Torbjorn Bjerke 
 Tel: +46727444158 

Email: torbjorn.bjerke@arctic.com 
 Richard Beleson 

[XXX] 
 [XXX] 

[XXX] 
 [XXX] 

[XXX] 
 Fred E. Cohen and Carolyn B. Klebanoff Trust 

[XXX] 
 [XXX] 

[XXX] 
 JEM Family Partnership, LLC 

[XXX] 
 [XXX] 

[XXX][XXX] 
 Marc & Polly Murphy Revocable Family Trust
dated March 13, 2002 
 [XXX] 
 [XXX] 

[XXX] 

 Omega Fund VI, L.P. 

888 Boylston Street 
 Suite 1111 

Boston, MA 02199 
 Attn: General Counsel 

Tel: 617-512-1989 

Email : dac@omegafunds.com 
 Perceptive Life Sciences Master
Fund LTD 
 51 Astor Place, 10th floor 
 New York NY 10003 

Attn: James H. Mannix, COO 
 Tel: 646 205 5300 

Email: james@perceptivelife.com 
 RA Capital Healthcare Fund,
L.P. 
 200 Berkley Street 
 18th Floor 
 Boston MA 02116 

Tel: 617-778-2500 

Email: legal@racap.com 
 Blackwell Partners LLC – Series A

 280 S. Mangum Street, Suite 210 
 Durham, NC 27701 

Attn: Jannie Lall 
 Tel: 617-778-2500 
 Email: legal@racap.com 

RA Capital Nexus Fund, L.P. 
 200 Berkley Street 

18th Floor 

Boston MA 02116 
 Tel: 617-778-2500 
 Email: legal@racap.com 

Redmile Biopharma Investments II, L.P. 
 One Letterman Drive,
Suite D3-300 
 The Presidio, San Francisco, CA 94129 

Tel: (415) 844-2604 

Email: operations@redmilegrp.com 

 Rock Springs Capital Master Fund LP 

650 South Exeter Street, Suite 1070 
 Baltimore MD 21202 

Attn: General Counsel 
 Email: kris@rockspringscapital.com,
ops@rockspringscapital.com, daphne@rockspringscapital.com, and jill@rockspringscapital.com 
 Four Pines Master Fund LP 

650 South Exeter Street, Suite 1070 
 Baltimore MD 21202 

Attn: General Counsel 
 Email: kris@rockspringscapital.com,
ops@rockspringscapital.com, daphne@rockspringscapital.com, and jill@rockspringscapital.com 
 T. Rowe Price Health Sciences Fund, Inc. 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn.: Andrew Baek, Vice President 

Phone: 410-345-2090 

E-mail: andrew.baek@troweprice.com 

TD Mutual Funds—TD Health Sciences Fund 
 T. Rowe Price
Associates, Inc. 
 100 East Pratt Street 
 Baltimore, MD 21202

 Attn.: Andrew Baek, Vice President 
 Phone: 410-345-2090 
 E-mail:
andrew.baek@troweprice.com 
 VALIC Company I—Health Sciences Fund 

T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn.: Andrew Baek, Vice President 

Phone: 410-345-2090 

E-mail: andrew.baek@troweprice.com 

T. Rowe Price Health Sciences Portfolio 
 T. Rowe Price
Associates, Inc. 
 100 East Pratt Street 
 Baltimore, MD 21202

 Attn.: Andrew Baek, Vice President 
 Phone: 410-345-2090 
 E-mail:
andrew.baek@troweprice.com 

 Mark McDade 

[XXX] 
 [XXX] 

[XXX] 
 [XXX] 

 SCHEDULE B 

Key Holders 
 JPM Partners LLC 

[XXX] 
 [XXX] 

Jean-Pierre Sommadossi Trust 12/10/98 
 [XXX] 

[XXX] 
 Chung K. Chu 

[XXX] 
 [XXX] 

 EXHIBIT A 

ADOPTION AGREEMENT 
 This
Adoption Agreement (“Adoption Agreement”) is executed on
                            , 20__, by the undersigned (the “Holder”) pursuant to the
terms of that certain Fourth Amended and Restated Stockholders Agreement dated as of
                            , 2020 (the “Agreement”), by and among the Atea
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and certain of its stockholders, as such Agreement may be amended or amended and restated hereafter. Capitalized terms used but not defined in this Adoption Agreement
shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Holder agrees as follows. 

1.1 Acknowledgement. Holder acknowledges that Holder is acquiring certain shares of the capital stock of the Company (the
“Stock”)[ or options, warrants, or other rights to purchase such Stock (the “Options”)], for one of the following reasons (Check the correct box): 

 

	 	☐	 As a transferee of Shares from a party in such party’s capacity as an “Investor” bound by the
Agreement, and after such transfer, Holder shall be considered an “Investor” and a “Stockholder” for all purposes of the Agreement. 

  

	 	☐	 As a transferee of Shares from a party in such party’s capacity as a “Key Holder” bound by the
Agreement, and after such transfer, Holder shall be considered a “Key Holder” and a “Stockholder” for all purposes of the Agreement. 

  

	 	☐	 As a new Investor in accordance with Subsection 11.9(a) of the Agreement, in which case Holder will be
an “Investor” and a “Stockholder” for all purposes of the Agreement. 

  

	 	☐	 In accordance with Subsection 11.9(b) of the Agreement, as a new party who is not a new Investor, in
which case Holder will be a “Stockholder” for all purposes of the Agreement. 

 1.2 Agreement. Holder
hereby (a) agrees that the Stock [Options], and any other shares of capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement and (b) adopts the Agreement with
the same force and effect as if Holder were originally a party thereto. 
 1.3 Notice. Any notice required or permitted by the
Agreement shall be given to Holder at the address or facsimile number listed below Holder’s signature hereto. 
  

			
		
	HOLDER:
                                        
                                	  	ACCEPTED AND AGREED:
		
	                                      
                                         
             	  	ATEA PHARMACEUTICALS, INC.
	Name of Signatory	  	
		
	Address:
                                         
                                    	  	By:
                                         
                   
		
	                                      
                                         
             	  	Name:
                                         
                   
		
	Facsimile Number:
                                         
                   	  	Title:
                                         
                   

 ATEA PHARMACEUTICALS, INC. 

AMENDMENT NO. 1 TO FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

This AMENDMENT NO. 1 TO FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (“Amendment”), dated as of August 17, 2020,
amends that certain Fourth Amended and Restated Stockholders Agreement, dated as of May 19, 2020, by and among Atea Pharmaceuticals, Inc., a Delaware corporation, the Founder (as defined in the Stockholders Agreement) and the Stockholders
identified therein (the “Stockholders Agreement”). Capitalized terms used and not defined herein shall have the meanings set forth in the Stockholders Agreement. 

WHEREAS, the Stockholders Agreement provides, among other things, that each Stockholder agrees to vote, or cause to be voted, all Shares owned
by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board of Directors of the Company (the “Board”)
shall be set at and remain at nine members, and sets forth the agreement of the Stockholders with respect to voting for the election of individuals to the Board; 

WHEREAS, the Company, the Founder and the Requisite Preferred Holders (as defined in the Stockholders Agreement) desire to amend the
Stockholders Agreement to set the size of the Board at eleven directors and to increase the number of Independent Designees to five and designate Polly Murphy as an Independent Designee and leave one seat vacant; and 

WHEREAS, Subsection 11.6 of the Stockholders Agreement provides that the Stockholders Agreement may be amended with the written consent of
(i) the Company, (ii) the Founder and (iii) the Requisite Preferred Holders. 
 NOW, THEREFORE, in consideration of the
mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company, the Founder and the undersigned, who constitute the Requisite Preferred Stockholders, hereby
agree as follows: 
 1. Section 5.1 of the Stockholders Agreement is hereby amended and restated in its entirety to read as follows: 

“5.1 Size of the Board. Each Stockholder agrees to vote, or cause to be voted, all Shares (as defined below) owned
by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and remain at eleven (11) directors and may
be increased only with the written consent of the Founder Holders and the Requisite Preferred Holders.” 
  

 2. Section 5.2(g) of the Stockholders Agreement is hereby amended and restated in its
entirety to read as follows: 
 “(g) Five (5) persons who are each not otherwise an Affiliate of the Company or of
any Stockholder and who are mutually acceptable to (i) the Founder and (ii) the holders of a majority in voting power of the outstanding shares of Preferred Stock (the “Independent Designees”), who shall initially be
Franklin Berger, Bruce Polsky, Bruno Lucidi and Polly Murphy, and one seat shall initially be vacant.” 
 3. Entire Agreement.
The Stockholders Agreement, as amended by this Amendment, contains the entire agreement among the parties with respect to the subject matter thereof and amends, restates and supersedes all prior and contemporaneous arrangements or understandings
with respect thereto. 
 4. Effectiveness. Each reference in the Stockholders Agreement to “this Agreement,”
“hereunder,” “hereof,” “herein” or words of like import, and each reference in the other documents entered into in connection with the Stockholders Agreement, shall mean and be a reference to the Stockholders Agreement,
as amended hereby. Except as specifically amended above, the Stockholders Agreement shall remain in full force and effect and is hereby ratified and confirmed. 

5. Governing Law. This Amendment and any controversy arising out of or relating to this Amendment shall be governed by and construed in
accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6. Counterpart Signature Pages. This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

[Remainder of Page Intentionally Left Blank] 
  

  
 - 2 - 

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto as of the day and
year first above written. 
  

			
	ATEA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jean-Pierre Sommadossi, Ph.D.

	Name:	 	Jean-Pierre Sommadossi, Ph.D.
	Title:	 	Chief Executive Officer and President
	
	FOUNDER:
	
	 /s/ Jean-Pierre Sommadossi, Ph.D.

	Jean-Pierre Sommadossi, Ph.D.

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto as of the day and
year first above written. 
  

			
	INVESTORS:
	
	9W INVESTMENT FUND I LP
		
	By:	 	 /s/ Brandon L. Jones

	Name:	 	Brandon L. Jones
	Title:	 	Authorized
	
	ABG-ATEAB LIMITED
		
	By:	 	 /s/ Shan-ju YEH

	Name:	 	Shan-ju YEH
	Title:	 	Director
	
	ABG-ATEA LIMITED
		
	By:	 	 /s/ Shan-ju YEH

	Name:	 	Shan-ju YEH
	Title:	 	Director
	
	  

	Pauline Abou Gergi

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	AJU LIFE SCIENCE OVERSEAS EXPANSION PLATFORM FUND, LP

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	

 
			
	
	AJU PHARM CO., LTD.

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  

	Jean-Marc Allaire
	
	  

	Jean Luc Allavena
	
	  

	Khalil Michel Amiouni
	
	AMP FAMILY PARTNERSHIP III, LP

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	
	
	  

	Josiah T. Austin
	
	BERDON VENTURE ASSOCIATES LLC

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	
	
	  

	Franklin M. Berger
	
	  

	John G. Bradley

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	BROOKLINE SPECIAL SITUATIONS FUND, LLC

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	CARINA LEVINTOFF, TRUSTEE OF THE CARINA LEVINTOFF TRUST

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	  

	Jaclyn Chu
	
	  

	Thomas M. Fitzgerald III
	
	  

	Robert Flammang
	
	  

	Steven J. Gilson
	
	  

	Jimmie Harvey

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	HESSLER FINANCE LIMITED

 
			
		
	By:	 	
             

 
			
	Name:
	Title:
	
	  

	Roman Ivanov
	
	JAY PRYSTAWOSKY, TRUSTEE OF THE REY FAMILY TRUST

 
			
		
	By:	 	
             

 
			
	Name:
	Title:
	
	KATO INVESTMENTS, LLC

 
			
		
	By:	 	
             

 
			
	Name:
	Title:
	
	  

	John Kellenyi
	
	  

	Joong Kil Kim
	
	  

	Sung Koo Kim
	
	  

	Mario Kozma

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  

	Klaus Kretschmer
	
	  

	Robert Masters
	
	  

	Blandine Medecin
	
	MORNINGSIDE VENTURE INVESTMENTS LIMITED
		
	By:	 	 /s/ Hon Kit Bing, Jill Marie Franklin

	Name:	 	Hon Kit Bing/Jill Marie Franklin
	Title:	 	Authorized Signatures
	
	  

	Robert L. Murphy
	
	NEW EMERGING MEDICAL OPPORTUNITIES FUND II
		
	By:	 	 /s/ Michael Sjöström

	Name:	 	Michael Sjöström
	Title:	 	Senior Partner
	
	  

	Robert Niecestro

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	ORDERSPEAK HOLDING LIMITED

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	  

	Ryan Pearson
	
	PHARMAPROS LLC

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	  
 RAQ,
LLC

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	REINFRANK LIVING TRUST DTD 6/13/95

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	RMI INVESTMENTS S.A.R.L.
		
	By:	 	 /s/ Alexander Waechter

	Name:	 	Alexander Waechter
	Title:	 	Category A Manager

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  

	Lindsay A. Rosenwald
	
	  

	Richard A. Smith
	
	STARLIGHT INVESTMENT HOLDINGS LIMITED (ANGUILLA)
		
	By:	 	
                 

	Name:
	Title:
	
	STEFAN P. AND JANE R. SHOUP AS TRUSTEES OF THE SHOUP REVOCABLE TRUST U/A/D 4/29/03
		
	By:	 	
                 

	Name:
	Title:
	
	STERN AGEE & LEACH, INC. C/F JOHN A. COLEMAN R/O IRA
		
	By:	 	              

	Name:
	Title:
	
	STRIKER ASIA OPPORTUNITIES FUND CORPORATION
		
	By:	 	              

	Name:
	Title:

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  

	Sally H. Sullivan
	
	TISU INVESTMENTS LIMITED
		
	By:	 	          

	Name:
	Title:
	
	  

	Bert K. Waits
	
	  

	Marie M. Warburg
	
	  

	Steven J. Wice
	
	WIDDER FAMILY LIMITED PARTNERSHIP
		
	By:	 	              

	Name:
	Title:
	
	  

	Patrick S. Wilmerding
	
	  

	Jinn Wu
	
	  

	Patricia Abouhalka

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  

	Mathieu Bigois
	
	  

	David Blanchard
	
	BROOKLINE GROUP, LLC
		
	By:	 	              

	Name:
	Title:
	
	  

	Gerald Chan
	
	  

	Susan Chu Walley
	
	  

	Chung K. Chu
	
	  

	Jaelyn Chu
	
	 /s/ Andrea J. Corcoran

	Andrea J. Corcoran

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	FIRESTONE ASSET MANAGEMENT LLC
		
	By:	 	
                 

	Name:
	Title:
	
	  

	Bradley L. Freilich
	
	  

	Cynthia Gagne
	
	  

	Steven S. Good
	
	  

	Anton Gopka
	
	JEAN-PIERRE SOMMADOSSI TRUST 12/10/98
		
	By:	 	              

	Name:
	Title:
	
	JPM PARTNERS LLC
		
	By:	 	 /s/ Jean-Pierre Sommadossi

	Name: Jean-Pierre Sommadossi
	Title: Manager
	
	  

	Scott Katzmann

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
	
	  

	Sherry Knowles
	  

	Paolo LaColla
	  

	Bruno Lucidi
	  

	Harris Lydon
	  

	Adel Moussa
	  

	John Dexter Pearson
	
	 /s/ Bruce Polsky

	Bruce Polsky
	  

	Jean-Marie Vallet
	  

	Xiao-Jian Zhou
	
	ATEA-BROOKLINE LLC
	
	 By: /s/
William B. Buchanan Jr.                                   
             
 Name: William B. Buchanan Jr.

Title: Managing Partner

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
	
	 Jinn Wu, as the trustee of The Diana Wu Family Trust dated May 19, 2016

 

By:                         
                                         
               
 Name:

Title:

	
	 CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
 By:
Cormorant Global Healthcare GP, LLC
 By: Bihua Chen, Managing Member of the GP
  

By: /s/ Bihau Chen                    
                                    

Name: Bihau Chen
 Title:

	
	 CORMORANT PRIVATE HEALTHCARE FUND I, LP
 By:
Cormorant Private Healthcare GP, LLC
 By: Bihua Chen, Managing Member of the GP
  

By: /s/ Bihau Chen                    
                                    

Name: Bihau Chen
 Title:

	
	 CRMA SPV, L.P.
 By: Cormorant Asset Management,
LLC
 By: Bihua Chen, Managing Member of the
 Special Limited
Partner
  

By: /s/ Bihau Chen                    
                                    

Name: Bihau Chen
 Title:

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	John Vavricka as Trustee of the John F. Vavricka Deed of Trust
		
	 By:
	 	
                 

	 Name:

	 Title:

	
	Goran Strokirk, as trustee of the Goran Strokirk Trust (8-27-2002)
		
	 By:
	 	
                 

	 Name:

	 Title:

	
	Lena S. Helms, as Trustee of the Helms Family Trust dated August 5, 1991
		
	 By:
	 	              

	 Name:

	 Title:

	
	Ryan W. Pearson and Brittany McQuarry Pearson, as co-trustees of The Ryan and Brittany Pearson Living Trust, u/a dated June 3, 2016
		
	 By:
	 	
                 

	 Name:

	 Title:

	              

	Adin Campbell Murray
	              

		 	
	Nick Sadowsky

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  
 Ze-ai C. Wu

	
	THE JAMES S. GINSBURG DYNASTY TRUST

 
			
		
	By:	 	  

 
			
	Name:	 	Linda Ginsburg
	Title:	 	Trustee
	
	AJU GROWTH & HEALTHCARE FUND

 
			
		
	By:	 	
                     
    

 
			
	Name:	 	
	Title:	 	
	
	SAMAMBIA INVESTMENTS LTD

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	
	
	Chung K. Chu and Jee H. Chu
	
	CARL AND TONI SADOWSKY TENANTS BY ENTIRETY

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	
	
	  

	John Sonnier
	
	  

	Laurence Lytton

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	SATTERFIELD VINTAGE INVESTMENTS, L.P.

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	
	
	  

	Ellen B. Friedler
	
	  

	Mark Afrasiabi
	
	BAIN CAPITAL LIFE SCIENCES FUND II, L.P.
	
	By: Bain Capital Life Sciences Investors II, LLC, its General Partner
	
	 By: Bain Capital Life Sciences Investors, LLC,

its Manager

		
	By:	 	 /s/ Andrew Hack

	Name:	 	Andrew Hack
	Title:	 	Managing Director

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

  

			
	BCIP LIFE SCIENCES ASSOCIATES, LP
	
	By: Boylston Coinvestors, LLC, its General Partner
		
	By:	 	 /s/ Andrew Hack

	Name: Andrew Hack
	Title: Authorized Signatory
	
	BAIN CAPITAL PUBLIC EQUITY GLOBAL PARTNERS FUND, L.P.
	
	By: Bain Capital Public Equity Global Investors, LLC, its general partner
	
	By: Bain Capital Public Equity Management II, LLC, its Manager
		
	By:	 	 /s/ Joshua Ross

	Name: Joshua Ross
	Title: Managing Director

  

			
	 ADAGE CAPITAL PARTNERS, L.P.

		
	 By:
	 	 /s/ Dan Lehan 

	 Name:Dan Lehan

Title: COO

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	 ALLY BRIDGE MEDALPHA MASTER FUND, L.P.
  

By: Ally Bridge MedAlpha General Partner, L.P., its General Partner
  

By: Ally Bridge MedAlpha GP LLC, its General Partner

		
	 By:
	 	 /s/ Fan Yu

	 Name: Fan Yu

Title: Manager

	
	 ARCTIC FUNDS PLC

 
 By: Arctic Fund Management AS, the Investment Manager for Arctic Funds
plc

		
	 By:
	 	
                 

	 Name: Torbjorn Bjerke

Title: Portfolio Manager

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	  

	Richard Beleson
	
	FRED E. COHEN AND CAROLYN B. KLEBANOFF TRUST

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	
	
	JEM FAMILY PARTNERSHIP, LLC

 
			
		
	By:	 	
                 

 
			
	Name:	 	
	Title:	 	
	
	Mark McDade
	
	MARC & POLLY MURPHY REVOCABLE FAMILY TRUST DATED MARCH 13, 2002

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	OMEGA FUND VI, L.P.
	
	By: Omega Fund VI GP, L.P., its General Partner
	
	By: Omega Fund VI GP Manager, Ltd., its General Partner

 
			
		
	By:	 	  

 
			
	Name:	 	Anne-Mari Paster
	Title:	 	Director
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

 
			
		
	By:	 	  

 
			
	Name:	 	James H Mannix
	Title:	 	C.O.O.
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Healthcare Fund GP, LLC, its General Partner
		
	By:	 	 /s/ Peter Kolchinsky

	Name:	 	Peter Kolchinsky
	Title:	 	Manager

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
	
	 BLACKWELL PARTNERS LLC – SERIES A
  

By: RA Capital Management, L.P., solely with respect to the assets for which it acts as investment manager

 
 By: RA Capital Management GP, LLC, its General
Partner

  

			
	By:	 	 /s/ Peter Kolchinsky

	
	 Name: Peter Kolchinsky
 Title: Authorized
Signatory

  

	
	 RA CAPITAL NEXUS FUND, L.P.
  

By: RA Capital Nexus Fund GP, LLC its General Partner

 

			
	By:	 	 /s/ Peter Kolchinsky

	
	 Name: Peter Kolchinsky
 Title:
Manager

  

	
	 REDMILE BIOPHARMA INVESTMENTS II, L.P.

 
 By: Redmile Biopharma Investments II (GP),
LLC
 its General Partner

  

			
	By:	 	 /s/ Joshua Garcia

 

	
	 Name: Joshua Garcia
 Title: CFO

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	ROCK SPRINGS CAPITAL MASTER FUND LP
	
	 By: Rock Springs General Partner, LLC

its General Partner

 
			
		
	By:	 	  

 
			
	 Name:

	 Title: Member

	
	FOUR PINES MASTER FUND LP
	
	By: Four Pines General Partner LLC, its General Partner

 
			
		
	By:	 	  

 
			
	 Name:

	 Title: Member

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	CY CAPITAL LIMITED

 
			
		
	By:	 	
         

			
	Name:	 	
	Title:	 	Director
	
	HARNAT CAPITAL HOLDINGS LIMITED

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	Director
	
	JAMBOREE INVESTMENTS LIMITED

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	Director
	
	WESTLAND PROMENADE INVESTMENT INC

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	Director
	
	  

	Peter A. Magolske

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	WINDSOR SQUARE INVESTMENT HOLDING
	INC

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	Director
	
	FINANCE 1805 SA

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	NEW EMERGING MEDICAL OPPORTUNITIES
	FUND IV SCSP
	
	By: Sectoral Asset Management Inc., its Manager
		
	By:	 	 /s/ Michael Sjöström

	Name:	 	Michael Sjöström
	Title:	 	Senior Partner

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	APPLIED FOOD SCIENCES, INC.

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	VALENCE HELIX INVESTMENTS II LLC.

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	
	
	ERNEST W. MOODY REVOCABLE TRUST

 
			
		
	By:	 	
             

 
			
	Name:	 	
	Title:	 	Trustee

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement] 

 
			
	T. ROWE PRICE HEALTH SCIENCES FUND,
	INC.
	
	TD MUTUAL FUNDS – TD HEALTH
	SCIENCES FUND
	
	VALIC COMPANY I – HEALTH SCIENCES
	FUND
	
	T. ROWE PRICE HEALTH SCIENCES
	PORTFOLIO
	
	Each account, severally and not jointly
	
	By: T. Rowe Price Associates, Inc.,
	Investment Adviser or Subadvisor, as applicable

 
			
		
	By:	 	
             

 
			
	Name:	 	Andrew Baek
	Title:	 	Vice President

  
 [Atea
Pharmaceuticals, Inc. – Signature Page to Amendment No. 1 to Fourth Amended and Restated Stockholders Agreement]EX-10.8

 Exhibit 10.8 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Execution Version

 Confidential 

License Agreement 
 This Agreement is
entered into with effect as of the Effective Date (as defined below) 
 by and between 

F. Hoffmann-La Roche Ltd 

with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) 

and 
 Genentech, Inc. 

with an office and place of business at 1 DNA Way, South San Francisco, California 94080, U.S.A. (“Genentech”; Roche Basel and Genentech
together referred to as “Roche”) 
 on the one hand 

and 
 Atea Pharmaceuticals, Inc. 

with an office and place of business at 125 Summer Street, Boston, Massachusetts 02110, U.S.A. (“Atea”) 

on the other hand. 

 Table of Contents 

 

							
	1.	  	Definitions	  	1
		  	1.1	  	Accounting Standards	  	1
		  	1.2	  	Affiliate	  	1
		  	1.3	  	Agreement	  	2
		  	1.4	  	Agreement Term	  	2
		  	1.5	  	API	  	2
		  	1.6	  	Applicable Law	  	2
		  	1.7	  	Atea Base Patent Rights	  	2
		  	1.8	  	Atea Know-How	  	2
		  	1.9	  	Atea Ongoing Studies	  	2
		  	1.10	  	Atea Patent Rights	  	2
		  	1.11	  	Atea Territory	  	2
		  	1.12	  	Back-Up Compound	  	2
		  	1.13	  	Calendar Quarter	  	3
		  	1.14	  	Calendar Year	  	3
		  	1.15	  	cGMP	  	3
		  	1.16	  	Change of Control	  	3
		  	1.17	  	Change of Control Group	  	3
		  	1.18	  	Clinical Study	  	3
		  	1.19	  	CMO	  	3
		  	1.20	  	Combination Product	  	3
		  	1.21	  	Commercially Reasonable Efforts	  	4
		  	1.22	  	Companion Diagnostic	  	4
		  	1.23	  	Completion	  	4
		  	1.24	  	Composition of Matter Claim	  	4
		  	1.25	  	Compound	  	4
		  	1.26	  	Compulsory Sublicense Compensation	  	4
		  	1.27	  	Confidential Information	  	4
		  	1.28	  	Continuation Election Notice	  	5
		  	1.29	  	Control	  	5
		  	1.30	  	Cover	  	5
		  	1.31	  	COVID19	  	5
		  	1.32	  	Drug Product	  	5
		  	1.33	  	Drug Substance	  	5
		  	1.34	  	Effective Date	  	5
		  	1.35	  	EU	  	5
		  	1.36	  	Excluded Claim	  	5
		  	1.37	  	Expert	  	5
		  	1.38	  	FDA	  	6
		  	1.39	  	FDCA	  	6
		  	1.40	  	Field	  	6
		  	1.41	  	First Commercial Sale	  	6
		  	1.42	  	First Generation Process	  	6
		  	1.43	  	FTE	  	6
		  	1.44	  	FTE Costs	  	6
		  	1.45	  	Fully Burdened Manufacturing Cost	  	6
		  	1.46	  	Generic Product	  	6
		  	1.47	  	Global Development Plan	  	7
		  	1.48	  	Global Development Plan Budget	  	7
		  	1.49	  	Handle	  	7
		  	1.50	  	HCV Combination Use	  	7

  
 - ii - 

									
		  	1.51	  	HCV Combination Use Studies	  	 	7	 
		  	1.52	  	Hospitalized Patients	  	 	7	 
		  	1.53	  	IFRS	  	 	7	 
		  	1.54	  	IND	  	 	7	 
		  	1.55	  	Indication	  	 	7	 
		  	1.56	  	Indirect Taxes	  	 	7	 
		  	1.57	  	Initial Year	  	 	7	 
		  	1.58	  	Initiation	  	 	8	 
		  	1.59	  	Insolvency Event	  	 	8	 
		  	1.60	  	Invention	  	 	8	 
		  	1.61	  	Joint Know-How	  	 	8	 
		  	1.62	  	Joint Patent Rights	  	 	8	 
		  	1.63	  	JOT	  	 	8	 
		  	1.64	  	JSC	  	 	8	 
		  	1.65	  	Know-How	  	 	8	 
		  	1.66	  	Lead Compound	  	 	8	 
		  	1.67	  	Lead Product	  	 	8	 
		  	1.68	  	Manufacturing Third Party Rights	  	 	9	 
		  	1.69	  	New Drug Application	  	 	9	 
		  	1.70	  	Net Sales	  	 	9	 
		  	1.71	  	Non-Manufacturing Third Party Rights	  	 	9	 
		  	1.72	  	Out of Pocket Expenses	  	 	9	 
		  	1.73	  	Out-Patients	  	 	10	 
		  	1.74	  	Party	  	 	10	 
		  	1.75	  	Patent Product	  	 	10	 
		  	1.76	  	Patent Rights	  	 	10	 
		  	1.77	  	Phase I Study	  	 	10	 
		  	1.78	  	Phase II Study	  	 	10	 
		  	1.79	  	Phase III Study	  	 	10	 
		  	1.80	  	Phase IV Study	  	 	10	 
		  	1.81	  	Post-Approval Commitment Studies	  	 	10	 
		  	1.82	  	Product	  	 	10	 
		  	1.83	  	Qualifying Second Generation Batch	  	 	11	 
		  	1.84	  	Regulatory Approval	  	 	11	 
		  	1.85	  	Regulatory Authority	  	 	11	 
		  	1.86	  	Respective Territory	  	 	11	 
		  	1.87	  	Roche Group	  	 	11	 
		  	1.88	  	Roche Inability to Supply	  	 	11	 
		  	1.89	  	Roche Know-How	  	 	11	 
		  	1.90	  	Roche Patent Rights	  	 	11	 
		  	1.91	  	Roche Royalty Territory	  	 	11	 
		  	1.92	  	Roche Territory	  	 	11	 
		  	1.93	  	Royalty Exclusion Countries	  	 	12	 
		  	1.94	  	Royalty Term	  	 	12	 
		  	1.95	  	Sales	  	 	12	 
		  	1.96	  	SARS-COV-2	  	 	12	 
		  	1.97	  	Second Generation Process	  	 	12	 
		  	1.98	  	Stockpiling	  	 	12	 
		  	1.99	  	Sublicensee	  	 	12	 
		  	1.100	  	Territory	  	 	12	 
		  	1.101	  	Therapeutic Use Claim	  	 	13	 
		  	1.102	  	Third Party	  	 	13	 

  
 - iii - 

									
		  	1.103	  	US	  	 	13	 
		  	1.104	  	US$	  	 	13	 
		  	1.105	  	Valid Claim	  	 	13	 
		  	1.106	  	Additional Definitions	  	 	15	 
			
	 2.
	  	 Grant of License
	  	 	15	 
				
		  	2.1	  	Licenses	  	 	16	 
		  	2.2	  	Sublicense	  	 	17	 
		  	2.3	  	Atea Right to Request U.S. Co-Promotion	  	 	17	 
			
	 3.
	  	 Subcontracting
	  	 	18	 
			
	 4.
	  	 Exclusivity
	  	 	18	 
			
	 5.
	  	 Governance
	  	 	18	 
		  	5.1	  	Joint Steering Committee	  	 	18	 
		  	5.2	  	Members	  	 	18	 
		  	5.3	  	Responsibilities of the JSC	  	 	19	 
		  	5.4	  	Meetings	  	 	19	 
		  	5.5	  	Minutes	  	 	19	 
		  	5.6	  	Decisions	  	 	20	 
		  	5.7	  	Subcommittees (JOC and JMC)	  	 	20	 
		  	5.8	  	Joint Operational Teams	  	 	23	 
		  	5.9	  	Information Exchange	  	 	23	 
		  	5.10	  	Alliance Director	  	 	23	 
		  	5.11	  	Limitations of Authority	  	 	23	 
		  	5.12	  	Expenses	  	 	23	 
		  	5.13	  	Lifetime	  	 	23	 
			
	 6.
	  	 Development
	  	 	23	 
				
		  	6.1	  	Atea Ongoing Studies	  	 	23	 
		  	6.2	  	Global Development Plan	  	 	23	 
		  	6.3	  	Additional Clinical Studies and Other Studies	  	 	24	 
		  	6.4	  	Intravenously-Administered Formulation of Lead Compound	  	 	24	 
		  	6.5	  	Development Records	  	 	25	 
		  	6.6	  	Back-Up Compounds	  	 	25	 
			
	 7.
	  	 Regulatory
	  	 	25	 
				
		  	7.1	  	Responsibility	  	 	25	 
		  	7.2	  	Pharmacovigilance Agreement	  	 	27	 
			
	 8.
	  	 Manufacture and Supply
	  	 	27	 
				
		  	8.1	  	Clinical Supply of Product and Technology Transfer	  	 	27	 
		  	8.2	  	Commercial Supply of Products	  	 	28	 
		  	8.3	  	Manufacturing Process Development and Specifications	  	 	28	 
		  	8.4	  	Supply for Retained Indications	  	 	29	 
			
	 9.
	  	 Commercialization
	  	 	29	 
				
		  	9.1	  	Responsibility	  	 	29	 
		  	9.2	  	Pricing	  	 	29	 
		  	9.3	  	Diligence	  	 	33	 
			
	 10.
	  	 Payment
	  	 	30	 
				
		  	10.1	  	Initiation Payment	  	 	30	 
		  	10.2	  	Development and Regulatory Event Payments	  	 	30	 
		  	10.3	  	Sales Based Events	  	 	31	 
		  	10.4	  	Royalty Payments	  	 	31	 
		  	10.5	  	Payments for Products containing [***]	  	 	32	 
		  	10.6	  	Third Party Payments	  	 	33	 
		  	10.7	  	Disclosure of Payments	  	 	33	 
			
	 11.
	  	 Accounting and reporting
	  	 	33	 

  
 - iv - 

									
		  	11.1	  	Timing of Royalty Payments	  	 	33	 
		  	11.2	  	Late Payment	  	 	33	 
		  	11.3	  	Method of Payment	  	 	33	 
		  	11.4	  	Currency Conversion	  	 	33	 
		  	11.5	  	Blocked Currency	  	 	34	 
		  	11.6	  	Royalty Reporting	  	 	34	 
		  	11.7	  	Reimbursement	  	 	34	 
			
	 12.
	  	 Taxes
	  	 	35	 
				
		  	12.1	  	Indirect Taxes	  	 	35	 
		  	12.2	  	Tax Withholding	  	 	35	 
		  	12.3	  	Assistance	  	 	35	 
		  	12.4	  	Tax Documentation	  	 	35	 
		  	12.5	  	Tax Information	  	 	35	 
			
	 13.
	  	 Auditing
	  	 	35	 
				
		  	13.1	  	Atea Right to Audit	  	 	35	 
		  	13.2	  	Audit Reports	  	 	36	 
		  	13.3	  	Over-or Underpayment	  	 	36	 
			
	 14.
	  	 Intellectual Property
	  	 	37	 
				
		  	14.1	  	Ownership of Inventions and Collaboration Know-How	  	 	37	 
		  	14.2	  	German Statute on Employee Inventions	  	 	38	 
		  	14.3	  	Trademarks	  	 	38	 
		  	14.4	  	Prosecution of Atea Patent Rights	  	 	38	 
		  	14.5	  	Abandonment of Atea Patent Rights	  	 	38	 
		  	14.6	  	Prosecution of Roche Patent Rights Claiming Roche Inventions	  	 	38	 
		  	14.7	  	Abandonment of Roche Patent Rights Claiming Roche Inventions	  	 	39	 
		  	14.8	  	Prosecution of Joint Patent Rights	  	 	39	 
		  	14.9	  	Abandonment of Joint Patent Rights	  	 	39	 
		  	14.10	  	Patent Coordination Team	  	 	39	 
		  	14.11	  	[***]	  	 	39	 
		  	14.12	  	CREATE Act	  	 	41	 
		  	14.13	  	Infringement	  	 	41	 
		  	14.14	  	Defense	  	 	41	 
		  	14.15	  	Third Party Licenses	  	 	41	 
		  	14.16	  	Common Interest Disclosures	  	 	42	 
		  	14.17	  	Hatch-Waxman	  	 	42	 
		  	14.18	  	Patent Term Extensions	  	 	42	 
			
	 15.
	  	 Representations and Warranties
	  	 	43	 
				
		  	15.1	  	Atea Representations and Warranties	  	 	43	 
		  	15.2	  	Mutual Representations and Warranties	  	 	44	 
		  	15.3	  	No Other Representations and Warranties	  	 	45	 
			
	 16.
	  	 Indemnification
	  	 	45	 
				
		  	16.1	  	Indemnification by Roche	  	 	45	 
		  	16.2	  	Indemnification by Atea	  	 	46	 
		  	16.3	  	Procedure	  	 	46	 
			
	 17.
	  	 Liability
	  	 	46	 
				
		  	17.1	  	Limitation of Liability	  	 	46	 
			
	 18.
	  	 Obligation Not to Disclose Confidential Information
	  	 	46	 
				
		  	18.1	  	Non-Use and Non-Disclosure	  	 	46	 
		  	18.2	  	Permitted Disclosure	  	 	46	 
		  	18.3	  	Press Releases	  	 	46	 
		  	18.4	  	Publications	  	 	46	 
		  	18.5	  	Commercial Considerations	  	 	47	 
		  	18.6	  	Complying with Applicable Law or Judicial Process	  	 	48	 

  
 - v - 

									
	 19.
	  	 Term and Termination
	  	 	48	 
				
		  	19.1	  	Commencement and Term	  	 	48	 
		  	19.2	  	Termination	  	 	48	 
		  	19.3	  	Consequences of Termination	  	 	49	 
		  	19.4	  	Survival	  	 	52	 
			
	 20.
	  	 Bankruptcy
	  	 	53	 
			
	 21.
	  	 Miscellaneous
	  	 	53	 
				
		  	21.1	  	Governing Law	  	 	53	 
		  	21.2	  	Disputes	  	 	53	 
		  	21.3	  	Arbitration	  	 	53	 
		  	21.4	  	Assignment	  	 	53	 
		  	21.5	  	Effects of Change of Control	  	 	54	 
		  	21.6	  	Independent Contractor	  	 	54	 
		  	21.7	  	Unenforceable Provisions and Severability	  	 	54	 
		  	21.8	  	Waiver	  	 	54	 
		  	21.9	  	Interpretation	  	 	54	 
		  	21.10	  	Entire Understanding	  	 	55	 
		  	21.11	  	Amendments	  	 	55	 
		  	21.12	  	Invoices	  	 	55	 
		  	21.13	  	Notice	  	 	55	 

  
 - vi - 

 License Agreement 

WHEREAS, Atea has discovered proprietary compounds with antiviral activity, including compound known as AT-527 and
potential back-up compounds, and possesses proprietary technology and intellectual property rights relating thereto; and 

WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products; and 

WHEREAS, Roche wishes to develop for commercialization such compounds and explore their potential applications in various therapeutic areas; and 

WHEREAS, Atea is willing to grant to Roche exclusive rights to use certain of its intellectual property rights to research, develop, register, use, import,
export, market, distribute, and sell Compounds, Products and Companion Diagnostics in the Roche Territory for use in the Field, non-exclusive rights to make, import, and export Compounds, Products and
Companion Diagnostics in the Field in the Territory for use in the Field, and non-exclusive rights to research and develop Compounds, Products and Companion Diagnostics in the Atea Territory for use in the
Field (as such terms are respectively defined below), as contemplated herein; and 
 WHEREAS, Roche and Atea agree that Roche and Atea will perform certain
activities to develop, manufacture and commercialize Compounds and Products, as contemplated herein. 
 NOW, THEREFORE, in consideration of the mutual
covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 

1. Definitions 
 As used in this Agreement, the following
terms, whether used in the singular or plural, shall have the following meanings: 
 1.1 Accounting Standards 

The term “Accounting Standards” shall mean with respect to a given Party, its Affiliate, or its Sublicensee, either (a) IFRS or (b) United
States generally accepted accounting principles (GAAP), in either case, as currently used at the applicable time by, and as consistently applied by, such applicable Party or its Affiliate or Sublicensee.  

1.2 Affiliate 
 The term “Affiliate” shall mean
any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term
“control” shall mean the direct or indirect ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business
entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, [***]. 

 1.3 Agreement 

The term “Agreement” shall mean this document including any and all appendices and amendments to it as may be added or amended from time to time in
accordance with the provisions of this Agreement. 
 1.4 Agreement Term 

The term “Agreement Term” shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided
in Article 19, expiring on the date when no royalty or other payment obligations under this Agreement are or will become due. 
 1.5 API 

The term “API” shall mean the Compound as pharmaceutically active agent that is used for manufacturing the Product. 

1.6 Applicable Law 
 The term “Applicable Law”
shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the
Agreement Term, in each case to the extent that the same is applicable to the performance by the Parties of their respective obligations under this Agreement. 

1.7 Atea Base Patent Rights 
 The term “Atea Base
Patent Rights” shall mean Patent Rights in the Territory that are Controlled by Atea at the Effective Date, said Patent Rights being exhaustively listed in Appendix 1.7. 

1.8 Atea Know-How 

The term “Atea Know-How” shall mean the Know-How that Atea Controls
at the Effective Date and during the Agreement Term relating to or arising from the discovery, manufacture, development or commercialization of or necessary or reasonably useful to discover, manufacture, develop or commercialize a Product. 

1.9 Atea Ongoing Studies 
 The term “Atea Ongoing
Studies” shall mean the non-clinical studies and Clinical Studies that are being conducted by Atea with respect to Compounds and Products as of the Effective Date, [***]. The Atea Ongoing Studies are
described in Appendix 1.9. 
 1.10 Atea Patent Rights 

The term “Atea Patent Rights” shall mean the Patent Rights that Atea Controls, relating to or arising from the discovery, manufacture, development or
commercialization of or Covering a Product. The term Atea Patent Rights shall include Atea Base Patent Rights. 
 1.11 Atea Territory 

The term “Atea Territory” shall mean the US. 
 1.12 Back-Up Compound 
 The term “Back-Up Compound” shall mean a molecule
other than the Lead Compound, [***] and that: 
  

	 	a)	 (i) [***], or (ii) has [***]; and/or 

 

	 	b)	 is an [***] of a compound described in subclause (a) above, 

in each case a) and b), that was generated by or on behalf of Atea, or that is otherwise proprietary to and Controlled by Atea, at the Effective Date or
during the Agreement Term. 

  
 - 2 - 

 1.13 Calendar Quarter 

The term “Calendar Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30,
September 30, and December 31. 
 1.14 Calendar Year 

The term “Calendar Year” shall mean the period of time beginning on January 1 and ending December 31, except for the first year which shall
begin on the Effective Date and end on December 31. 
  

	1.15	  cGMP 

The term “cGMP” means the regulatory requirements for current good manufacturing practices promulgated by the FDA under the FD&C Act, 21
C.F.R. §§ 210, 211 and 600 et seq. and under the PHS Act, 21 C.F.R. §§ 600-610, as the same may be amended from time to time and with respect to the Product, the corresponding or similar
laws, rules and regulations of those jurisdictions in which the Product is sold. 
  

	1.16	  Change of Control 

The term “Change of Control” shall mean, with respect to a Party: (a) the acquisition by any Third Party of beneficial ownership of fifty
percent (50%) or more of the then outstanding common shares or voting power of such Party, other than acquisitions by employee benefit plans sponsored or maintained by such Party; (b) the consummation of a business combination involving such
Party, unless, following such business combination, the stockholders of such Party immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%) of the then outstanding common shares or voting
power of the entity resulting from such business combination; or (c) the sale of all or substantially all of such Party’s assets or business relating to the subject matter of the Agreement; provided, however, that notwithstanding
(a) through (c) above, a sale or issuance of a Party’s securities in an equity financing for capital raising purposes, including a public offering of securities, shall not constitute a Change of Control. 

1.17  Change of Control Group 
 The term “Change
of Control Group” shall mean with respect to a Party, the person or entity, or group of persons or entities, that is the acquirer of, or a successor to, a Party in connection with a Change of Control, together with affiliates of such persons or
entities that are not Affiliates of such Party immediately prior to the completion of such Change of Control of such Party. 
 1.18 Clinical Study

 The term “Clinical Study” shall mean a Phase I Study, Phase II Study or a Phase III Study, as applicable. 

1.19 CMO 
 The term “CMO” shall mean a Third
Party contract manufacturing organization. 
 1.20 Combination Product 

The term “Combination Product” shall mean 
  

	a)	 a single pharmaceutical formulation containing as its active ingredients both a Compound and one or more other
therapeutically or prophylactically active ingredients, 

  

	b)	 [***] or 

  

	c)	 [***] 

in each case, including all dosage forms, formulations, presentations, line extensions, and package configurations. All references to Product in this
Agreement shall be deemed to include Combination Product. 

  
 - 3 - 

 1.21 Commercially Reasonable Efforts 

The term “Commercially Reasonable Efforts” shall mean, [***]. It is understood that such product potential may change from time to time based upon
changing scientific, business and marketing and return on investment considerations. 
 [***]. 

1.22 Companion Diagnostic 
 The term “Companion
Diagnostic” shall mean any product that is used for predicting or monitoring the response of a human being to treatment with a Product [***]. 

1.23 Completion 
 The term “Completion” shall
mean the availability of the final study report. 
 1.24 Composition of Matter Claim 

The term “Composition of Matter Claim” shall mean, for a given Product in a given country of the Territory, a Valid Claim of an Atea Patent Right
that Covers the Compound per se that is included in such Product. 
 1.25 Compound 

The term “Compound” shall mean the Lead Compound and each Back-up Compound. 

1.26 Compulsory Sublicense Compensation 
 The term
“Compulsory Sublicense Compensation” shall mean, for a given country or region in the Territory, the compensation paid to Roche by a Third Party (a “Compulsory Sublicensee”) under a license or sublicense of Atea Patent
Rights and Joint Patent Rights granted to the Compulsory Sublicensee (the “Compulsory Sublicense”) through the order, decree or grant of a governmental authority having competent jurisdiction in such country or region, authorizing
such Third Party to manufacture, use, sell, offer for sale, import or export a Product in such country or region. 
 1.27 Confidential Information

 The term “Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or
its Affiliates (“Receiving Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	 was generally available to the public at the time of disclosure, or becomes available to the public after
disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates, 

  

	 	(ii)	 can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior
to its receipt from the Disclosing Party without obligations of confidentiality, 

  

	 	(iii)	 is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure,

  

	 	(iv)	 is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than
through knowledge of Confidential Information of the Disclosing Party, or 

  

	 	(v)	 is approved in writing by the Disclosing Party for release by the Receiving Party. 

The terms of this Agreement shall be considered Confidential Information of both Parties. For purposes of this Agreement, Confidential Information of a Party
shall include any information disclosed by or on behalf of such Party pursuant to the Non-Disclosure Agreement between the Parties dated [***] (the “NDA”). 

  
 - 4 - 

 1.28 Continuation Election Notice 

The term “Continuation Election Notice” shall mean the notice Atea provides to Roche under Section 19.3.1 describing (i) Atea’s
bona fide intentions to continue ongoing development and commercialization of Product(s) and (ii) Atea’s request for Roche’s continuation of activities during the termination period or transfer of the data, material and
information relating to the Product(s) in accordance with Section 19.3.1. 
 1.29 Control 

The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled”
or “Controlling”) (a) with respect to Patent Rights or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights or
Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to
supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 

1.30 Cover 
 The term “Cover” shall mean (as an
adjective or as a verb including conjugations and variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given
compound, formulation or product would infringe a Valid Claim in the absence of a license under or ownership of Patent Rights including such Valid Claim under this Agreement. [***] 

1.31 COVID19 
 The term “COVID19” shall mean the
disease caused by the causative agent SARS-CoV-2. 
 1.32 Drug Product

 The term “Drug Product” shall mean a Product formulated and filled (if applicable) that meets the applicable Specifications. 

1.33 Drug Substance 
 The term “Drug Substance”
shall mean drug substance of Product in formulated bulk form that meets the applicable Specifications. 
 1.34 Effective Date 

The term “Effective Date” shall mean October 21, 2020. 

1.35 EU 
 The term “EU” shall mean the European
Union and all its then-current member countries but including in any case [***] regardless of whether they are then-current member countries. 
 1.36
Excluded Claim 
 The term “Excluded Claim” shall mean a dispute, controversy or claim between the Parties that concerns (a) [***], or
(b) [***]. 
  

	1.37	 Expert 

The term “Expert” shall mean a person with no less than [***] years of pharmaceutical industry experience and commercial expertise having occupied at
least [***] but excluding [***]. Such person shall be fluent in the English language. 

  
 - 5 - 

 1.38 FDA 

The term “FDA” shall mean the Food and Drug Administration of the United States of America. 

1.39 FDCA 
 The term “FDCA” shall mean the Food,
Drug and Cosmetics Act. 
 1.40 Field 
 The term
“Field” shall mean all pharmaceutical, medical and diagnostic uses, excluding the HCV Combination Use with respect to a Lead Compound, (the “Excluded Field”). 

1.41 First Commercial Sale 
 The term “First
Commercial Sale” shall mean, on a country-by-country basis, the first invoiced sale of the Product to a Third Party by the Roche Group in a country following the
receipt of any Regulatory Approval required for the sale of such Product in such country, or if no such Regulatory Approval is required, the date of the first invoiced sale of a Product to a Third Party by the Roche Group in such country. 

1.42 First Generation Process 
 The term “First
Generation Process” shall mean the manufacturing process for Drug Substance that is used by Atea at the Effective Date for development purposes, [***]. 

1.43 FTE 
 The term “FTE” shall mean a full-time
equivalent person-year, based upon a total of no less than [***] working hours per year, undertaken in connection with the conduct of research in the development or manufacturing activities under this Agreement. [***]. 

1.44 FTE Costs 
 The term “FTE Costs” shall mean
an amount equal to the product of the applicable standard internal FTE rate (for employees or contract personnel. as applicable) and the number of FTEs performing the applicable activity under and in accordance with the applicable Global Development
Plan and the number of FTEs performing the applicable activity included in the definition of Fully Burdened Manufacturing Cost (Section 1.45). The applicable FTE rate for each activity shall be consistent for each Party’s internal FTE rate as
consistently applied across such Party’s respective functions, [***]. [***] 
 1.45 Fully Burdened Manufacturing Cost 

The term “Fully Burdened Manufacturing Cost” shall mean with respect to a Product and a Party, the consolidated fully-burdened cost incurred by such
Party or any of its Affiliates in manufacturing such Product ([***] ) in accordance with this Agreement and calculated using the relevant Party’s Accounting Standards, in bulk, vialed or finished product form as the case may be, including: (a)
[***], (i) [***] (ii) [***]; and (b) [***]: [***]. 
 1.46 Generic Product 

The term “Generic Product” shall mean a product that is not produced, licensed or owned by the Roche Group that (i) contains a pharmaceutically
active ingredient that is the same as the Compound in the Product which is approved through in reliance, in whole or in part, on the prior Regulatory Approval (or on safety or efficacy data submitted in support of the prior Regulatory Approval) of
such Product, pursuant to Section 505(j) of the Act (21 U.S.C. 355(j)), or for countries outside the US, any international equivalent laws, and (ii) has the same or substantially the same labelling as the applicable Product for at least
one indication of such Product. 

  
 - 6 - 

 1.47 Global Development Plan 

The term “Global Development Plan” shall mean the plan of Clinical Studies intended to support Regulatory Approval of the Products in the Field and
in the Territory, [***]. The initial Global Development Plan is as attached in Appendix 1.47. 
 1.48 Global Development Plan Budget 

The term “Global Development Plan Budget” shall mean the non-binding, forecasted annual budget for the
development activities under the Global Development Plan, [***]. 
 1.49 Handle 

The term “Handle” shall mean preparing, filing, prosecuting (including interferences, reissue,
re-examination, post-grant reviews, inter-partes reviews, derivation proceedings, opposition and invalidation proceedings) and maintaining. 

1.50 HCV Combination Use 
 The term “HCV Combination
Use” shall mean pharmaceutical, medical or diagnostic use of a Compound solely (a) for the hepatitis C virus (“HCV”) Indication and (b) where the Compound is used in a product [***]. 

1.51 HCV Combination Use Studies 
 The term “HCV
Combination Studies” shall mean non-clinical studies, Clinical Studies, Post-Approval Commitment Studies and Phase IV Studies conducted by Atea that relate solely to the HCV Combination Use, [***]. 

1.52 Hospitalized Patients 
 The term “Hospitalized
Patients” shall mean patients that are treated in hospital institutions providing acute, in-patient medical and surgical treatment and nursing care. 

1.53 IFRS 
 The term “IFRS” shall mean
International Financial Reporting Standards. 
 1.54 IND 

The term “IND” shall mean an application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application to
the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of the Products in humans. 

1.55 Indication 
 The term “Indication” shall
mean a disease (i) for which the Product is indicated for treatment or prophylaxis and (ii) for Products for which Regulatory Approval has been obtained, that is described in the Product label as required by the Regulatory
Approval granted by the applicable Regulatory Authority. 
 1.56 Indirect Taxes 

The term “Indirect Taxes” shall mean customs, duties, value added taxes, excise taxes, use taxes and sales taxes, consumption taxes and other similar
taxes. 
 1.57 Initial Year 
 The term “Initial
Year” shall mean the twelve-month period beginning on the Effective Date. 

  
 - 7 - 

 1.58 Initiation 

The term “Initiation” shall mean the date that a human is first dosed with the Product in a Clinical Study in the Field approved by the
respective Regulatory Authority. 
 1.59 Insolvency Event 

The term “Insolvency Event” shall mean circumstances under which a Party (i) has a receiver or similar officer appointed over all or a material
part of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent
amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction), which order is not dismissed within thirty (30) days; (iii) enters into
any composition or arrangement with its creditors (other than relating to a solvent restructuring); (iv) ceases to carry on business; (v) is unable to pay its debts as they become due in the ordinary course of business. 

1.60 Invention 
 The term “Invention” shall mean
an invention that is conceived or first reduced to practice in connection with any activity carried out pursuant to this Agreement. Under this definition, an Invention may be made by employees of Atea solely or jointly with a Third Party (an
“Atea Invention”), by employees of the Roche Group solely or jointly with a Third Party (a “Roche Invention”), or jointly by employees of Atea and employees of the Roche Group with or without a Third Party (a
“Joint Invention”). 
 1.61 Joint Know-How 

The term “Joint Know-How” shall mean Know-How that is made jointly by
employees of Atea and the Roche Group, with or without a Third Party in connection with any activity carried out pursuant to this Agreement. 
 1.62
Joint Patent Rights 
 The term “Joint Patent Rights” shall mean all Patent Rights Covering a Joint Invention. 

1.63 JOT 
 The term “JOT” shall mean a joint
operating team described in Section 5.8. 
 1.64 JSC 

The term “JSC” shall mean the joint steering committee described in Article 5. 

1.65 Know-How 

The term “Know-How” shall mean data, knowledge and information, including materials, samples, chemical
manufacturing data, toxicological data, pharmacological data, preclinical and clinical data, assays, platforms, formulations, specifications, quality control testing data, that are confidential and necessary or useful for the discovery, manufacture,
development or commercialization of Products. 
 1.66 Lead Compound 

The term “Lead Compound” shall mean Atea’s proprietary compound AT-511 currently under development by
Atea, as set forth in Appendix 1.66, or [***] AT-527 currently under development by Atea, [***]. 
 1.67 Lead
Product 
 The term “Lead Product” shall mean any product, including without limitation any Combination Product, containing the Lead Compound
as pharmaceutically active agent, regardless of the finished form or formulation or dosage. 

  
 - 8 - 

	1.68	  Manufacturing Third Party Rights 

The term “Manufacturing Third Party Rights” means Patent Rights or other intellectual property rights of a Third Party that are necessary or useful
to make Products. 
  

	1.69	  New Drug Application 

The term “New Drug Application” shall mean the application, including all necessary documents, data, and other information concerning a Product,
required for Regulatory Approval of the Product as a pharmaceutical product by the applicable Regulatory Authority in any country or group of countries (e.g. the marketing authorization application (MAA) with the EMA/European Commission). 

1.70 Net Sales
 The term “Net Sales” shall mean,
for a Product in a particular period, the amount calculated by subtracting from the Sales of such Product for such period: (i) [***]; (ii) uncollectible amounts accrued during such period based on a proportional allocation of the total bad
debts accrued during such period and not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such
Product for such period; (iii) credit card charges (including processing fees) accrued during such period on such Sales and not already taken as a gross-to-net
deduction in accordance with the then currently used IFRS in the calculation of Sales of such Product for such period; and (iv) government mandated fees and taxes (excluding income or franchise taxes) and other government charges accrued during
such period not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Product for such period,
including, for example, any fees, taxes or other charges that become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other action of a government or regulatory body. For clarity, no deductions
taken in calculating Sales under Section 1.95 may be taken a second time in calculating Net Sales. 
 1.71 
Non-Manufacturing Third Party Rights 
 The term “Non-Manufacturing
Third Party Rights” means Third Party Patent Rights or other intellectual property rights that are necessary or useful to develop, use or sell Products. 
  

	1.72	  Out of Pocket Expenses 

The term “Out of Pocket Expenses” shall mean any [***] out-of-pocket
costs or expenses paid or accrued in accordance with the applicable Accounting Standard(s), by or on behalf of a Party or any of its Affiliates during the Agreement Term that are [***] identifiable or [***] allocable to development activities for
the Product, in each case in accordance with the Global Development Plan or other applicable plan or activities approved by the JOC. Subject to the foregoing and by way of example, Out of Pocket Expenses may include costs in connection with the
following activities: 
  

	 	a)	 [***]; 

  

	 	b)	 [***]; 

  

	 	c)	 [***]; and 

  

	 	d)	 [***].  

  
 - 9 - 

 1.73 Out-Patients 

The term “Out-Patients” shall mean patients that are not treated in hospital institutions providing acute, in-patient medical and surgical treatment and nursing care. 
 1.74 Party 

The term “Party” shall mean Atea or Roche, as the case may be, and “Parties” shall mean Atea and Roche collectively. 

1.75 Patent Product 
 The term “Patent Product”
shall mean any Product containing a Compound that is Covered by a Composition of Matter Claim. 
 1.76 Patent Rights 

The term “Patent Rights” shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing
on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, divisional, continuation or
continuation-in-part of any of the foregoing. 
 1.77 Phase I Study

 The term “Phase I Study” shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a)
(FDCA), as amended from time to time, and the foreign equivalent thereof. 
 1.78 Phase II Study 

The term “Phase II Study” shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges or a preliminary
determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof. 

1.79 Phase III Study 
 The term “Phase III
Study” shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market
such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof. 

1.80 Phase IV Study 
 The term “Phase IV Study”
means a human clinical study with respect to any approved Indication in a country commenced after Regulatory Approval for that Indication has been received for such product in such Indication in such country, excluding Post-Approval Commitment
Studies. 
 1.81 Post-Approval Commitment Studies 
 The
term “Post-Approval Commitment Studies” means clinical studies mandated by a Regulatory Authority to be performed after Regulatory Approval of a Product, as a condition of such Regulatory Approval. 

1.82 Product 
 The term “Product” shall mean any
product, including without limitation any Combination Product, containing a Compound as a pharmaceutically active agent, regardless of their finished forms or formulations or dosages. One Product may be distinguished from another Product by the
Compound being a distinctive active pharmaceutical ingredient. In the instance where more than one distinctive active pharmaceutical ingredient is contained in a Compound, one Product may be distinguished from another Product if at least one of the
distinctive active pharmaceutical ingredients is different. 

  
 - 10 - 

 1.83 Qualifying Second Generation Batch 

The term “Qualifying Second Generation Batch” shall mean the manufacture using the Second Generation Process of at least [***] of Drug Substance,
which shall (i) meet the same specifications as applicable to the First Generation Process, (ii) be compliant with Roche standard GMP requirements and (iii) outline the synthesis route towards the Second Generation Process for the
manufacturing of the campaign of [***] (the success criteria for such synthesis route are outlined in Appendix 8.3.3 and shall serve as orientation therefor). 

1.84 Regulatory Approval 
 The term “Regulatory
Approval” shall mean any approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations by a Regulatory Authority, necessary for the manufacture and sale of a Product in the Field in a regulatory
jurisdiction in the Territory. 
 1.85 Regulatory Authority 

The term “Regulatory Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the
European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of regulatory approval (including pricing and
reimbursement approvals) for the Product. 
 1.86 Respective Territory 

The term “Respective Territory” shall mean the Roche Territory with respect to Roche and the Atea Territory with respect to Atea. 

1.87 Roche Group 
 The term “Roche Group” shall
mean collectively Roche, its Affiliates and its Sublicensees. 
 1.88 Roche Inability to Supply 

The term “Roche Inability to Supply” means, [***], Atea’s reasonable belief that Roche will be unable to deliver to Atea [***] supply of Product
to meet the quantities set forth in the then-current Demand Forecast Plan for the Product allocated for commercialization purposes in the Atea Territory, despite (i) [***], and (ii) [***], and (iii) [***]. 

1.89 Roche Know-How 

The term “Roche Know-How” shall mean all Know-How that Roche Controls
during the Agreement relating to or arising from the discovery, manufacture, development or commercialization of or necessary or reasonably useful to discover, manufacture, develop or commercialize a Product. 

1.90 Roche Patent Rights 
 The term “Roche Patent
Rights” shall mean the Patent Rights that Roche Controls, relating to or arising from the discovery, manufacture, development or commercialization of or Covering a Product. 

1.91 Roche Royalty Territory 
 The term “Roche
Royalty Territory” shall mean the Roche Territory, excluding the Royalty Exclusion Countries. 
 1.92 Roche Territory 

The term “Roche Territory” shall mean all countries other than the US. 

  
 - 11 - 

 1.93 Royalty Exclusion Countries 

The term “Royalty Exclusion Countries” for a Calendar Year shall mean the countries [***]. 

1.94 Royalty Term 
 The term “Royalty Term”
shall mean, with respect to a Product and for a given country, the period of time commencing on the date of First Commercial Sale of the Product in such country and ending on the later of the date that is (a) ten (10) years after the date
of the First Commercial Sale of the Product in such country, or (b) the expiration of the last to expire Atea Patent Right containing a Composition of Matter Claim. With regard to the calculation of the ten (10) year period, the EU shall
be considered as one country.  
 1.95 Sales 

The term “Sales” shall mean, for a Product in a particular period, the sum of (i) and (ii): 

 

	(i)	 the amount stated in the Roche Holding AG “Sales” line of its externally published audited
consolidated financial statements with respect to such Product for such period [***]. This amount reflects the gross invoice price at which such Product was sold or otherwise disposed of (other than for use as clinical supplies or free samples) by
Roche and its Affiliates to such Third Parties [***] in such period reduced by gross-to-net deductions, if not previously deducted from such invoiced amount, taken in
accordance with the then currently used IFRS. 

 [***] 

For purposes of clarity, [***] any given deduction shall be taken only under one of subsections (a) through (e), and only once in
calculating Sales. 
  

	(ii)	 [***] 

1.96 SARS-COV-2 

The term “SARS-COV-2” shall mean the virus known as the severe acute
respiratory syndrome coronavirus 2. 
 1.97 Second Generation Process 

The term “Second Generation Process” shall mean the manufacturing process for Drug Substance that Atea conceptualized and started to develop
at the Effective Date, as outlined in Appendix 1.97. 
 1.98 Stockpiling 

The term “Stockpiling” shall mean activities conducted by a governmental authority to address public health emergencies by purchasing and maintaining
inventories of Product for distribution and use in responding to such emergencies. 
 1.99 Sublicensee 

The term “Sublicensee” shall mean an entity to which Roche has licensed rights (through one or multiple tiers), other than through a Compulsory
Sublicense, pursuant to this Agreement. 
 1.100 Territory 

The term “Territory” shall mean the Roche Territory and the Atea Territory. 

  
 - 12 - 

 1.101 Third Party 

The term “Third Party” shall mean a person or entity other than (i) Atea or any of its Affiliates or (ii) a member of the Roche Group. 

1.102 US 
 The term “US” shall mean the United
States of America and its territories and possessions. 
  

	1.103	 US$ 

The term “US$” shall mean US dollars. 
 1.104 Valid
Claim 
 The term “Valid Claim” shall mean: (i) with respect to a claim in any unexpired and issued patent within the Atea Patent Rights,
that such claim has not been disclaimed, revoked or held invalid by a final nonappealable decision of a court of competent jurisdiction or government agency, or (ii) with respect to a claim in any pending patent application within the Atea
Patent Rights, that such claim has been filed and prosecuted in good faith and no more than [***] years have elapsed from the earliest priority date of such claim. 

1.105 Additional Definitions 
 Each of the following
definitions is set forth in the Section of this Agreement indicated below: 
  

			
	 Definition
	  	 Section

	Accounting Period	  	11.1
	Acquired Party	  	21.5
	Alliance Director	  	5.10
	Atea	  	cover page
	Atea Indemnitees	  	16.1
	Atea Invention	  	1.60
	Atea-Originated Transfer Activities	  	19.3.4.4
	Bankruptcy Code	  	20
	Breaching Party	  	19.2.1
	[***]	  	1.1
	Commercial Scale-Up	  	8.3.2
	Competing Program	  	21.5
	Compulsory Profit Share Percentage	  	10.4.5
	Compulsory Sublicense	  	1.26
	Compulsory Sublicensee	  	1.26
	co-promote, co-promotion	  	2.3
	Co-Promotion Agreement	  	2.3
	Co-Promotion Option	  	2.3
	Decision Period	  	14.13
	Disclosing Party	  	1.27
	Demand Forecast Plan	  	8.2
	Dominant Party	  	14.13
	Early Second Generation Process Development	  	8.3.1
	Excluded Field	  	1.40
	Expert Committee	  	10.4.3
	First Generation Process Development	  	8.3.2
	Genentech	  	cover page
	Indemnified Party	  	16.3

  
 - 13 - 

			
	 Definition
	  	 Section

	Indemnifying Party	  	16.3
	Infringement	  	14.13
	Initiating Party	  	14.13
	IV Lead Compound Formulation	  	6.4
	JOC	  	5.7.3.1
	Joint Invention	  	1.60
	JMC	  	5.7.4.1
	Later Second Generation Process Development	  	8.3.2
	Lead Co-Chairperson	  	5.2
	Losses	  	16.1
	Manufacturing Third Party Payments	  	10.5
	Members	  	5.2
	Minimum Transfer Payment	  	19.3.4.4
	Misappropriation	  	14.13
	NDA	  	1.27
	Non-Acquired Party	  	21.5
	Non-Breaching Party	  	19.2.1
	Non-Manufacturing Third Party Payments	  	10.5
	Owed Party	  	11.7
	Owing Party	  	11.7
	Patent Term Extensions	  	14.18
	[***]	  	12.2
	[***]	  	12.2
	Payment Currency	  	11.3
	Peremptory Notice Period	  	19.2.1
	PII/Samples	  	19.3.4.4
	Primary Negotiation Party	  	14.15
	Product Trademarks	  	14.3
	Proposing Party	  	6.2
	Publishing Notice	  	18.4
	Publishing Party	  	18.4
	Receiving Party	  	1.27
	Reconciliation Interim Report	  	11.7
	Reconciliation Final Report	  	11.7
	Register	  	14.11
	Relative Commercial Value	  	10.4.3
	Retained Indications	  	2.1.4
	Roche	  	cover page
	Roche Basel	  	cover page
	Roche Indemnitees	  	16.2
	Roche Invention	  	1.60
	Roche Transfer Activities	  	19.3.4.4
	Sensitive Information	  	21.5
	Settlement	  	14.13
	SPCs	  	14.18
	Specifications	  	8.3.3
	Subcommittee	  	5.7.1

  
 - 14 - 

			
	 Definition
	  	 Section

	Subcontractor Notice	  	3
	Supply Agreement	  	8.2
	Suit Notice	  	14.13
	[***]	  	12.2
	Third Party Claims	  	16.1
	Third Party IP License	  	14.15
	Unilateral Study	  	6.2
	US-Dedicated Clinical Studies	  	5.6.3
	US Roche Know-How Misappropriation	  	14.13

 2. Grant of License 

2.1 Licenses 
  

	2.1.1	 License Grant to Roche 

Subject to the terms and conditions of this Agreement, Atea hereby grants to Roche under the Atea Patent Rights and Atea
Know-How and Atea’s interest in the Joint Patent Rights and Joint Know-How: 
  

	 	(a)	 an exclusive (even as to Atea) right and license to research, have researched, develop, have developed,
register, have registered, use, have used, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, and have offered for sale Compounds, Products and Companion Diagnostics in
the Field in the Roche Territory, including the right to sublicense pursuant to Section 2.2; provided that Atea retains the right to develop, manufacture and commercialize Compound and Product for the Retained Indications for the purposes set
forth in Section 2.1.4; 

  

	 	(b)	 a non-exclusive right and license to make, have made, import, have
imported, export, have exported Compounds, Products and Companion Diagnostics in the Field in the Territory, including the right to sublicense pursuant to Section 2.2; and 

 

	 	(c)	 a non-exclusive right and license to research, have researched, develop
and have developed Compounds, Products and Companion Diagnostics in the Field and in the Atea Territory, including the right to sublicense pursuant to Section 2.2.

The exclusivity of the above license is subject to the right of Atea and its respective Affiliates to conduct any activities expressly contemplated by this
Agreement. 
  

	2.1.2	 License Grant to Atea 

Subject to the terms and conditions of this Agreement, Roche hereby grants to Atea under the Roche Patent Rights and Roche
Know-How and Roche’s interest in the Joint Patent Rights and Joint Know-How: 
  

	 	(a)	 an exclusive (even as to Roche, except as set forth in Sections 2.1.1(b) and 2.1.1(c)) right and license to
distribute, have distributed, register, have registered, sell, have sold, offer for sale, and have offered for sale Compounds and Products in the Atea Territory, including the right to sublicense pursuant to Section 2.2; 

 

	 	(b)	 a non-exclusive right and license to research, have researched,
develop, have developed, use, have used, import, have imported, export, have exported, market, and have marketed, Compounds and Products in the Atea Territory, including the right to sublicense pursuant to Section 2.2; 

  
 - 15 - 

	 	(c)	 a non-exclusive right and license, including the right to sublicense
pursuant to Section 2.2, to practice any process improvements arising in the course of the manufacture of the Drug Substance or the Drug Product by or on behalf of Roche, its Affiliates or Sublicensees, solely in case of a Roche Inability to
Supply, and to make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold Compounds and Products in the Atea Territory and, solely in the Excluded Field (whether or
not there is a Roche Inability to Supply), the Roche Territory, and anywhere in the Territory to manufacture or have manufactured Compound and Product for the purposes set forth in Section 2.1.4; and 

 

	 	(d)	 a non-exclusive right and license to research, have researched, develop
and have developed Compounds and Products in the Field and in the Roche Territory, and anywhere in the Territory for purposes set forth in Section 2.1.4, including the right to sublicense pursuant to Section 2.2. 

 

	2.1.3	 Excluded Affiliates 

Notwithstanding anything to the contrary in this Article 2 or elsewhere in this Agreement, no licenses or rights are granted to Atea under any
information, data, proprietary materials or other intellectual property rights whether or not patentable that are owned or controlled by [***]. 
  

	2.1.4	 Retained Rights 

For clarity, Atea retains the exclusive ownership and right to use any compound that was generated by or on behalf of Atea, or that is otherwise Covered by
intellectual property rights Controlled by Atea, at the Effective Date or during the Agreement Term in the Excluded Field. 
 Notwithstanding anything to
the contrary in this Agreement, Atea retains the sole right to develop, manufacture and commercialize Compounds and Products in the Atea Territory for the treatment of Dengue Fever, Japanese Encephalitis, West Nile Virus, Yellow Fever and/or Zika
(the “Retained Indications”) in the Atea Territory, and to develop and manufacture Compounds and Products in the Roche Territory for the Retained Indications. Atea will notify Roche in writing promptly [***] for the Retained
Indication in the Atea Territory. For [***] months after Roche’s receipt of such notice from Atea, the Parties will negotiate in good faith an amendment to this Agreement specifying the terms pursuant to which Roche will commercialize the
Product in the Roche Territory for the Retained Indications, except if Roche decides to offer such commercialization right to Atea. Unless and until the Parties enter into such amendment, neither Party will have the right to commercialize the
Product in the Roche Territory for the Retained Indications. 
 2.2 Sublicense 

 

	2.2.1	 Right to Sublicense to its Affiliates 

Each Party shall have the right to grant sublicenses to its Affiliates (through multiple tiers), and, as to Roche, [***] under its rights granted under
Section 2.1 without prior approval of the other Party. 
  

	2.2.2	 Right to Sublicense to Third Parties 

Each Party and its Affiliates shall have the right to grant written sublicenses to non-Affiliate entities (through
multiple tiers) under its rights granted under Section 2.1 without prior approval of the other Party. Roche shall inform Atea promptly after the signature of any sublicense agreement it enters into under this Section 2.2.2. 

  
 - 16 - 

	2.2.3	 Requirements for Sublicenses 

Each sublicense shall be consistent in all material respects with the terms and conditions of the Agreement, provided that the sublicensing Party shall be
responsible for the payment of all amounts due hereunder, and for all other obligations of its sublicensees under the Agreement as if such obligations were those of such Party. 

2.3 Atea Right to Request U.S. Co-Promotion 

Atea shall have a one-time option right to request that Roche co-promote each
Product (other than for the Retained Indications), on a Product-by-Product basis, in the US on a royalty basis (each, a
“Co-Promotion Option”), subject to the provisions of this Section 2.3, and conditioned on Roche and Atea or their respective Affiliates entering into a
co-promotion agreement consistent with this Section 2.3. For purposes of this Agreement, “co-promote” and
“co-promotion” shall refer to marketing, promotion, detailing and advertisement of a Product by the Parties under the relevant Regulatory Approvals and the same trademark(s). “Co-promote” and “co-promotion” shall not mean the sale, contracting or distribution of a Product. Additional supportive customer and field
activities may be included in the agreement even if they are not related to promotion (i.e. medical or patient support services). Atea may exercise its Co-Promotion Option with respect to each Product by
giving written notice thereof to Roche at any time at least [***] prior to expected Regulatory Approval of such Product in the US. Upon Atea’s exercise of its Co-Promotion Option with respect to a Product
the Parties shall negotiate in good faith and enter into a written co-promotion agreement (the “Co-Promotion Agreement”). In addition to any other terms
agreed to by the Parties, the Co-Promotion Agreement shall contain the terms set forth in Appendix 2.3 hereto and other terms typically contained in agreements or the
co-promotion of similar products in the US. Upon Atea exercising the Co-Promotion Option in accordance with this Section 2.3, the Parties shall coordinate all sales
efforts and field activities in the US under the direction of the JSC, and such efforts and activities shall be more fully described in the Co-Promotion Agreement. Atea shall have the right to co-promote any Product with any Third Party, or to commercialize such Product itself, in the Atea Territory, unless and until Atea exercises its Co-Promotion Option and the
Parties enter into the Co-Promotion Agreement. If Atea exercises its right to co-promote or commercialize with a Third Party, then its
Co-Promotion Option expires on the date any such Third Party agreement takes effect. 
 3. Subcontracting

 Atea shall have the right to subcontract the performance of any of its activities under the Agreement (including the activities described under the
Global Development Plan and, if applicable, in the Co-Promotion Agreement), provided that (a) Atea shall be and remain responsible and liable for the performance of any such activities by any such
subcontractor and (b) such subcontractor must be bound by written obligations (i) of nondisclosure and non-use that are as protective of Roche’s Confidential Information as this Agreement and
(ii) to assign or license and transfer to Atea all right, title and interest to any Invention that is developed or, conceived and reduced to practice by such subcontractor that is related to the Compound or Product. 

Atea may not subcontract out its activities under the Global Development Plan to any Third Party other than those Third Parties listed on Appendix 3, which
Appendix lists Third Party subcontractors of Atea existing as of the Effective Date, or pursuant to the following procedure: (i) Atea shall notify [***] (which notice may be provided via e-mail) of any
such proposed Third Party subcontractor and the scope of work proposed to be subcontracted (such notice, a “Subcontractor Notice”); (ii) Roche may notify Atea of any reasonable concerns with respect to such proposed subcontractor,
if any, as expeditiously as practical but in no event later than [***] days of receipt of such Subcontractor Notice; (iii) Atea shall consider any such concerns in good 

  
 - 17 - 

 
faith; and (iv) if thereafter Atea continues to desire to use such Third Party subcontractor the matter shall be referred to the JOC for discussion and resolution. Notwithstanding the
foregoing, Atea shall have the right, without needing to so notify [***] and seek Roche’s prior approval, to subcontract non-crucial activities under the Global Development Plan to Third Parties that
would reasonably be acceptable to Roche if the total fees under the subcontract agreement do not exceed [***] and the activities being subcontracted are [***]. 

Roche shall have the right to subcontract the work performed under this Agreement without prior approval of Atea, provided that (A) Roche shall be and
remain responsible and liable for the performance of any such activities by any such subcontractor and (B) such subcontractor must be bound by written obligations (i) of nondisclosure and non-use
that are as protective of Atea’s Confidential Information as this Agreement and (ii) to assign or license and transfer to Roche all right, title and interest to any Invention that is developed or, conceived and reduced to practice by such
subcontractor that is related to the Compound or Product. 
 4. Exclusivity 

Until [***] and subject to Section 2.1.4, Atea shall work exclusively with Roche with regard to Compounds and Products and will not, either on its own or
in collaboration with a Third Party, research, develop or commercialize Compounds or Products in the Field other than pursuant to this Agreement, provided that the foregoing shall not limit Atea’s ability to engage subcontractors as provided in
Section 3 or, in case Atea does not exercise its Co-Promotion Option as provided in Section 2.3, to engage co-promotion partners or other Third Parties to
conduct commercialization activities in the Atea Territory. 
 5. Governance 

5.1 Joint Steering Committee 
 Promptly after the Effective
Date of this Agreement, the Parties shall establish a JSC to oversee the development, marketing and commercialization activities under this Agreement. 

5.2 Members 
 The JSC shall be composed of up to [***]
persons (“Members”). Roche and Atea each shall be entitled to appoint up to [***] Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy
arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [***] days prior to the next scheduled meeting of the JSC. Both Parties shall use reasonable efforts to keep an appropriate level of continuity
in representation. Both Parties may invite a reasonable number of additional experts or advisors to attend part or the whole JSC meeting with prior notification to the JSC provided that such experts or advisors are bound by written obligations
(i) of nondisclosure and non-use that are as protective of each Party’s Confidential Information as this Agreement and (ii) to assign or license and transfer to the relevant Party all right,
title and interest to any Invention that is developed or, conceived and reduced to practice by such experts or advisors that is related to the Compound or Product. Members may be represented at any meeting by another person designated by the absent
Member. The JSC shall be co-chaired by a Member from Atea and a Member from Roche. The Atea and Roche co-chairs will alternate each JSC meeting the lead co-chair responsibilities associated with that meeting (each, a “Lead Co-Chairperson”). 

  
 - 18 - 

 5.3 Responsibilities of the JSC 

The JSC shall have the responsibility and authority to: 
  

	(a)	 manage the overall strategic alignment between the Parties under this Agreement and maintain the relationship
between the Parties; 

  

	(b)	 approve initial Global Development Plan Budget (including FTE allocations by each Party) created by the JOC;

  

	(c)	 approve any development matters referred to the JSC by the JOC (examples may include but are not limited to
material Global Development Plan updates, material Global Development Plan Budget updates, material global medical affairs plan updates, and publication strategy and updates thereto), if these matters are referred to the JSC; 

 

	(d)	 review and discuss the initial plan for commercialization of the Product in the Field in the Territory referred
to the JSC by the JOC; 

  

	(e)	 approve the initial Demand Forecast Plan created by the JMC; 

 

	(f)	 review and approve the manufacturing process recommended by the JMC (i.e., First Generation Process or Second
Generation Process) that shall be used for supplying future commercial material for Product; 

  

	(g)	 approve any manufacturing matters that are referred to the JSC by the JMC, at the discretion of the JMC;

  

	(h)	 discuss and review updates on development of Compounds and Products for the Retained Indications;

  

	(i)	 create or disband JOTs as deemed appropriate; 

 

	(j)	 approve any efforts to develop Back-Up Compounds as an alternative to
the Lead Compound; 

  

	(k)	 establish and delegate specifically defined duties to the JOC or JMC; 

 

	(l)	 establish and set expectations and mandates for JOTs; 

 

	(m)	 oversee the JOTs; 

  

	(n)	 attempt to resolve any disputes, including those referred to it for resolution by the JOC and/or the JMC, on an
informal basis; and 

  

	(o)	 perform such other tasks as agreed by the Parties. 

The JSC shall have no responsibility and authority other than that expressly set forth in this Section. 

5.4 Meetings 
 The Lead
Co-Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JSC meetings to all Members at least [***] days before the next scheduled meeting of the JSC. The venue for
the meetings shall be agreed by the JSC. The JSC shall hold meetings at least once every [***], either in person or by tele-/video-conference, and in any case as frequently as the Members of the JSC may agree shall be necessary. The Alliance
Director of each Party may attend the JSC meetings as a permanent participant but shall not be a Member unless appointed as such. 
 5.5 Minutes 

The Lead Co-Chairperson will be responsible for designating a Member to record in reasonable detail and circulate draft
minutes of JSC meetings to all members of the JSC for comment and review within [***] days after the relevant meeting. An Atea Member will fulfill the role of drafting the minutes for meetings in which an Atea Member is the Lead Co-Chairperson and a Roche 

  
 - 19 - 

 
Member will fulfill the role of drafting the minutes for meeting in which a Roche Member is the Lead Co-Chairperson. The Members of the JSC shall have
[***] days to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JSC within [***] days of the relevant meeting. The Lead
Co-Chairperson shall approve the final version of the minutes before its distribution. 
 5.6 Decisions 

 

	5.6.1	 Decision Making Authority 

The JSC shall decide matters within its responsibilities set forth in Section 5.3, as well as on any matter that is referred to it by the JOC and/or the
JMC for resolution pursuant to Section 5.7.5. 
  

	5.6.2	 Consensus; Good Faith 

The Members of the JSC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JSC. The Parties
shall endeavor to make decisions by consensus. 
  

	5.6.3	 Failure to Reach Consensus 

If the JSC is unable to decide a matter by consensus, then: 
  

	 	(a)	 Atea shall have final decision authority on any matter relating to: (i) [***]; (ii) [***]; (iii) [***]; (iv)
[***]; (v) [***]; and (vi) [***]; 

  

	 	(b)	 Roche shall have final decision authority on any matter relating to: (i) [***]; (ii) [***]; (iii) [***]; (iv)
[***]; (v) [***]; (vi) [***]; (vii) [***]; and (viii) [***]; 

  

	 	(c)	 If the JSC is unable to resolve any other matters not addressed in the foregoing clause (a)—(b), such
matter shall be submitted for resolution pursuant to Section 21.2. 

 5.7 Subcommittees (JOC and JMC) 

 

	5.7.1	 Formation in general; Authority 

The JSC will establish and delegate specifically-defined duties to the JOC and the JMC (each a “Subcommittee”). Each Subcommittee and its
activities will be subject to the oversight of, and will report to, the JSC. No Subcommittee may exceed its authorities specified for the JSC in this Article 5 (Governance). Any disagreement between the representatives of the Parties on a
Subcommittee may, after a reasonably trying to solve such disagreement, at the discretion of either Party, be referred to the JSC for resolution in accordance with Section 5.6 (Decisions). 

 

	5.7.2	 Subcommittee Leadership and Meetings 

Atea will designate a co-chairperson of each Subcommittee and Roche will designate a
co-chairperson of each Subcommittee, each of whom will be a Party’s representative who is a member of such Subcommittee. Each [***], the co-chairpersons of each
Subcommittee will alternate serving in the role of “lead co-chairperson.” The lead co-chairperson for the first Calendar Year will be from [***]. The lead co-chairperson or his or her designee will be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and issuing minutes of each meeting within [***] days
thereafter. Such minutes will be finalized upon endorsement of all Subcommittee members. Each Party may replace its representatives and co-chairpersons on each such Subcommittee at any time upon written notice
to the other Party. Each Subcommittee will hold meetings at such times as it elects to do so and at such locations as the Parties may agree upon or, if agreed by the Parties, by audio or video teleconference, and will designate one of the
participants to minute the meetings. Each Party will be responsible for all of its own expenses of participating in any Subcommittee meeting. 

  
 - 20 - 

	5.7.3	 Joint Operating Committee. 

 

	5.7.3.1	 Formation and Purpose of the JOC 

Within [***] days after the Effective Date, Atea and Roche will establish a Joint Operating Committee (“JOC”), which will be a Subcommittee of
the JSC and will have the responsibilities set forth in this Article 5 (Governance). The JOC will dissolve upon completion of all development activities and medical affairs activities with respect to the Product and the expiration of the Royalty
Term. 
  

	5.7.3.2	 Membership of the JOC 

Each Party will designate up to [***] representatives with appropriate knowledge, expertise, and decision-making authority to serve as members of the JOC;
provided that each Party shall have the same number of representatives as the other Party. Each Party may replace its JOC representatives and co-chairpersons at any time upon written notice to the other
Party. The Alliance Director of each Party (or his or her designee) may attend meetings of the JOC as a non-voting participant. 
  

	5.7.3.3	 Specific Responsibilities of the JOC 

The responsibilities of the JOC will be to: 
  

	(a)	 approve amendments to the Global Development Plan and the Global Development Plan Budget;

  

	(b)	 review and oversee the execution of the Global Development Plan and relating activities; 

 

	(c)	 facilitate the exchange of information between the Parties with respect to the development and registration of
the Compounds and the Products in the Field and in the Territory; 

  

	(d)	 discuss and align on strategies for investigator-sponsored studies, and approve such studies, with respect to
the Compounds and the Products in the Field and in the Territory and any development activities with respect to any delivery device for the Products for incorporation in the Global Development Plan; 

 

	(e)	 review, discuss and refer to the JSC the initial plan for commercialization of the Product in the Field in the
Territory, as well as any later updates thereto; 

  

	(f)	 develop, approve, and adapt publication plans and medical affairs plans for the Compounds and Products in the
Field, as needed; 

  

	(g)	 facilitate the exchange of information between the Parties with respect to the commercialization of the
Compounds and the Products in the Field and in the Territory; 

  

	(h)	 discuss and consider in good faith any global guidelines and strategy for pricing (which shall be non-binding); 

  

	(i)	 coordinate with JOTs; 

 

	(j)	 attempt to resolve any disputes arising within its jurisdiction on an informal basis; 

 

	(k)	 discuss and evaluate if any disagreements relating to development or commercialization within the JOC’s
responsibility should be referred to the JSC (for clarity, each Party has the right to refer any disagreement to the JSC that is not resolved at the JOC, even without the other Party’s consent); and 

  
 - 21 - 

	(l)	 perform such other tasks as agreed by the Parties.  

The JOC shall have no responsibility and authority other than that expressly set forth in this Section. 

 

	5.7.4	 Joint Manufacturing Committee. 

 

	5.7.4.1	 Formation and Purpose of the JMC 

Within [***] days after the Effective Date, the Parties will establish a Joint Manufacturing Committee (the “JMC”), which will be a
Subcommittee of the JSC and will have the responsibilities set forth in this Article 5 (Governance). The JMC will dissolve upon the completion or earlier termination of all manufacturing activities under the Supply Agreement. 

 

	5.7.4.2	 Membership of the JMC 

Each Party will designate up to [***] representatives with appropriate knowledge, expertise, and decision-making authority to serve as members of the JMC;
provided that each Party shall have the same number of representatives as the other Party. Each Party may replace its JMC representatives and co-chairpersons at any time upon written notice to the other
Party. The Alliance Director of each Party (or his or her designee) may attend meetings of the JMC as a non-voting participant. 
  

	5.7.4.3	 Specific Responsibilities of the JMC 

The responsibilities of the JMC will be to: 
  

	(a)	 prepare the initial Demand Forecast Plan for JSC approval, and review and approve any subsequent updates;

  

	(b)	 develop, approve, and adapt capacity plans, manufacturing plans, and any other plans related to manufacturing
of the Compounds and Products, as needed; 

  

	(c)	 review and oversee the execution of the Demand Forecast Plan, and any other plans, if applicable;

  

	(d)	 review and oversee the Parties’ respective activities in First Generation Process Development, Early
Second Generation Process Development, Later Second Generation Process Development and Commercial Scale-Up, and recommend to the JSC which process (First Generation Process or Second Generation Process) shall
be used for supplying future commercial material for Product; 

  

	(e)	 discuss and decide on a hand-over plan of supply responsibilities pursuant to Section 8.1.1;

  

	(f)	 monitor and implement the technology transfer to Roche pursuant to Section 8.1.3; 

 

	(g)	 discuss, align, consolidate, update and approve the Demand Forecast Plan as needed; 

 

	(h)	 coordinate with JOTs; 

 

	(i)	 attempt to resolve any disputes arising within its jurisdiction on an informal basis; 

 

	(j)	 discuss and evaluate if any disagreements relating to manufacturing matters should be referred to the JSC (for
clarity, each Party has the right to refer any disagreement to the JSC that is not resolved at the JMC, even without the other Party’s consent); and 

  

	(k)	 perform such other tasks as agreed by the Parties. 

The JMC shall have no responsibility and authority other than that expressly set forth in this Section. 

  
 - 22 - 

	5.7.5	 Decision-Making of the Subcommittees 

Each Party shall have an equal number of representatives on the Subcommittees. The Subcommittees shall strive to take any decisions on a unanimous basis. If
any Subcommittee cannot reach unanimous agreement using good faith efforts on any matter within their respective scope of authority at the meeting at which such matter was discussed or if a meeting of such Subcommittee is not held within a
reasonable period of time or the meeting minutes are not finalized in due time, then a Party may refer such matter to the JSC for resolution. 
 5.8
Joint Operational Teams 
 The JSC shall have the right to establish JOTs, which may include but will not be limited to a Development JOT. 

5.9 Information Exchange 
 Atea and Roche shall exchange
the information in relation to its activities under this Agreement through the JSC and the Subcommittees, and Atea and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and each Party shall
give due consideration to the other Party’s input. The JSC may determine other routes of information exchange. 
 5.10 Alliance Director 

Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each,
an “Alliance Director”). The Alliance Directors shall be permanent participants of the JSC meetings (but not Members of the JSC) and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of
potential and pending issues and potential disputes to enable the JSC to reach consensus and avert escalation of such issues or potential disputes. 

5.11 Limitations of Authority 
 The JSC, JOC and JMC shall
have no authority to amend or waive any terms of this Agreement. 
 5.12 Expenses 

Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JSC, JOC and JMC. 

5.13 Lifetime 
 The JSC shall exist during the Agreement
Term, unless earlier discontinued by mutual agreement of the Parties. The lifetime of the JOC and the JMC is described under Section 5.7.3.1 (for the JOC) and Section 5.7.4.1 (for the JMC). 

 

	6.	 Development 

6.1 Atea Ongoing Studies 
 Atea shall, [***], use
Commercially Reasonable Efforts to conduct and complete the Atea Ongoing Studies. Atea shall provide Roche [***] updates at interim analysis points and at least once [***] regarding the progress and status of the Atea Ongoing Studies,
including [***]. 
 6.2 Global Development Plan 

Subject to the terms and conditions of this Agreement, and except as otherwise provided in Article 6, the Parties shall jointly develop the Products in the
Territory in accordance with the Global Development Plan and under the governance of the JSC. The responsibility of Roche and Atea to operationalize the global clinical development will be described in the Global Development

  
 - 23 - 

 
Plan. The Global Development Plan shall be regularly amended and updated. Roche and Atea shall each use Commercially Reasonable Efforts to perform their respective tasks and obligations in
conducting all activities ascribed to them in the then-current Global Development Plan, in accordance with the time parameters set forth therein. The parties will share the costs associated with activities conducted under the Global Development
Plan. FTE Costs and Out of Pocket Expenses incurred by or on behalf of either Party or any of its Affiliates in connection with its activities under the Global Development Plan[***] shall be share equally (50/50) by the Parties, [***]. Neither Party
shall pursue Third Party funding for any Clinical Study under the Global Development Plan that is not an Atea Ongoing Study without the approval of the JSC. 

The Parties shall disclose and make available to each other all data and information necessary to conduct the development activities under the Global
Development Plan. The Parties shall answer any questions reasonably posed by the other Party and provide any information reasonably requested by the other Party. 

6.3 Additional Clinical Studies and Other Studies 
 Prior
to initiating a new Clinical Study (including, for the purposes of this Section, any marketing studies, Post-Approval Commitment Studies, and Phase IV Studies for the Product) that is not an Ongoing Atea Study and is not an ongoing Unilateral Study
(as defined below) or included in the then-current Global Development Plan, the Party that desires to conduct such Clinical Study (the “Proposing Party”) shall propose such Clinical Study to the JOC, which proposal shall include a
synopsis of the protocol for such Clinical Study and an estimated budget for such Clinical Study. If the JOC agrees that the Parties should conduct such Clinical Study, then the Parties shall amend the Global Development Plan to
include such Clinical Study. If the JSC does not agree that the Parties should conduct such Clinical Study, then the Proposing Party shall have the right, but not the obligation, to conduct such Clinical Study at its sole expense (each such Clinical
Study, a “Unilateral Study”), provided that (i) [***], and (ii) [***]. For clarity, neither Party shall have the obligation to conduct or, except as may be required by Applicable Law or ethical requirements, complete any Unilateral
Study. 
 Notwithstanding anything to the contrary in the foregoing, the Party which is not the Proposing Party, after good faith discussion in the JSC,
shall have the right to require the Proposing Party to not conduct a proposed Unilateral Study, if [***] such Unilateral Study [***]. 
 With
respect to each Unilateral Study, if the Party not performing such Unilateral Study uses any data or results from such Unilateral Study to obtain, maintain or expand any Regulatory Approval or any pricing or reimbursement for, otherwise includes
such data or results in the label for, or uses such data and results to commercialize, a Product in its Respective Territory, then such non-performing Party shall reimburse the Party that performed such
Unilateral Study for [***] incurred by or on behalf of such performing Party or any of its Affiliates in connection with such Unilateral Study to the extent such costs are not funded by a Third Party. Notwithstanding the foregoing, the submission of
data and results from a Unilateral Study to a Regulatory Authority only for safety reporting purposes in connection with periodic safety reporting or as a courtesy copy shall not result in a reimbursement obligation under this paragraph. The Party
not performing the applicable Unilateral Study shall promptly notify the performing Party of any use of the data or results of such Unilateral Study that would result in a reimbursement obligation under this paragraph.  

6.4 Intravenously-Administered Formulation of Lead Compound 

To the extent the JSC determines that an intravenously-administered formulation of the Lead Compound (an “IV Lead Compound Formulation”) is
required for Clinical Studies for Hospitalized Patients, Roche may develop an IV Lead Compound Formulation. [***]. To the extent the JSC does not endorse the development of an IV Lead Compound Formulation, then Roche may, at its own cost and
expense, develop such IV Lead Compound Formulation. In each case, for [***], Atea will supply Roche with GMP API for use in the development of the formulation of the IV Lead Compound Formulation and for clinical supply of IV Lead Compound
Formulation as provided in Section 8.1. 

  
 - 24 - 

 6.5 Development Records 

Each Party shall maintain records of its activities under the Global Development Plan and for Clinical Studies, Post-Approval Commitment Studies and Phase IV
Studies of Product conducted pursuant to this Agreement outside the Global Development Plan (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or
on behalf of such Party in the performance of the development. 
 6.6 Back-Up Compounds 

The JSC will evaluate from time to time whether any non-clinical or clinical studies should be conducted for Back-Up Compounds. If the JSC determines to pursue development of Back-Up Compounds for potential development if the Lead Compound demonstrates material safety or efficacy
concerns, the Parties shall agree on an adjustment to the Global Development Plan and the Global Development Plan Budget to reflect such additional activities. 
  

	7.	 Regulatory 

  

	7.1	 Responsibility 

Atea shall have the right and the responsibility for all regulatory affairs related to Products in the Atea Territory, including the preparation and filing of
applications for Regulatory Approval (other than for manufacturing by Roche or its CMO or other Third Party manufacturer) in the Atea Territory (for clarity, for Unilateral Studies conducted by Roche in the Atea Territory, Atea shall transfer
responsibility for the conduct of such studies to Roche). Roche shall have the right to participate in all regulatory interactions, as well as in the preparations therefor, as an observer, other than for Products for the Retained Indications, where
permitted by such Regulatory Authority. All regulatory filings for all Products in all countries of the Atea Territory (other than regulatory filings for manufacturing by Roche or its CMO or other Third Party manufacturer) and all data related
thereto shall be owned by Atea, its Affiliates or licensees. 
 Atea shall also be solely responsible for all regulatory affairs related to the conduct of
the Atea Ongoing Studies until hand-over of responsibility therefor to Roche as determined by the JSC, any Unilateral Studies conducted by Atea in the Roche Territory, and all Clinical Studies of Products in the Roche Territory for the Retained
Indications. Atea shall provide reasonable advance notice of any meeting with any Regulatory Authority in the Roche Territory related to the Atea Ongoing Studies or Unilateral Studies conducted by Atea, and Roche shall have the right, at its own
discretion, to participate in any such meeting with Regulatory Authorities in the Roche Territory. 
 Roche shall have the right and the responsibility for
all regulatory affairs related to Products in the Roche Territory, including the preparation and filing of applications for Regulatory Approval in the Roche Territory (other than for Unilateral Studies, Clinical Studies for the Retained Indications
and, until hand-over of responsibility to Roche as determined by the JSC, Atea Ongoing Studies, in each case conducted by Atea in the Roche Territory). Atea shall have the right to participate in all regulatory interactions, as well as in the
preparations therefor, as an observer, where permitted by such Regulatory Authority. All regulatory filings for all Products in all countries of the Roche Territory (other than regulatory filings for the Atea Ongoing Studies conducted by Atea in the
Roche Territory prior to hand-over, and all Clinical Studies for the Retained Indications) and all data related thereto shall be owned by Roche, its Affiliates or licensees. 

  
 - 25 - 

 Roche shall also be solely responsible for all regulatory affairs related to the conduct of any Unilateral
Studies conducted by Roche in the Atea Territory. Roche shall provide reasonable advance notice of any meeting with any Regulatory Authority in the Atea Territory related to the Unilateral Studies conducted by Roche, and Atea shall have the right,
at its own discretion, to participate in any such meeting with Regulatory Authorities in the Atea Territory. 
 At a date to be defined by the JSC, Atea
shall transfer to Roche all (i) regulatory filings in its possession and control relating to the Product in the Field in the Roche Territory (other than for Unilateral Studies conducted by Atea in the Roche Territory, and Clinical Studies of
Product in the Retained Indications in the Roche Territory), (ii) copies of all relevant historical clinical data for the Product in the Field in the Roche Territory, (iii) copies of all material correspondence with the Regulatory Authorities
for the Product in the Field in the Roche Territory, (iv) copies of regulatory dossiers containing information necessary or useful to Roche in connection with its regulatory filings for all Products in the Field in the Roche Territory,
including, but not limited to clinical trial dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and clinical studies, and
(v) comprehensive electronic Clinical Study, Post-Approval Commitment Study and Phase IV Study data relevant to the Product in the Field in an appropriate format. For all completed study reports so transferred to Roche, Atea shall provide
necessary documentation to confirm data reliability, including, but not limited to original author signatures, raw data lists, GLP and GCP compliance information. All documentation is to be provided in English. Atea shall assist Roche in conducting
any required GMP audit related to the above-mentioned documentation. Roche shall have the right to use all data and documents provided to Roche under this paragraph in its own filings and interactions with Regulatory Authorities for the Product in
the Field in the Roche Territory, and for Unilateral Studies conducted by Roche in the Atea Territory, also in the Atea Territory. 
 From time to time as
agreed by the JSC, Roche shall transfer to Atea (i) copies of all relevant historical clinical data for the Product in Roche’s possession or control, (ii) copies of all material correspondence with the Regulatory Authorities for the
Product in the Field in the Roche Territory, (iii) copies of regulatory dossiers containing information necessary or useful to Atea in connection with its regulatory filings for all Products, including, but not limited to clinical trial
dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and clinical studies, and (iv) comprehensive electronic Clinical Study,
Post-Approval Commitment Study and Phase IV Study data relevant to the Products in an appropriate format. For all completed study reports so transferred to Atea, Roche shall provide necessary documentation to confirm data reliability, including, but
not limited to original author signatures, raw data lists, GLP and GCP compliance information. Roche shall assist Atea in conducting any required GMP audit related to the above-mentioned documentation. Atea shall have the right to use all data and
documents provided to Atea under this paragraph in its own filings and interactions with Regulatory Authorities for the Product in the Field in the Atea Territory, and for Unilateral Studies, Clinical Studies for the Retained Indications, and Atea
Ongoing Studies until hand-over of responsibility to Roche, in each case conducted by Atea in the Roche Territory, also in the Roche Territory. 
 In the
event a Party cannot conduct regulatory activities independent of the other Party which would be needed to pursue Regulatory Approval of Products in the Roche Territory (for Roche) or the Atea Territory (for Atea), the other Party shall use
Commercially Reasonable Efforts to assist the first Party and/or conduct any such regulatory activities on the first Party’s behalf at the first Party’s cost and expense. 

  
 - 26 - 

 Atea shall have, and Roche hereby grants to Atea, a right of reference and access to the regulatory filings
for Product made by Roche in the Roche Territory, for the purpose of making regulatory filings in the Atea Territory for Product. Roche shall have, and Atea hereby grants to Roche, a right of reference and access to the regulatory filings for
Product made by Atea in the Atea Territory, for the purpose of making regulatory filings in the Roche Territory for Product. 
 Notwithstanding the
foregoing, Atea shall have the right and the responsibility for all regulatory affairs related to Products in the Territory for the Retained Indications, including the preparation and filing of applications for Regulatory Approval in the Retained
Indications in the Territory. 
 7.2 Pharmacovigilance Agreement 

The Parties shall execute a separate pharmacovigilance agreement as deemed applicable as soon as practicable after the Effective Date, but no later than the
Initiation of the first Phase III Study in the Roche Territory or the first Regulatory Approval in the Roche Territory after the Effective Date (whichever comes first). Such pharmacovigilance agreement shall set forth the responsibilities and
obligations of the Parties with respect to the procedures and timeframes for compliance with the applicable laws and regulations pertaining to safety reporting of the Product(s) and their related activities. 

8. Manufacture and Supply 
 8.1 Clinical Supply of
Product and Technology Transfer
  

	8.1.1	 [***] Manufacture and Supply by Atea 

Atea shall have the responsibility for supplying API for technical development, as well as for clinical supply of the Products for the Field in the Territory
for [***], and [***] of such supply by Atea, other than for the Atea Ongoing Studies and any Unilateral Study conducted by Atea, shall be [***]. Notwithstanding the foregoing, Roche will have the right to take over any part of the manufacture and
supply of the Product for the Field in the Roche Territory at any time during [***]. The Parties will meet during [***] to discuss and decide on a hand-over plan of supply responsibilities in order to ensure a seamless continuation of manufacturing
and supply beyond [***]. 
  

	8.1.2	 Manufacture and Supply after [***] 

[***], after [***], Atea will remain responsible, at its own expense, for the manufacture and supply of clinical supplies of the Products for any Unilateral
Study conducted by Atea and any Atea Ongoing Studies, and Roche shall be responsible at its own expense for the manufacture and supply of clinical supplies of the Products for sites included in the Clinical Studies conducted pursuant to the Global
Development Plan other than any Atea Ongoing Studies, and for all sites for any Unilateral Study conducted by Roche. Notwithstanding the foregoing, the Parties will use Commercially Reasonable Efforts to ensure that the clinical supply of Products
for use in the Field is obtained in a manner that is cost efficient and practical, which may include utilizing the other Party or the other Party’s CMO or other Third Manufacturer, as applicable. 

 

	8.1.3	 First Generation Process Technology Transfer 

Atea shall initiate within [***] days of the Effective Date a technology transfer to Roche in accordance with the plan set forth in Appendix 8.1.3 (as may
be revised by mutual consent of the Parties) to enable Roche (or Roche’s designee(s)) to manufacture Compounds and Products using the First Generation Process. 
  

	8.1.4	 Second Generation Process Technology Transfer 

In addition, within [***] days after completion of the Early Second Generation Process Development for the Second Generation Process, Atea shall initiate
substantially the same 

  
 - 27 - 

 
technology transfer to Roche with respect to the Second Generation Process to enable Roche (or Roche’s designee(s)) to conduct the Later Process Development for the Second Generation Process
in accordance with a mutually agreed technology transfer plan. Atea shall inform Roche regularly at the JMC about its development efforts regarding the Second Generation Process, including about Atea’s interactions with Third Parties that are
involved in such development efforts. In addition, and upon Roche’s request, Atea shall provide Roche with all information and documents regarding such development efforts. In case the JSC decides to use the Second Generation Process for
commercial supply, Atea shall complete within [***] days substantially the same technology transfer to Roche as for the First Generation Process with respect to the Second Generation Process to enable Roche (or Roche’s designee(s)) to conduct
the Later Process Development for the Second Generation Process in accordance with a mutually agreed technology transfer plan. 
  

	8.1.5	 Costs and Expenses of Technology Transfer 

 

	[***].	 

8.2 Commercial Supply of Products 
 Roche shall be
responsible for the manufacture of commercial supplies of the Product for use in the Field in the Territory. Atea shall order all commercial supplies of the Product for use in the Field for the Atea Territory from Roche. Unless otherwise agreed by
the Parties, within [***] days after the Effective Date, the Parties will negotiate in good faith and enter into a written supply agreement for the commercial supply of Products for use in the Field by Roche to Atea, with a related quality agreement
providing for commercial supply of Product for use in the Field by Roche to Atea as the primary supplier and on the terms set forth in Appendix 8.2 hereto and other reasonable and customary terms (the “Supply Agreement”). 

Promptly after the Effective Date, each Party will prepare an initial good faith [***] rolling forecast of its demand, split into [***] buckets, in the Atea
Territory or the Roche Territory (as applicable) for the Product for commercialization purposes in the Field (each a “Demand Forecast Plan”). The Parties shall discuss and align the Demand Forecast Plans for consolidation to be
presented and approved at the JSC. 
 In the event of a Roche Inability to Supply, following discussion between the Parties, solely during the pendency of
such Roche Inability to Supply (unless otherwise agreed by the Parties, such agreement not to be unreasonably withheld), Atea may engage its own CMO(s) for commercial supply of the Product for use in the Field for the Atea Territory to the extent in
accordance with the Demand Forecast Plan and according to Roche’s Safety, Security, Health and Environmental Protection (SHE) and GMP standards. 

8.3 Manufacturing Process Development and Specifications 
  

	8.3.1	 Early Second Generation Process Development 

Atea shall have the responsibility at its own expense for the development of the Second Generation Process until the manufacture of a batch of at least [***]
of Drug Substance is achieved, consisting of [***], using the Second Generation Process and meeting the applicable Specifications (the “Early Second Generation Process Development”). Roche will cooperate with and provide reasonable
consultative and in-kind support of such Early Second Generation Process Development at its own expense. 

  
 - 28 - 

	8.3.2	 First Generation Process Development, Later Second Generation Process Development and Commercial Scale-Up 

 Subject to Atea’s technology transfer obligations pursuant to Section 8.1.3, Roche
shall have the responsibility [***] for (a) any further development and scale-up of the First Generation Process (“First Generation Process Development”), (b) the development and scale-up of the Second Generation Process after the Early Second Generation Process Development (the “Later Second Generation Process Development”), and
(c) scale-up of global commercial manufacturing of Drug Product (“Commercial Scale-Up”). Atea will cooperate with and provide reasonable
consultative and in-kind support of such First Generation Process Development, Later Second Generation Process Development and Commercial Scale-Up [***]. 

 

	8.3.3	 Specifications 

The Parties will mutually agree in good faith on the manufacturing and release specifications, including without limitation testing methods and acceptance
criteria, for Drug Substance and Drug Product, for each of the First Generation Process and the Second Generation Process (for the Second Generation Process as further specified in Appendix 8.3.3), in each case as updated by the JSC from time to
time (the “Specifications”). Each Party shall be solely responsible for establishing the specifications for packaging and labeling of finished Drug Product in its Respective Territory. 

 

	8.3.4	 Decision Making 

The Parties will collaborate and strive for consensus decision making on matters relating to First Generation Process Development, Early Second Generation
Process Development, Later Second Generation Process Development, Commercial Scale-Up, Specifications and the choice of whether to use the First Generation Process or Second Generation Process for commercial
manufacturing of Drug Substance, through the JMC. If the Parties are unable to agree on any such matters, the matter will be escalated to the JSC. 
 8.4
Supply for Retained Indications 
 Notwithstanding anything to the contrary in this Article 8, Atea shall have the sole right and responsibility for the
supply of Compound and Product in the Territory for the Retained Indications at its own cost, unless the Parties otherwise agree in writing. 
  

	9.	 Commercialization 

 

	9.1	 Responsibility 

Roche, at its own expense, shall have the sole responsibility and decision-making authority for the marketing, promotion, sale and distribution of Products in
the Field in the Roche Territory. 
 Atea, at its own expense, shall have the sole responsibility and decision-making authority for the marketing,
promotion, sale and distribution of Products in the Atea Territory (subject to Section 2.3 and any Co-Promotion Agreement). 

The JOC will review the Parties’ commercialization plans for their Respective Territories for Product for use in the Field, to monitor brand messaging
and to make recommendations for consistency and optimization of such messaging. Atea shall in good faith consider reasonable comments from Roche relating to commercialization plans for the Product in the Field in the Atea Territory, made through the
JOC or JSC. 
 9.2 Pricing 
 The Parties will consider
in good faith any global guidelines and strategy for pricing agreed to by the JSC (which shall be non-binding) in establishing pricing of Products. Notwithstanding any provision to the contrary set forth in
this Agreement, all decisions for each Product related to any 

  
 - 29 - 

 
pricing matter, including list price, targeted net pricing, sales-weighted average discounts and rebates, pricing strategy (including the approach to pricing with different types of accounts and
plans, including types of discounts and rebates), any non-U.S. equivalents of all of the foregoing, and modifications to any of the foregoing, will be solely made by (a) Roche for the Roche Territory and
(b) Atea for the Atea Territory. 
 9.3 Diligence 

Roche shall use Commercially Reasonable Efforts to pursue further development and commercialization of Products in the Field in the Roche Territory (other than
for the Retained Indications, unless and until the Parties enter into an amendment pursuant to Section 2.1.4). Atea shall use Commercially Reasonable Efforts to pursue further development (and commercialization, in case Atea exercises its Co-Promotion Option) of Products in the Field in the Atea Territory (other than for the Retained Indications). Roche shall be deemed to use Commercially Reasonable Efforts if Roche develops and commercializes at
least one Product in at least one Indication. Roche (and its Affiliates) shall not be obliged to seek to market such Product in every country or seek to obtain Regulatory Approval in every country of the Roche Territory. As a result, the exercise of
diligence by Roche is to be determined by judging Roche’s Commercially Reasonable Efforts in the Roche Territory, taken as a whole. 
 10. Payment

 10.1 Initiation Payment 
 Within [***] days after
the Effective Date and receipt of an invoice from Atea, Roche shall pay to Atea three hundred and fifty million US Dollars (US$ 350,000,000). 

10.2 Development and Regulatory Event Payments 
 Roche
shall pay up to a total of three hundred and thirty million US Dollars (US$ 330,000,000) in relation to the achievement of development and regulatory events with respect to Products. The development and regulatory event payments under this
Section 10.2 shall be paid by Roche according to the following schedule of development and regulatory events: 
  

			
	 Development and Regulatory Event
	  	US Dollars (in millions)
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	Total potential development and regulatory event payments:	  	330

 Each development and regulatory event payment shall be paid only once, the first time that any Product reaches the applicable
triggering event and receipt of an invoice, regardless of the number of times such events are reached and by how many Products, subject to Section 10.5. 

Upon reaching development and regulatory events (or in the case of manufacture by Atea of a Qualifying Second Generation Batch, receipt of notice by Roche
from Atea that Atea has reached such development and regulatory event and confirmation by Roche of the same), Roche shall notify Atea within [***] days of the achievement of each milestone event described in this Section 10.2 and shall be paid
by Roche to Atea within [***] days after receipt of an invoice from Atea. 

  
 - 30 - 

 10.3 Sales Based Events 

Roche shall pay to Atea up to a total of three hundred and twenty million US Dollars (US$ 320,000,000) based on Calendar Year Net Sales of a Product in
the Roche Royalty Territory: 
  

			
	 Sales-Based Event
	  	US Dollars (in millions)
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	Total potential sales-based event payments:	  	320

 Each of the sales-based event payments shall be paid no more than once [***] days after the end of the Calendar Quarter in
which the event first occurs for the Product in the Roche Royalty Territory first reaching the respective Calendar Year Net Sales threshold and receipt of an invoice from Atea, and shall be non-refundable 

10.4 Royalty Payments. 
 10.4.1 Royalty Term 

On a Product-by-Product and country-by-country basis, Roche shall pay to Atea royalties on Net Sales of Products in such country in the Roche Royalty Territory during the relevant Royalty Term. Thereafter, the licenses granted to Roche
for a given Product in such country shall be fully paid up, irrevocable and royalty-free. 
 10.4.2 Royalty Rates 

The following royalty rates shall apply to the respective tiers of aggregate Calendar Year Net Sales of a Product in the Roche Royalty Territory, on an
incremental basis, as follows: 
  

			
	 Tier of Calendar Year

Net Sales in million US$
	  	 Percent (%) of Net Sales

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 For example, if Net Sales of a Product in the Roche Royalty Territory for a given Calendar Year are US$ [***] million, and
such Product is a Patent Product, then royalties owed to Atea on such Net Sales of such Product for that Calendar Year shall equal US$ [***] calculated as follows: 

[***] 
 For the purpose of calculating royalties
for a Product, Calendar Year Net Sales and the royalty rates shall be subject to the following adjustments, as applicable: 
 10.4.3 Combination Product

 If Roche or its Affiliates intend to sell a Combination Product, then the Parties shall meet approximately [***] prior to the anticipated First Commercial
Sale of such Combination Product in the Territory to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative commercial value contributed by the components of the Combination Product (the “Relative
Commercial Value”). If, after such good faith negotiations not to exceed [***] days, the Parties cannot agree to an appropriate adjustment, the dispute shall be initially referred to the executive officers of the Parties in accordance with
Section 21.2. 

  
 - 31 - 

 If the Parties are unable to agree on the Relative Commercial Value within [***] days of such referral, then
the Relative Commercial Value shall be determined by the following procedure. Roche will select [***], Atea will select [***], and those [***] individuals shall select [***] and who shall be chairman of a committee of the [***] Experts (the
“Expert Committee”), each with a single deciding vote. The Expert Committee will promptly hold a meeting to review the issue under review, at which it will consider memoranda submitted by each Party at least [***] days before the
meeting, as well as reasonable presentations that each Party may present at the meeting. The determination of the Expert Committee as to the issue under review will be binding on both Parties. The Parties will share equally in the costs of the
Expert Committee. Unless otherwise agreed to by the Parties, the Expert Committee may not decide on issues outside the scope mandated under terms of this Agreement. 

10.4.4 No Valid Claim; Generic Competition 
 For a given Product,
if in a given country within the Territory there is: 
  

	(a)	 no Composition of Matter Claim that Covers such Product remains in such country (i.e., such Product is not a
Patent Product in such country); or 

  

	(b)	 entry of a Generic Product has occurred; 

then the royalty payments due to Atea for such Product in such country shall be reduced by [***]. If both a) and b) have occurred, then the Royalty Term for
such Product in such country shall end (unless the Royalty Term had expired prior to such time for a given Product in a given country), royalties shall no more be due by Roche in such country for such Product, and the license in that country for
such Product shall be fully paid-up and irrevocable. 
 10.4.5 Apportionment of Compulsory Sublicensee Consideration

 Compulsory Sublicense Compensation received by the Roche Group from a Compulsory Sublicensee during the Royalty Term for a Product in a country shall be
shared with Atea on an equivalent profit share percentage (the “Compulsory Profit Share Percentage”) calculated for the respective Calendar Year as follows: 

[***] 
 At the end of the Calendar Year, Roche shall pay to Atea
the [***]. For clarity, any sales or payments by Compulsory Sublicensees under a Compulsory Sublicense shall not be considered as Net Sales and shall not give rise to any royalty payment under Section 10.4.2 of this Agreement. 

10.5 Payments for Products containing [***] 
 In case the
JSC decides to pursue development or commercialization of a Product that contains a [***], then at the time such decision is made, the Parties shall discuss in good faith any reasonable adjustments that may be appropriate to make to the payments
from Roche to Atea based on Sections 10.2, 10.3, and 10.4, prior to commencement of any such activities, subject to the following sentence. [***]. 

  
 - 32 - 

 10.6 Third Party Payments 

[***] shall be responsible for and pay or have paid the entire consideration owed to any Third Party in relation to [***]. To the extent [***] fails to make
any [***] when due, [***] may make such payment to the applicable Third Party [***]. In such event, or if [***] as provided in [***] or enters into a [***] as provided in [***] and makes [***] thereunder, [***] may request [***] as provided in [***]
or [***] of such [***] under this Agreement. 
 The responsibility for payment of consideration owed to any Third Party in relation to [***] shall be [***].
The Party making [***] shall be [***] (or, in the case of [***]). 
 In the event that both [***] and [***] are made under the same agreement with the same
Third Party and cannot be clearly distinguished from each other, then the Parties will discuss in good faith and agree on which part of such payments is attributable to [***] or [***]. If, after such good faith negotiations not to exceed [***] days,
the Parties cannot agree to an appropriate allocation, the dispute shall be initially referred to the executive officers of the Parties in accordance with Section 21.2. If the Parties are unable to agree on the allocation within [***] days of
such referral, then such allocation shall be determined by the procedure described in the second paragraph of Section 10.4.3. 
 10.7 Disclosure of
Payments 
 Each Party acknowledges that the other Party may be obligated to disclose this financial arrangement, including all fees, payments and
transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act.     
 11. Accounting and
reporting
 11.1 Timing of Royalty Payments 
 Roche
shall calculate royalties on Net Sales quarterly as of March 31, June 30, September 30 and December 31 (each being the last day of an “Accounting Period”) and shall share with Atea within [***] days after the end
of each Accounting Period in which Net Sales occur a good faith estimate of the royalties payable to Atea for such Accounting Period. Within [***] days after the end of each Accounting Period, Roche shall pay the royalties on Net Sales to Atea in
line with the finally reported Net Sales for each Calendar Quarter as set forth in Section 11.6, which finally reported Net Sales (i) Roche shall report to Atea during such time period, (ii) may deviate from the good faith estimate
provided earlier, and (iii) shall be relevant for the purposes of calculating the royalty owed under Section 10.4. 
 11.2 Late Payment

 Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable
Law, at [***] percentage points above the [***], as reported by Reuters from time to time, calculated on the number of days such payment is overdue. 

11.3 Method of Payment 
 Royalties on Net Sales shall be
paid by Roche in US Dollars (the “Payment Currency”) to account(s) designated by Atea. All other amounts payable by a Party to the other Party hereunder shall be paid in the Payment Currency to account(s) designated by the other
Party. 
 11.4 Currency Conversion 
 When calculating
the Sales of any Product that occur in currencies other than the Payment Currency, Roche shall convert the amount of such sales into Swiss Francs and then into the Payment Currency using Roche’s then-current internal foreign currency
translation method actually used on a consistent basis in preparing its audited financial statements (at the Effective Date, YTD average rate as reported by Reuters). 

  
 - 33 - 

 11.5 Blocked Currency 

In a given country, if by reason of Applicable Law (for example governmental restrictions on foreign exchange trade) the local currency is blocked and cannot
be removed from such country, Roche will notify Atea in writing and 
  

	(a)	 Atea will have the right to receive the applicable royalties of Net Sales in such country in local currency by
deposit in a local bank designated by Atea, or 

  

	(b)	 if such local currency payment is not allowed by reason of Applicable Law or if otherwise requested by Atea,
then the royalties related to such Net Sales in such country shall continue to be accrued and shall continue to be reported, but such royalties will not be paid until the sales proceeds related to such Net Sales may be removed from such country. At
such time as Roche, its Affiliates or their Sublicensees, as the case may be, is able to remove the sales proceeds related to such Net Sales from such country, Roche shall also pay such accrued royalties in Payment Currency using the actual exchange
rate which is used to remove such sales proceeds from such country. 

 11.6 Royalty Reporting 

With each royalty payment Roche shall provide Atea in writing for the relevant Calendar Quarter on a Product-by-Product basis the following information: 
  

	(a)	 Sales in Swiss Francs; 

 

	(b)	 Net Sales in Swiss Francs; 

 

	(c)	 adjustments made pursuant to Section 10.4.3, adjustments made pursuant to Sections 10.4.4 or 10.5; and

  

	(d)	 total royalty payable in the Payment Currency after adjustments made pursuant to Sections 10.4.4 or 10.5 and
the conversion rate used to calculate the same. 

 11.7 Reimbursement 

For reimbursement of Out of Pocket Expenses and FTE Costs incurred by or on behalf of either Party or any of its Affiliates in connection with its activities
under [***], as soon as practicable after the end of each Calendar Quarter, but in any event no later than [***] days after the end of each such Calendar Quarter, each Party shall share with the other Party a good faith estimate of such reimbursable
costs incurred by such Party. In no event later than [***] days after the end of such Calendar Quarter each Party shall update the good faith estimate to reflect changes in the Out of Pocket Expenses and FTE Costs (each, a
“Reconciliation Interim Report”), together with reasonable supporting documentation for such costs. Each Party shall have [***] days after the delivery of the other Party’s Reconciliation Interim Report to review
and ask questions. 
 Within [***] days following the end of such Calendar Quarter, each Party shall update its Reconciliation Interim Report to reflect the
final amounts and the Parties shall coordinate to aggregate the reports to calculate the total amount to be reimbursed under this Agreement (“Reconciliation Final Report”). The Party that owes payment to the other Party pursuant to
the Reconciliation Final Report shall pay such amount (to the extent not subject to a good faith dispute) within [***] days after receipt of an invoice from the Party that is due payment. 

For all amounts for which a Party (the “Owing Party”) is obligated to reimburse or pay the other Party (the “Owed Party”)
pursuant to this Agreement for which no specific provision is provided hereunder regarding how such payment shall be made, the Owed Party shall send to the Owing Party an invoice for such amount within [***] days after the Owed Party’s
determination that such amount is payable by the Owing Party, which invoice shall include a reference to the section of 

  
 - 34 - 

 
this Agreement under which the Owed Party is requesting reimbursement or payment and be accompanied by reasonable documentation of the incurrence or accrual of the costs to be reimbursed. Payment
with respect to each such invoice shall be due within [***] days after receipt by the Owing Party thereof. 
 12. Taxes 

12.1 Indirect Taxes 
 All payments provided for in this
Agreement are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any such payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of any such payments following the receipt, where
applicable, of an Indirect Taxes invoice issued by the payee Party in respect of those payments. The Parties shall cooperate in good faith to minimize Indirect Taxes addressed in this Section 12.1 in accordance with Applicable Law. 

12.2 Tax Withholding 
 Each Party shall be entitled to
deduct and withhold from any amounts payable under this Agreement such taxes as are required to be deducted or withheld therefrom under any provision of Applicable Law; provided, however, that [***]. The Party that is required by Applicable Law to
make such deduction or withholding shall deduct such amounts from such payment, promptly pay such amount on behalf of the other Party to the proper governmental authority, and promptly furnish the other Party with proof of payment on a timely basis
following such payment. [***]. 
 12.3 Assistance 
 Each
Party agrees to reasonably assist the other Party in claiming refunds or exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so
withheld or deducted. 
 12.4 Tax Documentation 
 Each
Party receiving payments under this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Party or as required by Applicable Law, such properly completed and duly executed documentation (for example, IRS
Form W-9 or applicable Form W-8) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes. 

12.5 Tax Information 
 [***] 

13. Auditing 
 13.1 Atea Right to Audit 

Roche shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be
necessary for the purpose of calculating all royalties payable under this Agreement. Such books of accounts shall be kept at their principal place of business. Atea shall, at its own expense, have the right to engage an internationally recognized
independent public accountant reasonably acceptable to Roche to perform, on behalf of Atea, an audit of such books and records of Roche and its Affiliates that are deemed necessary by the independent public accountant to report on Net Sales of
Product for the period or periods requested by Atea and the correctness of any financial report or payments made under this Agreement. 

  
 - 35 - 

	13.1.1	 Upon timely request and at least [***] working days’ prior written notice from Atea, such audit shall be
conducted for those countries Atea has specifically requested, during regular business hours in such a manner as to not unnecessarily interfere with Roche’s normal business activities. Such audit shall be limited to results in the [***]
Calendar Years prior to audit notification, and if Atea requests an audit for a given Calendar Year, no additional audits may be conducted in the Territory for such Calendar Year. If Atea does not request an audit of a given Calendar Year on or
before the [***] anniversary of the end of such Calendar Year, then Atea will be deemed to have accepted the royalty payments and reports in such Calendar Year. 

 

	13.1.2	 Such audit shall not be performed more frequently than [***] per Calendar Year nor more frequently than once
with respect to records covering any specific period of time. 

  

	13.1.3	 All information, data documents and abstracts herein referred to shall be used only for the purpose of
verifying royalty statements, shall be treated as Roche’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [***] year after completion of an audit hereof, if an audit has been
requested; nor more than [***] years from the end of the Calendar Year to which each shall pertain; nor more than [***] years after the date of termination of this Agreement. 

13.2 Audit Reports 
 The auditors shall only state factual
findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit findings with Roche before sharing such findings with Atea and before the final audit report is issued. The final audit report shall be
shared with Roche at the same time it is shared with Atea. 
 13.3 Over-or Underpayment 

If the audit reveals an overpayment, Atea shall reimburse Roche for the amount of the overpayment within [***] days. If the audit reveals an underpayment,
Roche shall make up such underpayment with the next royalty payment or, if no further royalty payments are owed by Roche, Roche shall reimburse Atea for the amount of the underpayment within [***] days. Roche shall pay for the audit costs if the
underpayment of Roche exceeds [***] of the aggregate amount of royalty payments owed with regard to the royalty statements subject to the audit. Section 11.2 shall apply to this Section 13.3. 

14. Intellectual Property 
 14.1 Ownership of
Inventions and Collaboration Know-How 
 Atea shall own all Atea Inventions, Roche shall own all Roche
Inventions, and Atea and Roche shall jointly own all Joint Inventions. Atea and Roche each shall require all of its employees to assign all inventions related to Products made by them to Roche and Atea, as the case may be. 

The determination of inventorship for Inventions shall be in accordance with US inventorship laws as if such Inventions were made in the US. 

Subject to the licenses granted under this Agreement, Atea and Roche will each have an equal undivided share in the Joint Patent Rights, without obligation to
account to the other for exploitation thereof, or to seek consent of the other Party for the grant of any license thereunder. Each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval, consent or
accounting with respect to jointly owned Inventions and Joint Patent Rights. Each Party hereby grants to the other party a nonexclusive, royalty-free (except as provided in this Agreement), worldwide license, with the right to grant sublicenses
through multiple tiers (except as otherwise expressly provided in this Agreement) under their undivided interest in jointly owned Inventions and Joint Patent Rights to exploit jointly owned Inventions. 

  
 - 36 - 

 Except as specifically set forth herein, this Agreement shall not be construed as (i) giving any of the
Parties any license, right, title, interest in or ownership to the Confidential Information; (ii) granting any license or right under any intellectual property rights; or (iii) representing any commitment by either Party to enter into any
additional agreement, by implication or otherwise. 
 With respect to Know-How (other than Inventions) generated
pursuant to the Global Development Plan, Atea shall own such Know-How made by employees of Atea solely or jointly with a Third Party, Roche shall own such Know-How made
by employees of the Roche Group solely or jointly with a Third Party, and the Parties shall jointly own such Joint Know-How. 

14.2 German Statute on Employee Inventions 
 In accordance
with the German Statute on Employees Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any activities conducted under the
Agreement by employees of any German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the obligations towards their employees under the German Statute of Employee’s Inventions. 

14.3 Trademarks 
 [***] shall have the right to obtain the
International Non-proprietary Name (INN) from the World Health Organization and the US Adopted Name (USAN) from the US adopted Names Council (USANC) as the generic name(s) for the Products other than [***].

 Atea shall own all trademarks used on or in connection with Products in the Atea Territory, and shall, at its sole cost, be responsible for procurement,
maintenance, enforcement and defense of all trademarks used on or in connection with Products in the Atea Territory. 
 Roche shall own all trademarks used
on or in connection with Products in the Roche Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and defense of all trademarks used on or in connection with Products in the Roche Territory. 

The Parties shall attempt to use a global trademark and logo for the Product; provided, that each Party may use such trademark as it selects to promote the
sale of the Product in its Respective Territory (the “Product Trademarks”). Each Party shall grant the other Party a non-exclusive, royalty-free license to use the Product Trademarks it
selects and owns solely for the purposes of manufacturing, distributing, promoting, selling and offering for sale the Product as permitted by this Agreement. Such trademark licenses shall be non-transferable,
except that Atea shall have the right to sublicense such rights to its licensees in the Atea Territory, and Roche shall have the right to sublicense such rights to its permitted Sublicensees in the Roche Territory. 

The Party owning each Product Trademark shall maintain all registrations of such Product Trademarks and the other Party shall not file any registrations or
other filings in respect of any of such Product Trademarks without the owner’s prior written consent. 
 Each Party shall use the Product Trademarks in
accordance with sound trademark and trade name usage principles and in accordance with all Applicable Law as reasonably necessary to maintain the validity and enforceability of the Product Trademarks. Each Party recognizes that the Product
Trademarks owned by the other Party represent a valuable asset of such other Party, and that substantial recognition and goodwill are associated with such name, logo and trademarks. Each Party hereby agrees that, except as expressly stated in this
Agreement or otherwise agreed in writing by the other Party, it shall not use such other Party’s Product Trademarks for any purpose. 

  
 - 37 - 

 14.4 Prosecution of Atea Patent Rights 

Atea shall, at its own expense (and with regard to (i) at its own discretion), (i) Handle all Atea Patent Rights, (ii) consult with Roche as to
the Handling of such Atea Patent Rights, and (iii) furnish to Roche copies of all documents relevant to any such Handling. Atea shall furnish such documents and consult with Roche [***] before any action by Atea is due to allow Roche to provide
comments thereon, [***]. At Atea’s expense and reasonable request, Roche shall cooperate, in all reasonable ways with the Handling of all Atea Patent Rights. 

14.5 Abandonment of Atea Patent Rights 
 If Atea
determines to abandon any Atea Patent Right that is licensed to Roche under this Agreement then, prior to such abandonment, Atea shall offer such Patent Right to Roche to Handle thereafter at its own cost and expense, subject to the following: Roche
shall (i) consult with Atea, through the patent coordination team as to the Handling thereof, and (ii) furnish to Atea copies of all documents relevant to any such Handling. 

14.6 Prosecution of Roche Patent Rights Claiming Roche Inventions 

Roche shall, at its own expense (and with regard to (i) at its own discretion), (i) Handle all Roche Patent Rights claiming Roche Inventions,
(ii) consult with Atea as to the Handling of such Roche Patent Rights, and (iii) furnish to Atea copies of all documents relevant to any such Handling. Roche shall furnish such documents and consult with Atea [***] before any action by
Roche is due with respect to such Roche Patent Rights to allow Atea to provide comments thereon, [***]. At Roche’s expense and reasonable request, Atea shall cooperate, in all reasonable ways with the Handling of all such Roche Patent Rights.

 14.7 Abandonment of Roche Patent Rights Claiming Roche Inventions 

If Roche determines to abandon any Roche Patent Right Covering Roche Inventions then, prior to such abandonment, Roche shall offer such Patent Right to Atea to
Handle thereafter at its own cost and expense, subject to the following: Atea shall (i) consult with Roche, through the patent coordination team as to the Handling thereof, and (ii) furnish to Roche copies of all documents relevant to any
such Handling. 
 14.8 Prosecution of Joint Patent Rights 

Atea shall, at its own expense (and with regard to (i) at its own discretion), (i) Handle all Joint Patent Rights that claim the Compound or Product, or
the composition or formulation, methods-of-treatment, or therapeutic uses of the Compound or Product (except such Joint Patent Rights that claim manufacturing processes,
intermediates, and IV formulations resulting from any IV Lead Compound Formulation activities), (ii) consult with Roche as to the Handling of such Joint Patent Rights, and (iii) furnish to Roche copies of all documents relevant to any such
Handling. Atea shall furnish such documents and consult with Roche [***] before any action by Atea is due to allow Roche to provide comments thereon, [***]. At Atea’s expense and reasonable request, Roche shall cooperate, in all reasonable ways
with the Handling of all such Joint Patent Rights.  
 Roche shall, at its own expense and discretion, (i) Handle all Joint Patent Rights that
are not Handled by Atea, (ii) consult with Atea as to the Handling of such Joint Patent Rights, and (iii) furnish to Atea copies of all documents relevant to any such Handling. Roche shall furnish such documents and consult with Atea [***]
before any action by Roche is due to allow Atea to provide comments thereon, [***]. At Roche’s expense and reasonable request, Atea shall cooperate, in all reasonable ways with the Handling of all such Joint Patent Rights. 

  
 - 38 - 

 14.9 Abandonment of Joint Patent Rights 

If the Party Handling Joint Patent Rights pursuant to Section 14.8 determines to abandon any Joint Patent Right then, prior to such abandonment, such
Party shall offer such Joint Patent Right to the other Party to Handle thereafter at its own cost and expense, subject to the following: the other Party shall (i) consult with the abandoning Party, through the patent coordination team as to the
Handling thereof, and (ii) furnish to the abandoning Party copies of all documents relevant to any such Handling. 
 14.10 Patent Coordination Team

 Where the Parties need to consult with each other on the Handling of Patent Rights, the Parties shall establish a patent coordination team and shall
adopt procedures for interacting on patent matters. 
 14.11 [***] 

14.12 CREATE Act 
 It is the intention of the Parties that
this Agreement is a “joint research agreement” as that phrase is defined in 35 USC § 102(c) (AIA). In the event that either Party to this Agreement intends to overcome a rejection of a claimed invention covered by Joint
Patent Rights or the Atea Patent Rights pursuant to the provisions of 35 USC §§ 102(a)-(d), such Party shall first obtain the prior written consent of the other Party. Following receipt of such written consent, such Party
shall limit any amendment to the specification or statement to the patent office with respect to this Agreement to that which is strictly required by the applicable subsection of 35 USC § 102 and the rules and regulations
promulgated thereunder and which is consistent with the terms and conditions of this Agreement (including the scope of the Global Development Plan). To the extent that the Parties agree that, in order to overcome a rejection of a claimed invention
covered by Joint Patent Rights or the Atea Patent Rights pursuant to the provisions of the applicable subsection of 35 USC § 102, if the filing of a terminal disclaimer is required or advisable, the Parties shall first agree on
terms and conditions under which the patent application subject to such terminal disclaimer and the patent or application over which such application is disclaimed shall be jointly enforced, to the extent that the Parties have not previously agreed
to such terms and conditions. In the event that Roche enters into an agreement with a Third Party with respect to the further research, development or commercialization of a Product, Atea shall, upon Roche’s request, similarly enter into such
agreement with such Third Party for the purposes of furthering the Parties’ objectives under this Agreement, provided that such agreement does not place any material obligation on Atea. 

14.13 Infringement 
 Each Party shall promptly provide
written notice to the other Party during the Agreement Term of any (a) known infringement or suspected infringement by a Third Party of any Atea Patent Rights, Roche Patent Rights or Joint Patent Rights (an “Infringement”), or
(b) known or suspected unauthorized use or misappropriation by a Third Party of any Atea Know-How, Roche Know-How or Joint
Know-How (a “Misappropriation”), and shall provide the other Party with all evidence in its possession supporting such Infringement or Misappropriation. 

Within [***] days after the Dominant Party provides or receives such written notice (“Decision Period”), the Dominant Party, in its sole
discretion, shall decide whether or not to initiate a suit or action in the Territory regarding such infringement or unauthorized use or misappropriation and shall notify other Party of its decision in writing (“Suit Notice”). The
“Dominant Party” shall be (i) Roche in the case of (A) a Misappropriation of Roche Know-How in the Atea Territory (a “US Roche
Know-How Misappropriation” or (B) an Infringement or Misappropriation in the Roche Territory, and (ii) Atea in the case of an Infringement or Misappropriation of in the Atea Territory other
than a US Roche Know-How Misappropriation. 

  
 - 39 - 

 If the Dominant Party decides to bring a suit or take action, once the Dominant Party provides Suit Notice,
the Dominant Party may immediately commence such suit or take such action. In the event that the Dominant Party (i) does not in writing advise the other Party within the Decision Period that the Dominant Party will commence suit or take action,
or (ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, the other Party shall thereafter have the right to commence suit or take action and shall provide written notice to the Dominant Party of any
such suit commenced or action taken by it. 
 Upon written request, the Party bringing suit or taking action (“Initiating Party”) shall
keep the other Party informed of the status of any such suit or action and shall provide the other Party with copies, to the extent the Initiating Party is lawfully permitted to do so, of all substantive documents or communications filed in such
suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action; provided that the other Party may engage counsel to monitor such suit or action at such other Party’s expense. 

The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including the Initiating Party’s attorneys’ fees and
court costs. Unless otherwise agreed by the Parties, and subject to the Parties’ respective obligations under Article 16, all monies recovered upon the final judgment or settlement of any action described in this Section 14.13 shall
be used as follows: 
  

	(a)	 First, to reimburse the Initiating Party for its costs associated with such action and, if any remains, to the
other Party for any fees and costs incurred in connection with such action; and 

  

	(b)	 Second, 

  

	 	(i)	 [***]; and 

  

	 	(ii)	 [***]. 

If the Initiating Party believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to be
joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the Initiating Party’s written
request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable
out-of-pocket expenses incurred by the other Party in rendering such assistance. The other Party shall have the right to participate and be represented in any such suit
or action by its own counsel at its own expense. 
 The Initiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action
(“Settlement”) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party or its Affiliates (including their interest in and to the Product or to any of
their Patent Rights). If a Settlement could adversely affect the other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld. 

For any patent that is not an Atea Patent Right or a Joint Patent Right, Roche, in its sole discretion, shall decide whether or not to initiate such suit or
action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement and retain all damages, settlement fees or other consideration under any terms and conditions it desires and retain whatever
proceeds are realized in such suit or action. Only if a Settlement could adversely affect Atea or its Affiliates (including their interest in and to the Product or to any of their Patent Rights) shall the written consent of Atea be required, which
consent shall not be unreasonably withheld. 

  
 - 40 - 

 14.14 Defense 

14.14.1 Notice 
 If a Third Party asserts that a Patent Right
controlled by it is, or will be, infringed by the exploitation of the Product in the Territory in accordance with this Agreement, then the Party first obtaining knowledge of such claim will promptly provide the other with prompt written notice
thereof and the related facts in reasonable detail. 
 14.14.2 Responsibility to Defend 

During the Agreement Term, if a Third Party asserts that a Patent Right controlled by such Third Party is infringed, or will be infringed, by the exploitation
of the Product, then the JSC will promptly discuss the matter and the appropriate course of action. If the JSC cannot agree on a course of action within [***] days following the date on which the JSC receives notice of such Third Party claim, then:
(a) Atea will have the first right, but not the obligation, to defend such claim in the Atea Territory using counsel of its own choosing, and (b) Roche will have the first right, but not the obligation, to defend such claim in the Roche
Territory using external counsel agreed by the Parties. If the Party having the first right does not take affirmative steps to defend such claim in the Respective Territory within [***] days (or such shorter period of time as is legally required to
answer to such claim), then the other Party may defend such claim in such territory. 
 The Party defending such claim will (i) keep the other Party
reasonably informed regarding any such assertion, including by providing the other Party with copies of all pleadings and other documents filed in any proceeding relating to such claim, (ii) consider reasonable input from the other Party during
the course of the claim, and (iii) provide the other Party with the opportunity to attend any substantive meetings, hearings, or other proceedings related to such claim (together with its own counsel, at its own expense) and to review and
comment on all substantive documents related to such claim prior to filing or submission of such documents. The Parties will reasonably assist each other and cooperate and share information with respect to any such claim. Each Party will bear its
own costs and expenses with respect to any such claim. 
 14.14.3 Settlement 

Each Party is free to pursue or enter into any settlement or license agreement with any Third Party with respect to the Patent Rights that are the subject of a
claim brought by a Third Party that a Patent Right controlled by such Third Party is infringed by the exploitation of the Product in the Relevant Territory without the other Party’s prior written consent provided such settlement or license
agreement does not affect the other Party or its Affiliates (including their interest in and to the Product or to any of their Patent Rights). The Parties acknowledge and agree that [***]. 

14.15 Third Party Licenses 
 If in either Party’s
opinion a license to Third Party Patent Rights or other intellectual property rights is necessary or reasonably useful to develop, make, use or sell Products, then such Party may notify the other Party in writing of the Third Party and the
applicable intellectual property rights, and the Parties will cooperate to negotiate and enter into a license or other agreement with the Third Party to obtain a license to such Third Party intellectual property rights (a “Third Party IP
License”). [***] shall have the first right to negotiate and enter into a Third Party IP License with a Third Party to obtain [***] Third Party Rights, and [***] shall have the first right to negotiate and enter into a Third Party IP
License to obtain [***] Third Party Rights (the Party having the first right to negotiate and enter into any such license or other agreement being the “Primary Negotiating Party”). The Primary Negotiating Party will have the right
for a reasonable period following such 

  
 - 41 - 

 
notice to negotiate the Third Party IP License or otherwise resolve the matter by, for example, challenging the relevant Third Party Patent Rights or conducting any oppositions, inter partes
reviews or similar proceedings. If the Primary Negotiating Party is unable or unwilling to obtain such license within such reasonable period, then the other Party shall have the right to obtain such license from the Third Party or otherwise resolve
the matter by, for example, challenging the relevant Third Party Patent Rights or conducting any oppositions, inter partes reviews or similar proceedings. Notwithstanding which Party negotiates and enters into a Third Party IP License pursuant to
this Section 14.15, the Parties will mutually agree on the terms and conditions of any such Third Party IP License. If the Parties are unable to agree on the terms and conditions of any Third Party IP License, the matter will be escalated to
the JSC.     
 14.16 Common Interest Disclosures 

With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property or technology owned
by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the development or manufacturing activities under this
Agreement or Compounds or Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the conduct of
the development or manufacturing activities under this Agreement or Compounds or Products. Accordingly, the Parties agree that all such information and materials obtained by Atea and Roche from each other will be used solely for purposes of the
Parties’ common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may
otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any
privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party.
Notwithstanding the foregoing, neither Party’s attorney represents the other Party. 
 14.17 Hatch-Waxman 

Notwithstanding anything herein to the contrary, should a Party receive a certification for a Product pursuant to the Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as amended, or its equivalent in a country other than the US, then such Party shall immediately provide the other Party with a copy
of such certification. 
 Atea shall have the sole right to bring suit, at its expense, within a [***] day period from the date of any such certification in
the Atea Territory. 
 Roche shall have the sole right to bring suit, at its expense, within the applicable, country-specific maximum period of time from
the date of any such certification in the Roche Territory. 
 14.18 Patent Term Extensions 

Atea shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection
certificates (“SPCs”, and together with patent term extensions, adjustments and restorations, “Patent Term Extensions”) for Atea Patent Rights or Joint Patent Rights with respect to the Product that Atea Handles
pursuant to Section 14.8. All filings for such Patent Term Extensions shall be made by Atea (unless the Parties otherwise agree in writing); provided, that in the event that Atea elects not to file for a Patent Term Extension, Atea shall
(a) promptly inform Roche of its intention not to file and (b) grant Roche the right to file for such Patent Term Extension. 

  
 - 42 - 

 Roche shall use Commercially Reasonable Efforts to obtain all available SPCs and Patent Term Extensions for
Roche Patent Rights or Joint Patent Rights with respect to the Product that Roche Handles pursuant to Section 14.8. All filings for such Patent Term Extensions shall be made by Roche (unless the Parties otherwise agree in writing); provided,
that in the event that Roche elects not to file for a Patent Term Extension, Roche shall (a) promptly inform Atea of its intention not to file and (b) grant Atea the right to file for such Patent Term Extension. 

Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such
Patent Term Extensions. The Parties shall cooperate with each other in gaining patent term restorations, extensions or SPCs wherever applicable to such Atea Patent Rights, Roche Patent Rights or Joint Patent Rights. 

15. Representations and Warranties 
 15.1 Atea
Representations and Warranties. 
 Atea represents and warrants to Roche as follows as of the Effective Date: 

 

	15.1.1	 Safety Data 

Atea has disclosed to Roche and will immediately continue to disclose to Roche (i) the material results of all preclinical testing and human clinical
testing of Products in its possession or control and (ii) all material information in its possession or control concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to Products, if
any. 
  

	15.1.2	 Third Party Patent Rights 

Atea has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party, in which the researching, having
researched, developing, having developed, registering, having registered, using, having used, making, having made, importing, having imported, exporting, having exported, marketing, having marketed, distributing, having distributed, selling or
having sold Compounds, Products and Companion Diagnostics in the Field and in the Roche Territory would infringe a valid and enforceable claim of such patent or patent application (determined as if such application were to issue with substantially
the same scope of claim existing as of the Effective Date). 
  

	15.1.3	 Ownership of Patent Rights 

Atea is the sole and exclusive owner of the Atea Patent Rights. To Atea’s knowledge, no Third Parties have any right, title or interest in or to the Atea
Patent Rights. Except for rights granted under this Agreement, the Atea Patent Rights are free and clear of all liens, claims, security interests and other encumbrances of any kind or nature. Atea has not granted any licenses to the Atea Patent
Rights to any Third Party for the development and commercialization of Compounds or Products in the Field in the Roche Territory (excluding rights granted to Third Parties performing activities on behalf of Atea), nor has Atea effectuated any prior
transfer, sale or assignment of any part of the Atea Patent Rights. 
  

	15.1.4	 Inventors 

Atea warrants that the inventors of the inventions claimed in Atea Patent Rights have transferred to Atea full ownership of the Patent Rights and Know-How licensed to Roche under this Agreement. All of Atea’s employees, officers and consultants performing activities with respect to Compounds and Products have executed agreements requiring assignment to
Atea of all inventions made by such individuals during the course of and as a result of their association with Atea. 

  
 - 43 - 

	15.1.5	 Grants 

To Atea’s knowledge, Atea has the lawful right to grant Roche and its Affiliates the rights and licenses described in this Agreement. 

 

	15.1.6	 Validity of Patent Rights 

Atea has no knowledge of information that could reasonably be deemed to render invalid or unenforceable any claims that are in any of the issued Atea Patent
Rights. Atea has no knowledge of any inventorship disputes concerning any Atea Patent Rights. 
  

	15.1.7	 Ownership and Legitimacy of Know-How 

Atea’s Know-How is legitimately in the possession of Atea and to Atea’s knowledge has not been
misappropriated from any Third Party. Atea has taken reasonable measures to protect the confidentiality of its Know-How. 
  

	15.1.8	 No Claims 

There are no claims or investigations, pending or, to Atea’s knowledge, threatened against Atea or any of its Affiliates, at law or in equity, or before
or by any governmental authority (excluding ordinary course prosecution before a patent authority) relating to the matters contemplated under this Agreement or that would materially adversely affect Atea’s ability to perform its obligations
hereunder. 
 15.2 Mutual Representations and Warranties 
  

	15.2.1	 Authorization 

The execution, delivery and performance of this Agreement by either Party and all instruments and documents to be delivered by either Party, hereunder:
(i) are within the corporate power of such Party; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in contravention of any provision of the certificate of formation or limited liability company
agreement of such Party; (iv) to the knowledge of such Party, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of
trust, lease, agreement, or other instrument to which such Party is a party or by which such Party or any of its property is bound, which violation would have an adverse effect on the financial condition of such Party or on the ability of such Party
to perform its obligations hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other
than Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products). 
  

	15.2.2	 No Conflict 

Neither Party nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this
Agreement or that would impede the fulfillment of such Party’s obligations hereunder. 
  

	15.2.3	 Insurance 

During the Agreement Term and for a minimum period of [***] years thereafter and for an otherwise longer period as may be required by Applicable Law, each
Party will procure and maintain insurance consistent with industry practice or required by Applicable Law, which may be through self-insurance. Such insurance shall insure against liability arising from this Agreement

  
 - 44 - 

 
on the part of either party or any of its respective Affiliates, due to injury, disability or death of any person or persons, or property damage arising from activities performed by such Party or
its Affiliates in connection with this Agreement. Any insurance proceeds received by a Party in connection with any indemnified claim shall be retained by such Party and shall not reduce any obligation of the other Party under Article 16 with
respect to such claim. 
  

	15.2.4	 Debarment 

Each Party represents and warrants that as of the Effective Date it and its Affiliates and its and their respective employees, in each case involved in the
development of the Compounds or the Products under this Agreement, are not debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C
§1320 a-7b(f)), including the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar federal or state agency or program in
the United States or any other country. In the event a Party, any of its Affiliates or an employee of such Party or its Affiliates, in each case involved in development of the Compounds or the Products under this Agreement, receives notice of
debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes or any other similar federal or state agency or program in the United States or any other country, such Party shall immediately notify
the other Party in writing. 
  

	15.2.5	 Anti-Bribery and Anti-Corruption Compliance 

Each Party represents and warrants to the other Party that it, with respect to the development, manufacture and commercialization of the Compounds or the
Products under this Agreement, has complied and will comply with all Applicable Laws governing bribery, money laundering, and other corrupt practices and behavior. 

15.3 No Other Representations and Warranties 
 EXCEPT AS
OTHERWISE PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OF PRODUCTS AND FREEDOM FROM INFRINGEMENT OF THIRD PARTY RIGHTS. 
 16. Indemnification 

16.1 Indemnification by Roche 
 Roche shall indemnify, hold
harmless and defend Atea, Atea’s Affiliates and their directors, officers, employees and agents (“Atea Indemnitees”) from and against any and all losses, damages, expenses, costs of defense (including without limitation
reasonable attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any other amounts (collectively, “Losses”) resulting from Third Party claims or suits (“Third Party
Claims”) arising out of or relating to (a) the breach of the Agreement by Roche, (b) the development, manufacture, commercialization, storage, transportation, handling, formulation or other exploitation of Compounds or Products by
or on behalf of Roche in the Roche Territory or pursuant to a Unilateral Study conducted by Roche in the Territory (e.g. product liability claims), or (c) the negligence or willful misconduct of Roche Indemnitees, except, in each case (a), (b)
and (c), to the extent such Losses are subject to indemnification by Atea pursuant to Section 16.2. 

  
 - 45 - 

 16.2 Indemnification by Atea 

Atea shall indemnify, hold harmless and defend Roche, Roche’s Affiliates and their directors, officers, employees and agents (“Roche
Indemnitees”) from and against any and all Losses resulting from Third Party Claims arising out of or relating to (a) the breach of the Agreement by Atea, (b) the development, manufacture, commercialization, storage,
transportation, handling, formulation or other exploitation of Compounds or Products by or on behalf of Atea in the Atea Territory or pursuant to a Unilateral Study conducted by Atea in the Territory (e.g. product liability claims), or (c) the
negligence or willful misconduct of Atea Indemnitees, except, in each case (a), (b) and (c), to the extent such Losses are subject to indemnification by Roche pursuant to Section 16.1.  

16.3 Procedure 
 In the event of a Third Party Claim
against a Party entitled to indemnification under this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying
Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such
action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not
settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 

17. Liability 
 17.1 Limitation of Liability 

EXCEPT IN THE CASE OF A BREACH OF ARTICLE 18, AND WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER ARTICLE 16, NEITHER PARTY SHALL BE LIABLE TO THE OTHER
PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS, OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR
WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 
 18. Obligation Not to Disclose
Confidential Information 
 18.1 Non-Use and Non-Disclosure 

During the Agreement Term and for [***] years thereafter, a Receiving Party shall (i) treat Confidential Information provided by Disclosing Party as it
would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties, without the Disclosing Party’s prior written consent, and (iii) not use such
Confidential Information other than for fulfilling its obligations under this Agreement. 
 18.2 Permitted Disclosure 

Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 18.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, certain commercial considerations and for the purposes of
complying with Applicable Law. 
 18.3 Press Releases 

The Parties may issue a press release announcing the existence and selected key terms of this Agreement, in a form substantially similar to the template
attached as Appendix 18.3. 

  
 - 46 - 

 Subject to the first sentence of this Section 18.3, during the Agreement Term, each Party may only
issue press releases making reference to the other Party in connection with this Agreement, this Agreement and/or any activities or information related to this Agreement, that in each case either (i) have been approved by the other Party or
(ii) are required to be issued as a matter of Applicable Law (including, for clarity, the rules of any securities exchange). Prior to issuing such press release, the issuing Party shall provide the other Party with a copy of a substantially
final draft press release at least [***] (or such shorter amount of time to comply with Applicable Law, including the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934, and the rules of any securities regulator, where it was
not possible to provide the other Party such draft [***] in advance) prior to its intended publication for the other Party’s review. The non-issuing Party may provide the issuing Party with suggested
modification to the draft press release. The issuing Party shall consider the other Party’s suggestions in good faith in issuing its press release. 

To ensure communication alignment, responses (if any) to inquiries by media or other Third Parties after issuance of a permitted press release by a Party
(solely or jointly with the other Party) shall consist solely of the press release language or shall follow the response guidelines that may be mutually developed by the Parties. 

18.4 Publications
 During the Agreement Term, the
following restrictions shall apply with respect to disclosure by any Party of Confidential Information relating to the Product in any publication or presentation: 
  

	a)	 Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and
published in accordance with their internal guidelines. Each Party, in accordance with its internal policies and procedures, shall have the right to publish all studies, clinical trials and results thereof on the clinical trial registries that are
maintained by or on behalf of such Party. 

  

	b)	 A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed
publication or presentation at least [***] days (or at least [***] days in the case of oral presentations) prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are
necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably
refused; and if such other Party notifies (“Publishing Notice”) the Publishing Party in writing, within [***] days after receipt of the copy of the proposed publication or presentation (or at least [***] days in the case of oral
presentations), that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent
protection or (ii) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay
such publication for a mutually agreeable period of time. In the case of inventions disclosed therein, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and
in no event less than [***] days from the date of the Publishing Notice. With respect to proposed publications from any Clinical Studies conducted pursuant to the Global Development Plan that are not Atea Ongoing Studies or studies in the Retained
Indications, the Parties shall also coordinate and collaborate on such publications. In order to facilitate such coordination and collaboration, the Parties shall strive to develop a joint publication strategy, and discuss and review such proposed
publications, through the JOC. 

  
 - 47 - 

 18.5 Commercial Considerations 

Nothing in this Agreement shall prevent either Party or its Affiliates from disclosing Confidential Information of the other Party to (i) governmental
agencies [***] to secure government approval for the development, manufacture or sale of Product in the Territory, including with respect to Roche as permitted in Section 2.1, (ii) Third Parties acting on behalf of such Party, [***] for
the development, manufacture or sale of Product in the Territory, as permitted under this Agreement, (iii) [***] or (iv) Third Parties to the extent reasonably necessary to market the Product in the Territory, as set forth in this Agreement.
Each Party may further disclose Confidential Information of the other Party, including the terms of this Agreement, to its actual or potential sublicensees; provided that such sublicensees are subject to obligations of confidentiality and non-use with respect to such Confidential Information that are no less restrictive than the obligations of confidentiality and non-use of any Receiving Party pursuant to this
Article 18. 
 18.6 Complying with Applicable Law or Judicial Process 

The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed
by the Receiving Party to comply with Applicable Law, including the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934, to comply with the rules of any securities regulator, to defend or prosecute litigation or to comply with
governmental regulations or any judicial process, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party to the extent permitted under Applicable Law and, to the extent practicable, takes
reasonable and lawful actions to minimize the degree of such disclosure. 
 19. Term and Termination 

19.1 Commencement and Term 
 This Agreement shall commence
upon the Effective Date and continue for the Agreement Term. 
 19.2 Termination 

 

	19.2.1	 Termination for Breach 

A Party (“Non-Breaching Party”) shall have the right to terminate this Agreement in its entirety or on
a country-by-country basis in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and the countries in which the Non-Breaching Party intends to
have this Agreement terminate. The Breaching Party shall have a period of ninety (90) days after such written notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a dispute as to
whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to
Section 21.2. Upon a determination of breach or failure to cure, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent
withdrawal of the Non-Breaching Party’s request for termination, this Agreement shall terminate in its entirety or such identified countries effective as of the expiration of the Peremptory Notice Period.

  

	19.2.2	 Insolvency 

A Party shall have the right to terminate this Agreement, if the other Party experiences an Insolvency Event; provided, however, in the case of any involuntary
bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing
thereof. 

  
 - 48 - 

	19.2.3	 Termination by Roche without a Cause 

Roche shall have the right to terminate this Agreement at any time as a whole or on a
Product-by-Product or country-by-country basis upon either (i) three (3)
months prior written notice if such notice is provided before First Commercial Sale of the first Product under this Agreement, provided that at the time when Roche sends the termination notice under this Section 19.2.3(i) the Post-Exposure
Prophylaxis study as described in the Global Development Plan in Appendix 1.47 is not ongoing, but if Roche sends its termination notice under this Section 19.2.3(i) during the time when the Post-Exposure Prophylaxis study as described in the
Global Development Plan in Appendix 1.47 is ongoing (“ongoing” shall mean, for the purposes of this Section, that the first patient has been dosed and the last patient has not yet been dosed in such study), then the earlier of the end of
such study (but not earlier than three (3) months after the time Roche sends the termination notice), or six (6) months after such termination notice is sent; or (ii) nine (9) months prior written notice if such notice is provided on
or after the First Commercial Sale of the first Product under this Agreement. The effective date of termination under this Section 19.2.3 shall be the date three (3) months (as adjusted in accordance with subsection (i) above), or
nine (9) months, as the case may be, after Roche provides such written notice to Atea. 
 19.3 Consequences of Termination 

 

	19.3.1	 Termination by Atea for Breach by Roche or by Roche without a Cause 

Upon any termination by Atea for breach by Roche or by Roche without a cause, the rights and licenses granted by Atea to Roche under this Agreement shall
terminate in their entirety or on a country-by-country and Product-by-Product basis, as
applicable, on the effective date of termination. 
 If Atea desires to continue development or commercialization of Product(s), Atea shall give a
Continuation Election Notice to Roche within [***] days of Atea’s notice of termination for breach by Roche or Atea’s receipt of Roche’s notice of termination without cause. If Roche receives such a timely Continuation Election
Notice, and to the extent reasonably requested by Atea: 
  

	(a)	 After the effective date of termination Roche shall, to the extent Roche has the right to do so, transfer and
assign to Atea all regulatory filings and approvals, all final pre-clinical and clinical study reports and clinical study protocols, Product Trademarks and all data, including clinical data, in Roche’s
possession or control related to Product(s) in the Roche Territory necessary for Atea to continue to develop and commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Original paper
copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to Atea. Roche shall use reasonable efforts to secure from any Sublicensee
or Third Party or Affiliate performing activities under this Agreement sufficient rights in and to the foregoing items to enable Roche to provide to Atea all of the foregoing items. 

 

	(b)	 Roche shall assign all clinical trial agreements or other manufacturing or vendor agreements to which Roche is
a party related to the Product to the extent legally possible, and to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment of any such
agreement. If Roche cannot assign such agreements it will reasonably cooperate with Atea to enable Atea to negotiate and enter into a separate agreement with the relevant counterparty by, for example, waiving any exclusivity obligations of such
counterparty that may prevent Atea from entering into such agreement with such counterparty. 

  
 - 49 - 

	(c)	 Roche shall and hereby does grant to Atea, effective as of the effective date of termination, an exclusive
license under the Roche Know-How and Roche Patent Rights, including Roche’s interest in the Joint Patent Rights, solely to the extent necessary to allow Atea, its Affiliates or licensees to develop, make,
have made, use, sell, offer to sell, import, and export the Product(s) in the Territory, provided that with respect to any Roche Know-How or Roche Patent Right obtained pursuant to an agreement with a Third
Party, Atea assumes all of Roche’s obligations (including payment obligations) under such agreement to the extent applicable to such Product(s). 

  

	(d)	 Roche shall assign or license to Atea the Product Trademarks with respect to the Product(s) in the Roche
Territory. 

  

	(e)	 Atea shall, upon transfer, have the right to disclose and file such filings, approvals and data to
(i) governmental agencies of the relevant country(ies) to the extent required or desirable to secure government approval for the development, manufacture or sale of Product(s) in the Roche Territory; (ii) Third Parties acting on behalf of
Atea, its Affiliates or licensees, to the extent reasonably necessary solely for the development, manufacture, or sale of Product(s) in the Roche Territory; or (iii) Third Parties to the extent reasonably necessary to market Product(s) in the
Roche Territory. 

  

	(f)	 Roche shall provide reasonable assistance and technical expertise, at Atea’s cost, in a technology
transfer from Roche to a Third Party designated by Atea with respect to the manufacturing of the Product(s), including the transfer of chemistry, manufacturing and controls processes with respect thereto. 

19.3.2 Termination by Roche for Breach by Atea or for Atea Insolvency 

Upon any termination by Roche for breach by Atea or Atea’s Insolvency Event, the rights and licenses granted by one Party to the other Party under this
Agreement shall terminate in their entirety or on a country-by-country and a
Product-by-Product basis, as applicable, on the effective date of termination. 

19.3.3 Direct License 
  

	(a)	 Irrespective of anything to the contrary in this Agreement, any Compulsory Sublicense shall remain in full
force and effect as may be required by Applicable Law, and 

  

	(b)	 any existing, permitted sublicense granted by Roche under Section 2.2 of this Agreement (and any further
sublicenses thereunder) shall, upon the written request of Roche, remain in full force and effect, provided that (i) such Sublicensee is not then in breach of its sublicense agreement (and, in the case of termination by Atea for breach by
Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by Atea); and (ii) and such Sublicensee agrees to be bound to Atea under the terms and conditions of such sublicense agreement.
Roche shall remain responsible for and shall ensure that each Sublicensee (including any further permitted sublicensee thereof) complies with the terms and conditions of this Agreement. 

  
 - 50 - 

 19.3.4 Other Obligations 

19.3.4.1 Obligations Related to Ongoing Activities 
 If Atea does
not provide a timely Continuation Election Notice, then Roche (a) shall have the right to cancel all ongoing obligations and (b) shall complete all non-cancellable obligations at its own expense,
except in each case to the extent inconsistent with protecting patient safety. 
 If Atea provides such timely Continuation Election Notice, then from the
date of notice of termination until the effective date of termination, Roche shall continue activities, including preparatory activities, ongoing as of the date of notice of termination unless otherwise agreed by the Parties, with expenses thereof
incurred prior to the effective date of termination to be shared equally (50/50) by the Parties consistent with Section 6.2. Such obligation to continue activities may include without limitation continuing to perform under any then-effective
contracts applicable to the development, manufacture or commercialization of Compound or Product until completion all of such relevant activities, unless Atea otherwise agrees in writing or requests in writing, subject to Atea’s obligations to
bear any portion thereof or to pay for any supply of Product as set forth in this Agreement. However, Roche shall not be obliged to initiate any new activities not ongoing at the date of notice of termination. 

Except in case Roche terminates for Atea’s uncured material breach (Section 19.2.1) or for Atea’s insolvency (Section 19.2.2), Roche shall also be
solely responsible for any reasonable cancellation or early termination fees that become due under vendor contracts by reason of such termination, if such contracts are not transferred to Atea as provided in Section 19.3.1(b). 

After the effective date of termination, Roche shall have no obligation to perform or complete any activities or to make any payments for performing or
completing any activities under this Agreement, except as expressly stated herein. 
 19.3.4.2 Further Supply; Transfer of Inventory 

In the case of termination by Atea according to Section 19.2.1 or 19.2.2 or by Roche under Section 19.2.3, upon the request of Atea, Roche shall
transfer all of its existing and available clinical supplies and commercial supplies of Products to Atea at [***]. If a Product is marketed in any country of the Territory on the date of the notice of termination of this Agreement, upon the request
of Atea, Roche shall manufacture and supply reasonable amounts of such Product to Atea under a manufacturing transfer and transition plan for a period that shall not exceed [***] months from the effective date of the termination of this Agreement at
a price to be agreed by the Parties in good faith, but in no event exceeding (i) [***], or (ii) [***]. Atea shall use Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of
termination. 
 19.3.4.3 Ancillary Agreements 
 Unless
otherwise agreed by the Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, including but not limited to the Co-Promotion Agreement(s)
or, subject to Section 19.3.4.2, Supply Agreement(s), if any, except to the extent such ancillary agreements are related to or necessary for the Parties’ activities under this Section 19.3, in which case the relevant agreement(s)
shall terminate upon completion of the relevant activity(ies). 
 19.3.4.4 Limitations on Grant-Backs; Transfer Expenses 

For purposes of clarity, irrespective of anything to the contrary in this Agreement: 
  

	(a)	 All transfers and licenses from Roche to Atea (or other obligations of Roche) under Section 19.3 are
solely with respect to Product(s) that are not Combination Product(s) or Diagnostic Product(s). Such transfers, licenses and obligations do not extend to other therapeutically active ingredients or products, even if physically mixed, combined or
packaged together with a Product, and even if a Product is intended (according to the investigation plan, proposed labeling or actual labeling, as applicable) for use with such other therapeutically active ingredients or products.

  
 - 51 - 

	(b)	 In connection with research studies, clinical trials or other activities associated with the development and
commercialization of Products, Roche may have collected (i) personally identifiable information about individual human subjects or (ii) human biological samples (collectively, “PII/Samples”). Legal and contractual
restrictions may apply to such PII/Samples. Roche shall have no obligation to transfer such PII/Samples unless necessary for the continued development of the Product, in which case Roche shall not be obliged to transfer any PII/Samples that Roche in
good faith believes would be prohibited or would subject Roche to potential liability by reason of Applicable Law, contractual restrictions or insufficient patient consent; provided that Roche shall notify Atea of the basis for such belief and
cooperate with Atea to identify potential means to avoid such lability (including, by way of example, seeking new patient consents). If Roche transfers any such PII/Samples, Atea shall use for the sole purpose of developing and commercializing the
Product, and Atea shall be responsible for the correct use of the PII/Samples in line with the informed consent forms ([***]). 

  

	(c)	 Atea shall promptly reimburse Roche for all reasonable out-of-pocket costs and expenses (including FTE Cost charges) incurred by or on behalf of Roche for transfer activities from Roche to Atea under Section 19.3.1 (“Roche Transfer
Activities”); however transfer activities corresponding to the return of material remains, data, reports, records, documents, regulatory filings and Regulatory Approvals originally provided by Atea to Roche no less than [***] years from the
effective date of termination (“Atea-Originated Transfer Activities”) shall be returned to Atea free of charge. If Atea desires Roche Transfer Activities other than Atea-Originated Transfer Activities, then except as expressly
provided above, Atea shall make a payment to Roche of [***] (“Minimum Transfer Payment”). [***] Roche shall be under no obligation to provide Roche Transfer Activities (beyond than Atea-Originated Transfer Activities) prior to
receipt of the Minimum Transfer Payment or if the Minimum Transfer Payment is received after the effective date of the termination. 

  

	(d)	 Unless otherwise agreed to by the Parties, transfer of physical materials that are required under Roche
Transfer Activities shall be delivered[***] (Incoterms 2020). 

 19.3.4.5 Royalty and Payment Obligations 

Termination of this Agreement by a Party, for any reason, shall not release either Party from any obligation to pay royalties or make any payments to the other
Party that are payable prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release each Party from any obligation to pay royalties or make any payments to the other Party that would otherwise
become payable on or after the effective date of termination. 
 19.4 Survival 

Article 1 (Definitions, to the extent necessary to interpret this Agreement), Articles 10, 11 and 12 (Payment, Accounting and Reporting, and Taxes,
each to the extent payments accrued but remain unpaid at the effective date of termination), Article 13 (Auditing), Section 14.1 (Ownership of Inventions and Collaboration Know-How); Article 16
(Indemnification), Article 17 (Liability), Article 18 (Obligation Not to Disclose Confidential Information), Section 19.3 (Consequences of Termination), Section 19.4 (Survival), Section 21.1 (Governing Law),
Section 21.3 (Arbitration), Section 21.4 (Assignment), and Sections 21.6 (Independent Contractor) – 21.13 (Notice) shall survive any expiration or termination of this Agreement for any reason. 

  
 - 52 - 

 20. Bankruptcy 

All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by Atea to Roche are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. Unless Roche elects to
terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued
performance of its obligations under this Agreement. 
 21. Miscellaneous 

21.1 Governing Law 
 This Agreement shall be governed by
and construed in accordance with the laws of New York, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

Notwithstanding anything to the contrary in this Agreement, issues regarding the scope, construction, validity or enforceability of any Patent Rights shall be
determined in a court of competent jurisdiction under the local patent laws of the jurisdictions have issued the Patent Rights in question. 
 21.2
Disputes 
 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred
to the Alliance Directors for resolution for a [***] day period before being escalated to the respective executive officers of the Parties designated below or their designees, who shall use reasonable and good faith efforts to resolve the dispute
within [***] days after the date such matter is referred to them. The designated executive officers are as follows: 
 For Atea: CEO 

For Roche: VP, Pharma Partnering 
 21.3
Arbitration 
 Except for an Excluded Claim, should the Parties fail to agree on a matter pursuant to Section 21.2 within [***] months after a
dispute has first arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (AAA) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The
place of arbitration shall be New York, New York, US. The language to be used shall be English.  
  

	21.4	 Assignment 

Neither this Agreement nor any of the rights or obligations created herein may be assigned by either Party, in whole or in part, without the prior written
consent of the other Party, not to be unreasonably withheld, conditioned or delayed, except that either Party shall be free to assign this Agreement, without the prior consent of the non-assigning Party,
(a) to an Affiliate of such Party, provided that such Party shall remain liable and responsible to the other Party for the performance and observance of all such duties and obligations by such Affiliate, or (b) in connection with any
merger, consolidation or sale of such Party or sale of all or substantially all of the assets of the Party that relate to this Agreement. Any assignment of this Agreement in contravention of this Section 21.4 is null and void. This Agreement
shall bind and inure to the benefit of the successors and permitted assigns of the Parties hereto. 

  
 - 53 - 

 21.5 Effects of Change of Control 

If there is a Change of Control, then the Party experiencing such Change of Control (“Acquired Party”) shall provide written notice to the
other Party (“Non-Acquired Party”) at least [***] days [***] of such Change of Control, subject to any confidentiality obligations of the Acquired Party then in effect [***]. 

The Change of Control Group in connection with such Change of Control shall agree in writing with the Non-Acquired
Party that it will not utilize any of the Non-Acquired Party’s Know-How, Patent Rights, Inventions, or Confidential Information or Joint Know-How, Joint Patent Rights or Joint Inventions (collectively, “Sensitive Information”).  

[***] the Non-Acquired Party and the Change of Control Group shall adopt in writing reasonable procedures to prevent
the disclosure of Sensitive Information beyond the Acquired Party’s personnel who need to know the Sensitive Information solely for the purpose of fulfilling the Acquired Party’s obligations under this Agreement. In the event that the
Change of Control Group is engaged in [***] (a “Competing Program”), then the Acquired Party shall [***] inform the Non-Acquired Party thereof in writing. The Acquired Party shall
either [***] or [***]. [***]. 
 21.6 Independent Contractor 

No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner
whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes (including U.S. federal and state tax purposes), and notwithstanding any other provision of
this Agreement to the contrary, Atea legal relationship to Roche under this Agreement shall be that of independent contractor, and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment,
franchise, agency or fiduciary relationship between the Parties. 
 21.7 Unenforceable Provisions and Severability 

If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and
enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not
affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 
 21.8 Waiver 

The failure by either Party to require strict performance or observance of any obligation, term, provision or condition under this Agreement will neither
constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute a
waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
 21.9 Interpretation 

Except where the context expressly requires otherwise: 
  

	(a)	 the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of
the singular shall be deemed to include the plural (and vice versa), 

  

	(b)	 the words “include”, “includes” and “including” shall be deemed to be followed by
the phrase “without limitation”, 

  
 - 54 - 

	(c)	 the word “will” shall be construed to have the same meaning and effect as the word “shall”,

  

	(d)	 any definition of or reference to any agreement, instrument or other document herein shall be construed as
referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), 

 

	(e)	 any reference herein to any Party or Third Party or person shall be construed to include the Party’s or
Third Party’s or person’s permitted successors and assigns, 

  

	(f)	 the words “herein”, “hereof” and “hereunder”, and words of similar import, shall
be construed to refer to this Agreement in its entirety and not to any particular provision hereof, 

  

	(g)	 all references herein to Articles, Sections or Appendices shall be construed to refer to Articles, Sections or
Appendices of this Agreement, and references to this Agreement include all Appendices hereto, 

  

	(h)	 references to any specific law, rule or regulation, or article, section or other division thereof, shall be
deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and 

  

	(i)	 the term “or” shall be interpreted in the inclusive sense commonly associated with the term
“and/or”. 

 21.10 Entire Understanding 

This Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior
agreements, understandings and arrangements, whether written or oral, including the NDA. 
 21.11 Amendments 

No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties. 

21.12 Invoices 
 All invoices that are required or
permitted hereunder shall be in writing and sent by Atea to Roche at the following address or such other address as Roche may later provide: 

F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 

Grenzacherstrasse 124 
 4070 Basel

 Switzerland 
 Attn: (name of
a Roche contact at time of invoice, e.g. the Alliance Director) 
 21.13 Notice 

All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by
personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier, sent by registered or certified mail, postage prepaid, return receipt requested, or sent by electronic mail (if to Atea),
addressed as follows: 

  
 - 55 - 

			
	if to Atea, to:	  	 Atea Pharmaceuticals, Inc.
 125 Summer
Street
 Boston, Massachusetts 02110
 U.S.A.

Attn: General Counsel
 Email: notices@ateapharma.com

 

	with a copy to:	  	 Latham & Watkins LLP
 140 Scott
Drive
 Menlo Park, CA 94025
 Attn: Judith Hasko

 

	if to Roche, to:	  	 F. Hoffmann-La Roche Ltd

[***]
 Attn: Legal Department

		
	and:	  	 Genentech, Inc.
 [***]

Attn. Corporate Secretary
 [***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 56 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

	
	Atea Pharmaceuticals, Inc.
	
	/s/ Jean-Pierre Sommadossi
	 Name: Jean-Pierre Sommadossi, Ph.D.
 Title:
Chairman & CEO

  

					
	F. Hoffmann-La Roche Ltd	 		 	
			
	/s/ Vikas Kabra	 		 	/s/ Stefan Arnold
	 Name: Vikas Kabra
 Title: Global Head
Transaction Excellence
	 		 	 Name: Stefan Arnold
 Title: Head Legal
Pharma

  

	
	Genentech, Inc.
	
	/s/ Edward Harrington
	 Name: Edward Harrington
 Title: CFO,
Genentech

  
 - 57 - 

 Appendix 1.7 

Atea Base Patent Rights 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 64 - 

 Appendix 1.9 

Atea Ongoing Studies 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 65 - 

 Appendix 1.47 

Global Development Plan 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 66 - 

 Appendix 1.66 

AT-511 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 67 - 

 Appendix 1.97 

Second Generation Process 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 68 - 

 Appendix 2.3 

Co-Promotion Agreement Terms 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 69 - 

 Appendix 3 

Permitted Third Party Subcontractors 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 70 - 

 Appendix 8.1.3 

Technology Transfer Plan 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 71 - 

 Appendix 8.2 

Supply Agreement Terms 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 72 - 

 Appendix 8.3.3 

Success criteria for manufacturing and release specifications for the 

Second Generation Process 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 - 73 - 

 Appendix 18.3 

Form of Press Release 
 Atea Form of
Press Release 
  
 

     
 Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and
Distribute AT-527 for Patients with COVID-19 
 Roche
Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States 
 BOSTON, Mass.,
October 22, 2020 – Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from
life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the exclusive rights to research, develop and distribute AT-527 as
an oral antiviral treatment for COVID-19 in territories outside of the United States. Under the terms of the agreement, Atea will receive an upfront payment of $350 million in cash from Roche with the
potential for future milestone payments and royalties. 
 “Roche shares our passion for delivering innovative new medicines to address great unmet
medical needs. The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Chief
Executive Officer and Founder of Atea Pharmaceuticals. “This collaboration with Roche enhances Atea’s efforts and underscores the potential for AT-527 to effectively address the COVID-19 crisis on a global scale. AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by
interfering with viral RNA polymerase, a key component in the replication machinery of RNA viruses. Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce
AT-527 quickly and at scale.” 
 “The ongoing complexities of
COVID-19 require multiple lines of defence. By joining forces with Atea, we hope to offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and provide important relief for hospital infrastructures during a global pandemic.” said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “In jointly developing and
manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.” 

  
 - 74 - 

 About AT-527 

AT-527 is an orally administered, direct-acting antiviral agent derived from Atea’s purine nucleotide prodrug
platform. At-527 is currently under evaluation as a treatment for patients with COVID-19. AT-527 is designed to inhibit viral
replication by interfering with viral RNA polymerase, a key component in the replication machinery of RNA viruses, such as positive single-stranded human flaviviruses and human coronaviruses. AT-527 is
currently in a global Phase 2 clinical study for hospitalized patients with moderate COVID-19 and has plans to initiate a global, registrational Phase 3 clinical trial in outpatients in the first half of 2021.
Additionally, Atea is planning to study in a Phase 3 clinical trial the use of AT-527 in the post-exposure prophylaxis setting. 

Advisors 
 Evercore served as exclusive financial advisor
to Atea in connection with this transaction. 
 About Atea Pharmaceuticals 

Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of
patients with severe viral diseases. Our lead programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community
settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. Our medicinal chemistry, virology, and
pharmacology expertise, bolstered by our collective experience in drug development, enables us to pioneer new advancements in antiviral science. Leveraging the power of our purine nucleotide prodrug platform, our goal is to rapidly advance novel
drug candidates with optimal therapeutic profiles for RNA virus targets. Founded by its Chairman and Chief Executive Officer, Jean-Pierre Sommadossi, PhD, Atea began operations in 2014 and is headquartered in Boston, MA. For more information about
Atea and our pipeline of product candidates please visit our company website at www.ateapharma.com. 
 Contacts 

Investors: 
 Will O’Connor 

Stern Investor Relations 
 212-362-1200 
 will.oconnor@sternir.com 

Media: 
 Carol Guaccero 

301-606-4722 

contactus@ateapharma.com 

  
 - 75 - 

 Roche Form of Press Release 

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

  

	 	•	 	 Roche and Atea partner to jointly develop AT-527, an orally
administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials 

  

	 	•	 	 AT-527 has the potential to be the first novel oral antiviral to treat
COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings 

 

	 	•	 	 Oral, small-molecule DAAs for COVID-19 patients allow for large-scale
manufacturing and facilitate broad patient access 

  

	 	•	 	 If approved, Atea will distribute AT-527 in the United States and
Roche will be responsible for global manufacturing and distribution outside the United States 

 Basel, xx October 2020—Roche
(SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute
AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral
replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use
in patients outside of the hospital setting. In addition, AT-527 may be developed for post-exposure prophylactic settings. 

AT-527, while being a potential oral treatment option for hospitalised patients, also holds the potential to be the
first oral treatment option for COVID-19 patients that are not hospitalised. Additionally, the manufacturing process of small-molecule DAAs allows the ability to produce large quantities of a much needed
treatment. If successful, AT-527 could help treat patients early, reduce the progression of the infection, and contribute to decreasing the overall burden on health systems. 

The collaboration aims to accelerate the clinical development and manufacturing of AT-527, to investigate its safety
and efficacy, and to provide this potential treatment option to patients around the world as quickly as possible. If AT-527 proves safe and effective in clinical trials and regulatory approvals are granted,
Atea will be responsible for distributing this treatment option in the U.S, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the United States. 

“The ongoing complexities of COVID-19 require multiple lines of defence. By joining forces with Atea, we hope to
offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and to ease the burden on hospitals during a global pandemic.” said
Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the
world as we possibly can.” 

  
 - 76 - 

 “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs.
The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and
Founder of Atea Pharmaceuticals. “AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA
polymerase, a key component in the replication machinery of RNA viruses. Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at
scale.” 
 About AT-527 

AT-527 is an investigational, oral, purine nucleotide prodrug, which has demonstrated in vitro and in vivo antiviral
activity against several enveloped single-stranded RNA viruses, including human flaviviruses and coronaviruses. This highly selective purine nucleotide prodrug was designed to uniquely inhibit viral RNA dependent RNA polymerase, an enzyme that is
essential for the replication of RNA viruses. Antiviral activity and safety of AT-527 has been demonstrated in Phase 2 clinical studies of hepatitis C patients, and in preclinical in-vitro assays with SARS-CoV2 virus. AT-527 is not yet licensed or approved for any indication in the United States or any other country. 

About Roche’s response to the COVID-19 pandemic 

As a leading healthcare company we are doing all we can to support countries in minimising the impact of COVID-19. We
have developed a growing number of diagnostic solutions that help to detect and diagnose the infection in patients, as well as providing digital support to healthcare systems, and we continue to identify, develop and support potential therapies
which can play a role in treating the disease. 
 We understand the impact of COVID-19 goes beyond those who
contract it, which is why we are working with healthcare providers, laboratories, authorities and organisations to help make sure that patients continue to receive the tests, treatment and care they need during these challenging times. As we learn
from the pandemic, we are partnering with governments and others to make healthcare stronger and more sustainable in the future. 
 Our diagnostics
solutions: 
 Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic. Our portfolio includes: 

 

	 	•	 	 a high-volume molecular test to detect
SARS-CoV-2, the virus that causes COVID-19, (FDA Emergency Use Authorisation (EUA) and available in countries accepting the CE
Mark) 

  

	 	•	 	 a SARS-CoV-2 laboratory-based
antibody test, aimed at detecting the presence of antibodies in the blood targeting the nucleocapsid (FDA EUA and CE Mark) 

  

	 	•	 	 an IL-6 test to assist in identifying severe inflammatory response in
patients with confirmed COVID-19 (FDA EUA and CE Mark) 

  

	 	•	 	 Roche v-TAC, which could help simplify the screening, diagnosis and
monitoring of patients with respiratory compromise in the current COVID-19 pandemic 

  

	 	•	 	 a SARS-CoV-2 rapid antibody test
to help determine at the point of care whether a person has been exposed to the virus (CE Mark) 

  
 - 77 - 

	 	•	 	 a rapid antigen test to support in the detection of SARS-CoV-2 at the point of care within 15 minutes (CE Mark) 

  

	 	•	 	 a high-volume molecular test to simultaneously detect and differentiate between SARS-CoV-2 and influenza A/B, as the symptoms are similar for both (FDA EUA and CE Mark) 

  

	 	•	 	 a second SARS-CoV-2 antibody
test, aimed at measuring the spike protein to support vaccination development and complement our existing portfolio 

  

	 	•	 	 a point-of-care molecular PCR
test that simultaneously detects and differentiates between SARS-CoV-2 and influenza A/B infections to support urgent triage and diagnosis (FDA EUA and CE Mark)

 Our research into therapies: 

Roche is committed to improving the treatment of COVID-19. We are actively involved in understanding the potential of
our existing portfolio and are exploring the potential of our investigational molecules. 
 In August, we announced a partnership with Regeneron to develop,
manufacture, and increase global supply of their investigational antibody combination for COVID-19 if it proves safe and effective in clinical trials and regulatory approvals are granted. 

At the beginning of the pandemic, on 19 March, we announced the initiation of COVACTA— a global Phase III randomised, double-blind,
placebo-controlled clinical trial to evaluate the safety and efficacy of intravenous Actemra©/RoActemra© (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19
pneumonia compared to placebo plus standard of care. On 29 July we announced that COVACTA did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia or
the key secondary endpoint of reduced mortality. 
 Separately, we have studied Actemra©/RoActemra© in the EMPACTA study in COVID-19 associated hospitalised pneumonia in patients that are often underrepresented in clinical trials. On 18 September we announced that the phase III EMPACTA study showed Actemra/RoActemra plus standard of
care reduced the likelihood of progression to mechanical ventilation or death in hospitalised patients with COVID-19 associated pneumonia compared to placebo plus standard of care. However, there was no
statistical difference in mortality between patients who received Actemra/RoActemra or placebo 
 Actemra©/RoActemra© is also being studied in
combination with the investigational antiviral remdesivir in hospitalised patients with severe COVID-19 pneumonia in the REMDACTA trial in partnership with Gilead, announced 28 May.
Actemra©/RoActemra© is not approved by any health authority for use in COVID-19 pneumonia. Roche has further initiated an internal early research programme focused on the development of medicines for
COVID-19 and is engaged in multiple research collaborations. 
 In these exceptional times, Roche stands together
with governments, healthcare providers and all those working to overcome the pandemic. 

  
 - 78 - 

 About Roche 

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of
pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. 

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and
diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. 

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company
also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them
life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices
(DJSI). 
 The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com. 
 All trademarks used or mentioned in this release are protected by law. 

Roche Group Media Relations 
 Phone: +41 61 688 8888 / e-mail: media.relations@roche.com 

  
 - 79 - 

			
	 Dr. Nicolas Dunant
  

Phone: +41 61 687 05 17
	  	 Patrick Barth
  

Phone: +41 61 688 44 86

		
	 Daniel Grotzky
  

Phone: +41 61 688 31 10
	  	 Karsten Kleine
  

Phone: +41 61 682 28 31

		
	 Nina Mählitz
  

Phone: +41 79 327 54 74
	  	 Nathalie Meetz
  

Phone: +41 61 687 43 05

		
	 Barbara von Schnurbein
  

Phone: +41 61 687 89 67
	  	

  

			
	Roche Investor Relations	  	  

		
	 Dr. Karl Mahler
  

Phone: +41 61 68-78503

 
 e-mail:
karl.mahler@roche.com
	  	 Jon Kaspar Bayard
  

Phone: +41 61 68-83894

 
 e-mail:
jon_kaspar.bayard@roche.com

  
 - 80 - 

			
	 Dr. Sabine Borngräber

 
 Phone: +41 61
68-88027
  

e-mail: sabine.borngraeber@roche.com
	  	 Dr. Bruno Eschli
  

Phone: +41 61 68-75284

 
 e-mail:
bruno.eschli@roche.com

		
	 Dr. Birgit Masjost

 
 Phone: +41 61
68-84814
  

e-mail: birgit.masjost@roche.com
	  	 Dr. Gerard Tobin
  

Phone: +41 61 68-72942

 
 e-mail:
gerard.tobin@roche.com

		
	Investor Relations North America	  	  

		
	 Loren Kalm
  

Phone: +1 650 225 3217
  

e-mail: kalm.loren@gene.com
	  	 Dr. Lisa Tuomi
  

Phone: +1 650 467 8737
  

e-mail: tuomi.lisa@gene.com

  
 - 81 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]